
<html lang="en"     class="pb-page"  data-request-id="11d38687-703c-45e2-bdd1-3841bea26aa0"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2017.60.issue-14;article:article:10.1021/acs.jmedchem.7b00076;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer" /></meta><meta name="dc.Creator" content="Wei  Zhu" /></meta><meta name="dc.Creator" content="Hui  Chen" /></meta><meta name="dc.Creator" content="Yulan  Wang" /></meta><meta name="dc.Creator" content="Jiang  Wang" /></meta><meta name="dc.Creator" content="Xia  Peng" /></meta><meta name="dc.Creator" content="Xianjie  Chen" /></meta><meta name="dc.Creator" content="Yinglei  Gao" /></meta><meta name="dc.Creator" content="Chunpu  Li" /></meta><meta name="dc.Creator" content="Yulong  He" /></meta><meta name="dc.Creator" content="Jing  Ai" /></meta><meta name="dc.Creator" content="Meiyu  Geng" /></meta><meta name="dc.Creator" content="Mingyue  Zheng" /></meta><meta name="dc.Creator" content="Hong  Liu" /></meta><meta name="dc.Description" content="A novel series of pyridin-3-amine derivatives were designed, synthesized, and evaluated as multitargeted protein kinase inhibitors for the treatment of non-small cell lung cancer (NSCLC). Hit 1 was..." /></meta><meta name="Description" content="A novel series of pyridin-3-amine derivatives were designed, synthesized, and evaluated as multitargeted protein kinase inhibitors for the treatment of non-small cell lung cancer (NSCLC). Hit 1 was..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 17, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00076" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00076" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00076" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00076" /></link>
        
    
    

<title>Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00076" /></meta><meta property="og:title" content="Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0015.jpeg" /></meta><meta property="og:description" content="A novel series of pyridin-3-amine derivatives were designed, synthesized, and evaluated as multitargeted protein kinase inhibitors for the treatment of non-small cell lung cancer (NSCLC). Hit 1 was first disclosed by in silico screening against fibroblast growth factor receptors (FGFR), which was subsequently validated by in vitro experiments. The structure–activity relationship (SAR) of its analogues was then explored to afford novel FGFR inhibitors 2a–2p and 3a–3q. Among them, 3m showed potent inhibition against FGFR1, 2, and 3. Interestingly, compound 3m not only inhibited various phosphorylation and downstream signaling across different oncogenic forms in FGFR-overactivated cancer cells but also showed nanomolar level inhibition against several other NSCLC-related oncogene kinases, including RET, EGFR, EGFR/T790M/L858R, DDR2, and ALK. Finally, in vivo pharmacology evaluations of 3m showed significant antitumor activity (TGI = 66.1%) in NCI-H1581 NSCLC xenografts with a good pharmacokinetic profile." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00076"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00076">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00076&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00076&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00076&amp;href=/doi/10.1021/acs.jmedchem.7b00076" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 14</span><span class="cit-fg-pageRange">, 6018-6035</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/14" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b01850" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00140" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Zhu">Wei Zhu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol "><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hui++Chen">Hui Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol "><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yulan++Wang">Yulan Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol "><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jiang++Wang">Jiang Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xia++Peng">Xia Peng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xianjie++Chen">Xianjie Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yinglei++Gao">Yinglei Gao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chunpu++Li">Chunpu Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yulong++He">Yulong He</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jing++Ai">Jing Ai</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Meiyu++Geng">Meiyu Geng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mingyue++Zheng">Mingyue Zheng</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-3323-3092" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Liu">Hong Liu</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-0863-7853" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="AFF-d96e168-autogenerated"><span class="aff-text"><sup>†</sup>State Key Laboratory of Drug Research and <sup>‡</sup>CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai, 201203, China</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China</span></div><div class="corresp-info"><strong>*</strong>Phone: 86-021-50806600 ext. 2413. E-mail: <a href="/cdn-cgi/l/email-protection#b3d9d2daf3c0dadede9dd2d09dd0dd"><span class="__cf_email__" data-cfemail="640e050d24170d09094a05074a070a">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>Phone: 86-021-50271399. E-mail: <a href="/cdn-cgi/l/email-protection#761b0f0c1e13181136051f1b1b581715581518"><span class="__cf_email__" data-cfemail="137e6a697b767d7453607a7e7e3d72703d707d">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>Phone: 86-021-50807042. E-mail: <a href="/cdn-cgi/l/email-protection#e78f8b8e92a7948e8a8ac98684c98489"><span class="__cf_email__" data-cfemail="7b1317120e3b08121616551a18551815">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00076&amp;href=/doi/10.1021%2Facs.jmedchem.7b00076" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 14</span><span class="cit-pageRange">, 6018–6035</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 22, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>23 January 2017</li><li><span class="item_label"><b>Published</b> online</span>17 July 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 July 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00076" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00076</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6018%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DWei%2BZhu%252C%2BHui%2BChen%252C%2BYulan%2BWang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D14%26contentID%3Dacs.jmedchem.7b00076%26title%3DDesign%252C%2BSynthesis%252C%2Band%2BPharmacological%2BEvaluation%2Bof%2BNovel%2BMultisubstituted%2BPyridin-3-amine%2BDerivatives%2Bas%2BMultitargeted%2BProtein%2BKinase%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BNon-Small%2BCell%2BLung%2BCancer%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6035%26publicationDate%3DJuly%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00076"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3181</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">14</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00076" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Hui&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Yulan&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Jiang&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Xia&quot;,&quot;last_name&quot;:&quot;Peng&quot;},{&quot;first_name&quot;:&quot;Xianjie&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Yinglei&quot;,&quot;last_name&quot;:&quot;Gao&quot;},{&quot;first_name&quot;:&quot;Chunpu&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Yulong&quot;,&quot;last_name&quot;:&quot;He&quot;},{&quot;first_name&quot;:&quot;Jing&quot;,&quot;last_name&quot;:&quot;Ai&quot;},{&quot;first_name&quot;:&quot;Meiyu&quot;,&quot;last_name&quot;:&quot;Geng&quot;},{&quot;first_name&quot;:&quot;Mingyue&quot;,&quot;last_name&quot;:&quot;Zheng&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Liu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;17&quot;,&quot;issue&quot;:&quot;14&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;6018-6035&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00076&quot;},&quot;abstract&quot;:&quot;A novel series of pyridin-3-amine derivatives were designed, synthesized, and evaluated as multitargeted protein kinase inhibitors for the treatment of non-small cell lung cancer (NSCLC). Hit 1 was first disclosed by in silico screening against fibroblast growth factor receptors (FGFR), which was subsequently validated by in vitro experiments. The structure–activity relationship (SAR) of its analogues was then explored to afford novel FGFR inhibitors 2a–2p and 3a–3q. Among them, 3m showed potent inhibition against FGFR1, 2, and 3. Interestingly, compound 3m not only inhibited various phosphorylation and downstream signaling across different oncogenic forms in FGFR-overactivated cancer cells but also showed nanomolar level inhibition against several other NSCLC-related oncogene kinases, including RET, EGFR, EGFR/T790M/L858R, DDR2, and ALK. Finally, in vivo pharmacology evaluations of 3m showed significant antitumor activity (TGI = 66.1%) in NCI-H1581 NSCLC xenografts with a good pharmacokinetic profile.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00076&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00076" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00076&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00076" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00076&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00076" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00076&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00076&amp;href=/doi/10.1021/acs.jmedchem.7b00076" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00076" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00076" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00076%26sid%3Dliteratum%253Aachs%26pmid%3D28714692%26genre%3Darticle%26aulast%3DZhu%26date%3D2017%26atitle%3DDesign%252C%2BSynthesis%252C%2Band%2BPharmacological%2BEvaluation%2Bof%2BNovel%2BMultisubstituted%2BPyridin-3-amine%2BDerivatives%2Bas%2BMultitargeted%2BProtein%2BKinase%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BNon-Small%2BCell%2BLung%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D14%26spage%3D6018%26epage%3D6035%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/14" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/jmcmar.2017.60.issue-14/20170727/jmcmar.2017.60.issue-14.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/medium/jm-2017-00076u_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00076&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A novel series of pyridin-3-amine derivatives were designed, synthesized, and evaluated as multitargeted protein kinase inhibitors for the treatment of non-small cell lung cancer (NSCLC). Hit <b>1</b> was first disclosed by <i>in silico</i> screening against fibroblast growth factor receptors (FGFR), which was subsequently validated by <i>in vitro</i> experiments. The structure–activity relationship (SAR) of its analogues was then explored to afford novel FGFR inhibitors <b>2a</b>–<b>2p</b> and <b>3a</b>–<b>3q.</b> Among them, <b>3m</b> showed potent inhibition against FGFR1, 2, and 3. Interestingly, compound <b>3m</b> not only inhibited various phosphorylation and downstream signaling across different oncogenic forms in FGFR-overactivated cancer cells but also showed nanomolar level inhibition against several other NSCLC-related oncogene kinases, including RET, EGFR, EGFR/T790M/L858R, DDR2, and ALK. Finally, <i>in vivo</i> pharmacology evaluations of <b>3m</b> showed significant antitumor activity (TGI = 66.1%) in NCI-H1581 NSCLC xenografts with a good pharmacokinetic profile.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35551" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35551" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Lung cancer is one of the most common cancers, and non-small cell lung cancer (NSCLC) accounts for 80–85% of all lung cancers.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> An epidermal growth factor receptor (EGFR) inhibitor has recently been developed and has been shown to be effective against NSCLC as more than 60% of NSCLCs express genetic mutations of EGFR.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> However, the emergence of drug-resistant variants of NSCLC has greatly reduced the clinical efficacy of EGFR inhibitors such as gefitinib. Multitargeted tyrosine kinase inhibitors (TKIs), such as sunitinib, motesanib, sorafenib, lapatinib, and vandetanib, have therefore been designed based on these drug-resistant variants. For EGFR TKI-resistant patients with an unknown driving mechanism, the concept of a “cancer driver gene” may help to increase the efficacy of multitargeted drugs for NSCLC.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> In recent years, various driver oncogenic genes in NSCLC have been characterized, including EGFR mutations (15–20%), ALK rearrangements (5%), MET amplifications, ErbB2 mutations (1–3%), PI3KCA mutations (5–10%), NF1 mutations (5%), KRAS mutations (25–30%), FGFR1 amplifications (15–20%), FGFR 2/3/4 mutations/rearrangements (5–10%), DDR2 mutations (4%), ROS1 rearrangements (1–2%), RET rearrangements (1–2%), and so on.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">FGFRs are highly conserved transmembrane tyrosine kinase receptors. In humans, there are four FGFRs that are typical tyrosine kinase receptors (FGFR1–4), and they are involved in several basic biologic processes, including tissue development, angiogenesis, and tissue regeneration.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> An initial screen of 155 squamous cell lung cancer specimens using single nucleotide polymorphism arrays identified focal amplifications of the FGFR1 gene.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Survival of FGFR1-amplified lung cancer cell lines was additionally shown to be dependent on overexpression of FGFR1 kinase.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> As shown in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>, there are many FGFR inhibitors in development for NSCLC treatment, including both selective FGFR inhibitors (LY2874455<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a>) and multitargeted TKIs with FGFR activity. Currently, several multitargeted FGFR inhibitors have been approved for NSCLC treatment, including vandetanib,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> lenvatinib,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> nintedanib,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and ponatinib,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and several others are under clinical trial studies (anlotinib,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> cediranib,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> lucitanib,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> brivanib,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> danusertib,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> CP-547632,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> and AT-9283<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a>). For example, dovitinib has been investigated as a nonspecific FGFRs inhibitor, and it also targets vascular endothelial growth factor receptor 1/2/3 (VEGFR1/2/3), platelet-derived growth factor receptor α/β (PDGFR-α/β), stem cell factor receptor (c-Kit), FMS-like tyrosine kinase 3 (FLT3), and colony-stimulating factor 1 receptor (CSF1R). In a phase II trial, dovitinib exhibited efficacy in patients with advanced squamous NSCLC with FGFR1 amplification.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Another example is crizotinib, a dual inhibitor of ALK and ROS1 signaling, which showed marked antitumor activity in patients with ROS1- or ALK-rearranged advanced NSCLC.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a> In 2013 and 2016, the FDA approved crizotinib for the treatment of patients with advanced NSCLC whose tumors have ROS1 and ALK rearrangements, respectively. Because it has now been accepted that NSCLC is not a singular entity but is in fact multiple pathologies with unique molecular signatures, there has been a renewed interest in developing multitargeted TKIs targeting different signaling pathways and oncogenic drivers for enhancing efficacy and response rates. The discovery and development of multitargeted TKIs with FGFR activity is therefore a promising direction for the treatment of NSCLC.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/medium/jm-2017-00076u_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative structures of multitargeted and selective inhibitors with FGFR inhibitory activities for the treatment of NSCLC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00076&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In this study, molecular docking-based virtual screening was used to discover novel FGFR inhibitors based on the clarification of FGFR kinase structures. Fifty-seven compounds were selected for FGFR1 inhibitor bioactivity testing, and a compound with the pyridin-3-amine scaffold <b>1</b> showed a high inhibition ratio at a concentration of 50 μM. Further bioactivity testing on compound <b>1</b> revealed that this compound possesses a low micromolar level inhibitory activity with an IC<sub>50</sub> value of 3.8 ± 0.5 μM against FGFR1. To improve the inhibition potency of compound <b>1</b> against FGFR1, we analyzed its binding mode with FGFR1 and performed a structure-based optimization. The most potent compound <b>3m</b> displayed nanomolar IC<sub>50</sub> against FGFR and an FGFR-dependent cancer cell line. To better understand the pharmacological profile of <b>3m</b>, a kinase panel screening on <b>3m</b> was performed; the effects of <b>3m</b> on protein kinase phosphorylation and downstream signaling were studied, and the antiproliferative effects of <b>3m</b> against several cancer cell lines harboring the oncogenic kinases targeted by <b>3m</b> were detected. It was shown that compound <b>3m</b> targets several NSCLC-related oncogene kinases with nanomolar IC<sub>50</sub>, including against FGFRs, RET, EGFR, EGFR/T790M/L858R, DDR2, and ALK. Meanwhile, compound <b>3m</b> could inhibit cancer cell line proliferation harboring frequently occurring oncogenic forms of FGFRs, DDR2, EGFR, and RET. Finally, <i>in vivo</i> studies showed that compound <b>3m</b> has a good pharmacokinetic profile and <i>in vivo</i> activity against NCI-H1581 xenografts for the treatment of NSCLC.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Result and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54416" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54416" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Identification and Validation of Multisubstituted Pyridin-3-amine Scaffold by Structure-Based Virtual Screening</h3><div class="NLM_p">For novel chemotypes of FGFR inhibitors to be discovered, docking-based virtual screening<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> was performed on an in-house compound library that contains more than 6,000 compounds with structural diversity.<a onclick="showRef(event, 'ref25 ref26 ref27 ref28 ref29 ref30 ref31 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27 ref28 ref29 ref30 ref31 ref32 ref33">(25-33)</a> The crystal structure of FGFR1 in complex with potency inhibitor <b>15</b> (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3TT0">3TT0</a>)<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> was used as the receptor for docking by the Schrödinger Suite 2015 software package. The ligand database was prepared with the LigPrep module to generate energy-minimized three-dimensional (3D) coordinates in which the protonation states of molecules were calculated with Epik. The crystal structure of the receptor was converted into all-atom and refined with the Protein Preparation Wizard in Schrödinger, where the force field used was OPLS3. Finally, the prepared ligand database was docked into the prepared receptor with extra precision (XP) mode in the Glide module.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The top-ranked 1120 compounds with XP GScore lower than −7.0 kcal/mol were kept, and the duplicated compounds were removed. Then, the resulting compounds were clustered based on structure similarity using Pipeline Pilot 7.5 software. For each cluster, only one or two compounds with higher docking score were retained. In the end, by considering both the Glide XP GScore and structural diversity, 57 compounds were selected for FGFR1 inhibition assays to validate their <i>in vitro</i> activity. With the ELISA kinase assay at 50 μM, compound <b>1</b> showed inhibitory potency with an inhibition ratio of 76.5% (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>A). Further evaluation demonstrated that compound <b>1</b> possesses a low micromolar level activity with an IC<sub>50</sub> value of 3.8 ± 0.5 μM against FGFR1.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/medium/jm-2017-00076u_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Identification of compound <b>1</b> as a hit against FGFR. (A) Inhibitory activity of the 57 selected compounds at 50 μM. Compound <b>16</b> (black column) was used as a positive control, and the inhibition ratio of compound <b>1</b> (red column) is 76.5%. (B) Putative binding mode of compound <b>1</b> with FGFR1, where hydrogen bonds are depicted as dashed red lines and the hydrophobic pocket of FGFR1 is marked as an orange circle. (C) Superimposition of the binding mode of compound <b>1</b> (green) with the crystal structures of compounds <b>15</b> (slate) and <b>16</b> (orange), where the hydrophobic pocket of FGFR1 is marked as an orange circle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00076&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Binding Mode Analysis of Compound <b>1</b></h3><div class="NLM_p">To gain deeper insight into the molecular basis of the inhibitory activity, we analyzed the putative binding mode of compound <b>1</b> obtained by molecular docking. As shown in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>B, the active site of FGFR can be generally segmented into three sections: a hinge region, a hydrophobic pocket, and a P-loop region. As depicted in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>B, compound <b>1</b> binds in the active site of FGFR1. The pyrazolyl moiety establishes two hydrogen bonds with the backbone amino and carbonyl of Ala564 and Glu562 in the hinge region, and the furyl group is located in the hydrophobic pocket of the FGFR protein. The hydroxyl of compound <b>1</b> could form a hydrogen bond with the backbone carbonyl of Leu484 in the P-loop, and the amino group may form a weak hydrogen bond with the backbone carbonyl of Glu486. Comparing the putative binding modes of compound <b>1</b> with the crystal structures of reported FGFR inhibitors <b>15</b> and <b>16</b>,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> we find that the 3,5-dimethoxy-phenyls of the two reported inhibitors occupy the same hydrophobic pocket of the furyl of compound <b>1</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>C). However, the furyl ring does not fit the hydrophobic pocket well, which is more spacious and may accommodate a larger group. Intuitively, modifying the furyl group to better fill the hydrophobic pocket is the first approach for the chemical optimization of compound <b>1</b>. Cheng et al. reported a series of 3,5-disubstituted pyridine derivatives as CDK inhibitors for the treatment of cancer.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Compared with 3,5-disubstituted pyridine derivatives, the distinct substitutes at the 6-position of the pyridine ring may have a significant influence on the inhibitory activities against FGFR. Subsequently, the structure–activity relationship (SAR) at the P-loop interaction region, hydrophobic pocket, and hinge interaction region of the pyridine core will be further explored (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/medium/jm-2017-00076u_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. SAR Exploration of Pyridin-3-Amine Derivatives as Potent FGFR Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00076&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Chemistry</h3><div class="NLM_p">Two synthetic routes were exploited to access desired compounds <b>2</b> and <b>3</b> (<a class="ref internalNav" href="#sch2" aria-label="Schemes 2">Schemes 2</a> and <a class="ref internalNav" href="#sch3" aria-label="3">3</a>). With the treatment of Grignard reagent MeMgBr, aldehydes <b>4</b> were converted to ethanols, which yielded corresponding ketones <b>5</b> upon oxidation of MnO<sub>2</sub> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Pyrazoles <b>6</b> were then prepared by following refluxing with hydrazine hydrate and the following protection with a Boc group. Boronic esters <b>7</b> were provided via a Miyaura borylation reaction. Pyridin-3-amine <b>8</b> underwent a Sandmeyer reaction in the presence of NaI, NaNO<sub>2</sub>, and hydrochloric acid to afford <b>9</b>, which was coupled with (<i>R</i>)-2-amino-2-phenylethanol with CuI as catalyst to give key intermediate <b>10</b>. The Suzuki coupling of <b>7</b> and <b>10</b> provided chloropyridine <b>11</b>, which underwent another coupling with commercially available boronic acids to yield desired compounds <b>1</b>, <b>2a</b>–<b>2p</b>, <b>3a</b>, and <b>3k</b>–<b>3q</b>. The FGFR inhibitors <b>3b</b>–<b>3e</b> could be obtained by the coupling of intermediate <b>12</b> with different heteroboronic acids and 5-chloro-2-hydroxyphenylboronic acid. As shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, 3-bromo-2-chloropyridines <b>13</b> were prepared by copper-catalyzed coupling of intermediate <b>9</b> with amino alcohols. The following two-step Suzuki coupling of <b>13</b> with intermediate <b>7a</b> and 2-hydroxyphenylboronic acids afforded desired compounds <b>3f</b>–<b>3j</b>.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/medium/jm-2017-00076u_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Routes Exploited to Access Desired Compounds <b>2</b> and <b>3</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00076&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) MeMgBr, THF, 0 °C; then, MnO<sub>2</sub>, 1,4-dioxane, reflux; (b) N<sub>2</sub>H<sub>4</sub> (75% in H<sub>2</sub>O), reflux; (c) Boc<sub>2</sub>O, Et<sub>3</sub>N, DCM, rt; then, 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane), Pd(dppf)<sub>2</sub>Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, KOAc, 1,4-dioxane, 80 °C; (d) NaI, HCl (6 M), NaNO<sub>2</sub>, H<sub>2</sub>O, 0 °C – rt; (e) (<i>R</i>)-2-amino-2-phenyl-ethanol, CuI, K<sub>3</sub>PO<sub>4</sub>, ethylene glycol, <sup><i>i</i></sup>PrOH; (f) Pd(dppf)<sub>2</sub>Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, H<sub>2</sub>O, 90 °C; then TFA, DCM; (g) boronic acids, Pd(dppf)<sub>2</sub>Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, H<sub>2</sub>O, 120 °C, MW. (h) boronic acids, Pd(dppf)<sub>2</sub>Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, H<sub>2</sub>O, 90 °C; (i) 5-chloro-2-hydroxyphenylboronic acid, Pd(dppf)<sub>2</sub>Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, H<sub>2</sub>O, 120 °C, MW.</p></p></figure><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/medium/jm-2017-00076u_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Route to Desired Compounds <b>3f</b>–<b>3j</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00076&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) amines, CuI, K<sub>3</sub>PO<sub>4</sub>, ethylene glycol, <sup><i>i</i></sup>PrOH; (b) <b>7a</b>, Pd(dppf)<sub>2</sub>Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, H<sub>2</sub>O, 90 °C; then TFA, DCM; (c) boronic acids, Pd(dppf)<sub>2</sub>Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, H<sub>2</sub>O, 120 °C, MW.</p></p></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Structure–Activity Relationships of Multisubstituted Pyridine-3-amine Derivatives</h3><div class="NLM_p">On the basis of the modeled complex structure of hit compound <b>1</b> with FGFR1, we have designed and synthesized dozens of pyridine-3-amine derivatives to explore their structure–activity relationship (SAR). As shown in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, the preliminary SAR at the hydrophobic pocket was first investigated. Replacement of the 3-furan fragment of compound <b>1</b> with various heteroaryl moieties or a benzene ring afforded compounds <b>2a</b>–<b>2g</b>. Compared with furan and thiophene analogues <b>2a</b>–<b>2c</b>, benzene-substituted derivative <b>2d</b> displayed improved activity. Incorporation of <i>N</i>-containing heteroaryl substituents to yield compounds <b>2e</b>–<b>2g</b> resulted in decreased inhibitory activities. Encouraged by these results, analogues containing substituted phenyl groups at the 6-position of the pyridine nucleus were prepared for further activity optimization (<b>2h</b>–<b>2p</b>). Introduction of fluorine (<b>2h</b>) had only marginal influence on FGFR inhibition, whereas trifluoromethyl analogue <b>2i</b> showed complete loss of activity. Interestingly, compounds <b>2j</b>–<b>2l</b>, bearing a H-bond donor fragment such as amide or hydroxymethyl group, maintained or slightly enhanced inhibitory activity against FGFR. To our delight, 2-OH-substituted derivative <b>2m</b> demonstrated potent FGFR inhibition with an enzymatic IC<sub>50</sub> of 14.9, 3.0, and 8.0 nM against FGFR1, 2, and 3, respectively. Blocking of the phenolic hydroxyl group (<b>2n</b>) led to sharply reduced potency, which indicated the critical role of this potential hydrogen bond interaction with FGFR. Such pseudocyclic motifs have been reported for kinase inhibitor hinge binders with an intramolecular hydrogen bond. However, on the basis of the putative binding mode, it is unlikely to form an internal H-bond in compound <b>2m</b> in our case (for details, see <a href="/doi/suppl/10.1021/acs.jmedchem.7b00076/suppl_file/jm7b00076_si_001.pdf" class="ext-link">Figures S1 and S2</a>). Compared with compound <b>2m</b>, 3-OH-substituted analogue <b>2o</b> exhibited 5-fold decreased potency against FGFR1. With the incorporation of chlorine at the 4-position of the phenol moiety in <b>2m</b>, compound <b>2p</b> also showed potent FGFR inhibition.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR at the 6-Position of the Pyridine Scaffold<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/medium/jm-2017-00076u_0009.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char=" " /></col><col align="char" char=" " /></col><col align="char" char=" " /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=" ">IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd.</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center" char=" ">FGFR1</th><th class="colsep0 rowsep0" align="center" char=" ">FGFR2</th><th class="colsep0 rowsep0" align="center" char=" ">FGFR3</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">furan-3-yl</td><td class="colsep0 rowsep0" align="char" char=" ">3800 ± 500</td><td class="colsep0 rowsep0" align="char" char=" ">>1000</td><td class="colsep0 rowsep0" align="char" char=" ">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2a</b></td><td class="colsep0 rowsep0" align="left">furan-2-yl</td><td class="colsep0 rowsep0" align="char" char=" ">>1000</td><td class="colsep0 rowsep0" align="char" char=" ">100–1000</td><td class="colsep0 rowsep0" align="char" char=" ">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2b</b></td><td class="colsep0 rowsep0" align="left">thiophen-3-yl</td><td class="colsep0 rowsep0" align="char" char=" ">327.4 ± 35.1</td><td class="colsep0 rowsep0" align="char" char=" ">56.9 ± 9.0</td><td class="colsep0 rowsep0" align="char" char=" ">969.7 ± 236.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2c</b></td><td class="colsep0 rowsep0" align="left">thiophen-2-yl</td><td class="colsep0 rowsep0" align="char" char=" ">>1000</td><td class="colsep0 rowsep0" align="char" char=" ">100–1000</td><td class="colsep0 rowsep0" align="char" char=" ">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2d</b></td><td class="colsep0 rowsep0" align="left">Ph-</td><td class="colsep0 rowsep0" align="char" char=" ">127.9 ± 13.3</td><td class="colsep0 rowsep0" align="char" char=" ">26.3 ± 6.2</td><td class="colsep0 rowsep0" align="char" char=" ">279.9 ± 30.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2e</b></td><td class="colsep0 rowsep0" align="left">pyridin-3-yl</td><td class="colsep0 rowsep0" align="char" char=" ">>1000</td><td class="colsep0 rowsep0" align="char" char=" ">>1000</td><td class="colsep0 rowsep0" align="char" char=" ">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2f</b></td><td class="colsep0 rowsep0" align="left">quinolin-8-yl</td><td class="colsep0 rowsep0" align="char" char=" ">>1000</td><td class="colsep0 rowsep0" align="char" char=" ">>1000</td><td class="colsep0 rowsep0" align="char" char=" ">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2g</b></td><td class="colsep0 rowsep0" align="left">indol-7-yl</td><td class="colsep0 rowsep0" align="char" char=" ">456.0 ± 122.4</td><td class="colsep0 rowsep0" align="char" char=" ">56.4 ± 5.2</td><td class="colsep0 rowsep0" align="char" char=" ">560.7 ± 35.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2h</b></td><td class="colsep0 rowsep0" align="left">2-F-Ph-</td><td class="colsep0 rowsep0" align="char" char=" ">437.3 ± 113.3</td><td class="colsep0 rowsep0" align="char" char=" ">44.6 ± 12.9</td><td class="colsep0 rowsep0" align="char" char=" ">430.5 ± 68.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2i</b></td><td class="colsep0 rowsep0" align="left">2-CF<sub>3</sub>-Ph-</td><td class="colsep0 rowsep0" align="char" char=" ">>1000</td><td class="colsep0 rowsep0" align="char" char=" ">>1000</td><td class="colsep0 rowsep0" align="char" char=" ">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2j</b></td><td class="colsep0 rowsep0" align="left">2-NHAc-Ph-</td><td class="colsep0 rowsep0" align="char" char=" ">418.4 ± 64.6</td><td class="colsep0 rowsep0" align="char" char=" ">250.2 ± 49.1</td><td class="colsep0 rowsep0" align="char" char=" ">3653.5 ± 283.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2k</b></td><td class="colsep0 rowsep0" align="left">2-CH<sub>2</sub>OH-Ph-</td><td class="colsep0 rowsep0" align="char" char=" ">167.3 ± 49.7</td><td class="colsep0 rowsep0" align="char" char=" ">50.5 ± 0.6</td><td class="colsep0 rowsep0" align="char" char=" ">250.5 ± 35.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2l</b></td><td class="colsep0 rowsep0" align="left">2-CONH<sub>2</sub>-Ph-</td><td class="colsep0 rowsep0" align="char" char=" ">48.8 ± 10.5</td><td class="colsep0 rowsep0" align="char" char=" ">72.9 ± 10.3</td><td class="colsep0 rowsep0" align="char" char=" ">388.0 ± 73.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2m</b></td><td class="colsep0 rowsep0" align="left">2-OH-Ph-</td><td class="colsep0 rowsep0" align="char" char=" ">14.9 ± 2.9</td><td class="colsep0 rowsep0" align="char" char=" ">3.0 ± 1.0</td><td class="colsep0 rowsep0" align="char" char=" ">8.0 ± 1.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2n</b></td><td class="colsep0 rowsep0" align="left">2-OMe-Ph-</td><td class="colsep0 rowsep0" align="char" char=" ">>1000</td><td class="colsep0 rowsep0" align="char" char=" ">100–1000</td><td class="colsep0 rowsep0" align="char" char=" ">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2o</b></td><td class="colsep0 rowsep0" align="left">3-OH-Ph-</td><td class="colsep0 rowsep0" align="char" char=" ">66.5 ± 5.2</td><td class="colsep0 rowsep0" align="char" char=" ">21.4 ± 4.0</td><td class="colsep0 rowsep0" align="char" char=" ">433.8 ± 32.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2p</b></td><td class="colsep0 rowsep0" align="left">2-OH, 5-Cl-Ph-</td><td class="colsep0 rowsep0" align="char" char=" ">55.8 ± 3.9</td><td class="colsep0 rowsep0" align="char" char=" ">8.6 ± 2.0</td><td class="colsep0 rowsep0" align="char" char=" ">73.1 ± 4.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=" ">0.7 ± 0.2</td><td class="colsep0 rowsep0" align="char" char=" ">1.1 ± 0.1</td><td class="colsep0 rowsep0" align="char" char=" ">5.5 ± 0.4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">The IC<sub>50</sub> values are shown as the mean ± SD (nM) from two separate experiments.</p></div></div></div><div class="NLM_p">Panels A and B in <a class="ref internalNav" href="#fig3" aria-label="Figures 3">Figures 3</a> display the putative binding modes of compounds <b>1</b>, <b>2d</b>, and <b>2p</b> with FGFR1. Compared with compounds <b>1</b> and <b>2d</b>, the replacement of furyl to phenyl could gain more hydrophobic shape complementarity with the hydrophobic pocket of FGFR, which is consistent with their inhibitory potency difference in the enzymatic assays. In addition, the phenyl group of <b>2p</b> occupies the hydrophobic pocket like <b>2d</b>, and the hydroxyl substituent on the phenyl of <b>2p</b> could form two hydrogen bonds with the backbone amino and side chain carboxyl of Asp641. Accordingly, the inhibitory activity of <b>2p</b> was improved as compared with that of <b>2d</b>.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/medium/jm-2017-00076u_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Putative binding modes of pyridine-3-amine derivatives by docking in FGFR1 protein (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3TT0">3TT0</a>). (A) Binding modes of <b>1</b> (green), <b>2d</b> (yellow), and <b>2p</b> (pink) in the hydrophobic pocket of FGFR1, of which the front side of the pocket surface is clipped away for clarity and the hydrophobic pocket is depicted as a dashed orange circle. (B) Binding modes of <b>2d</b> (yellow) and <b>2p</b> (pink) with FGFR1. (C) Superimposition of the binding modes of <b>2p</b> (pink), <b>3c</b> (blue), and <b>3b</b> (green). (D) Binding modes of <b>2p</b> ((<i>R</i>)<i>-</i>isomer) and its enantiomer <b>3f</b> ((<i>S</i>)<i>-</i>isomer). Hydrogen bonds are depicted as dashed red lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00076&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As shown in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>, the SARs at the moiety interacting with the hinge region were also explored with the privileged 4-chlorophenol fragment retained. As mentioned above, the pyrazole group forms two hydrogen bonds with the hinge region. To investigate the importance of the interaction, we synthesized derivatives <b>3a</b>–<b>3e</b>, of which the pyrazole group was replaced with other aza-heterocyclic or noncyclic groups (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Among these derivatives, compound <b>3a</b>, isoquinoline analogue <b>3b</b>, and indolone analogue <b>3c</b> exhibited similar or slightly increased potency compared with that of compound <b>2p</b>, whereas the ring-opening derivative (<b>3d</b>) and indole derivative (<b>3e</b>) displayed significantly reduced activity, demonstrating the pivotal role of the hydrogen bond donating group at the hinge region of FGFR. To account for the chemical basis of this result, we analyzed the putative binding modes of <b>3b</b> and <b>3c</b>. As shown in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>C, <b>3b</b> could form one hydrogen bond with the hinge region through the quinolyl nitrogen atom to Ala564 and the hydroxyl forms a hydrogen bond with Glu484. Compound <b>3c</b> could maintain two hydrogen bonds with the hinge region, whereas the hydroxyl does not form any hydrogen bond interaction, which should be responsible for the decreased inhibitory potency of <b>3c</b>. In addition, the noncyclic derivative <b>3d</b> and indole-substituted derivative <b>3e</b> cannot form a stable anchoring interaction with hinge region, which may lead to its reduced inhibitory activity.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR of Substituents R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup> on the 2-(Pyridin-2-yl)phenol Scaffold<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/medium/jm-2017-00076u_0011.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/medium/jm-2017-00076u_0012.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/medium/jm-2017-00076u_0013.gif" alt="" id="fx3.5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub> values are shown as the mean ± SD (nM) from two separate experiments.</p></div></div><div></div></div><div class="NLM_p">The SAR of the 1-hydroxymethyl-1-phenyl-methylamnio moiety of <b>2p</b> was also explored, which interacts with P-loop through two hydrogen bonds based on the model. Either altering the chirality (<b>3f</b>) or removing the terminal hydroxyl group (<b>3g</b>) resulted in significant loss of potency, highlighting the importance of the P-loop region interaction. As shown in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>D, (<i>R</i>)<i>-</i>isomer <b>2p</b> could form two hydrogen bonds with Leu484 and Glu486 in the P-loop based on the docking, whereas (<i>S</i>)-isomer <b>3f</b> could only form one hydrogen bond through the amino to Glu486, thus showing decreased activity.</div><div class="NLM_p last">Finally, further modification at the phenol segment at the 6-position of the pyridine nucleus led to the preparation of compounds <b>3k</b>–<b>3q</b>. The replacement of the chlorine substituent with a methyl group (<b>3k</b>) retained the potent inhibition against FGFR; however, the bulky isopropyl group (<b>3l</b>) led to loss of inhibitory activity. Interestingly, the following F-scan at the phenol moiety afforded a handful of FGFR inhibitors <b>3m</b>–<b>3q</b> with significantly enhanced activities, which can be attributed to the feature of a relatively small and electron-withdrawing fluorine atom (for details, see <a href="/doi/suppl/10.1021/acs.jmedchem.7b00076/suppl_file/jm7b00076_si_001.pdf" class="ext-link">Figure S3</a>).<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38, 39)</a></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Cancer Cell Inhibitory Activities of the Selected Compounds</h3><div class="NLM_p">On the basis of the enzymatic inhibitory potency against FGFR, compounds <b>2d</b>, <b>2m</b>, <b>2n</b>, <b>2p</b>, <b>3a</b>, <b>3b</b>, and <b>3m</b>–<b>3q</b> were selected to further evaluate their inhibitory activities against FGFR2-amplified cell line SNU16 (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Pan-FGFR inhibitor <b>16</b> was tested as a positive control. As shown in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>, the selected compounds exhibited moderate to potent inhibition. Overall, the cell-based antiproliferative results of the selected compounds generally agree with the FGFR inhibition results at the molecular level. Among them, compound <b>3m</b> demonstrated the best inhibitory activity against a cell assay for SNU16 with an IC<sub>50</sub> of 24.8 nM, which was thus selected for further investigation.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Antiproliferative Activities of Derivatives against FGFR-Expressing Cancer Cell Line SNU16<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd.</th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2d</b></td><td class="colsep0 rowsep0" align="char" char="±">677.7 ± 30.5</td><td class="colsep0 rowsep0" align="left"><b>3m</b></td><td class="colsep0 rowsep0" align="char" char="±">24.8 ± 0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2m</b></td><td class="colsep0 rowsep0" align="char" char="±">57.5 ± 3.7</td><td class="colsep0 rowsep0" align="left"><b>3n</b></td><td class="colsep0 rowsep0" align="char" char="±">313.3 ± 25.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2o</b></td><td class="colsep0 rowsep0" align="char" char="±">36.2 ± 2.9</td><td class="colsep0 rowsep0" align="left"><b>3o</b></td><td class="colsep0 rowsep0" align="char" char="±">293.5 ± 27.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2p</b></td><td class="colsep0 rowsep0" align="char" char="±">24.8 ± 3.3</td><td class="colsep0 rowsep0" align="left"><b>3p</b></td><td class="colsep0 rowsep0" align="char" char="±">288.6 ± 84.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3a</b></td><td class="colsep0 rowsep0" align="char" char="±">2281.3 ± 20.0</td><td class="colsep0 rowsep0" align="left"><b>3q</b></td><td class="colsep0 rowsep0" align="char" char="±">280.1 ± 43.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3b</b></td><td class="colsep0 rowsep0" align="char" char="±">249.0 ± 44.8</td><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="char" char="±">25.4 ± 1.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values are shown as the mean ± SD (nM) from two separate experiments.</p></div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Compounds <b>2p</b>, <b>3b</b>, <b>3m</b>, and <b>3n</b> as Multitarget Kinase Inhibitors</h3><div class="NLM_p">Compounds <b>2p</b>, <b>3b</b>, <b>3m</b>, and <b>3n</b> were distinguished for their remarkable potency against recombinant human FGFR kinase. Accordingly, we were prompted to investigate whether this potency was specifically against FGFR. As shown in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>, compounds <b>2p</b>, <b>3b</b>, <b>3m</b>, and <b>3n</b> also strongly inhibited the kinase activity of KDR, VEGFR-1, Ret, EGFR, DDR2, ABL, ErbB4, and c-Src with IC<sub>50</sub> values at the nanomole or subnanomole level. Compounds <b>2p</b>, <b>3b</b>, <b>3m</b>, and <b>3n</b> are thus multitargeted protein kinase inhibitors.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Kinase Panel Screening Data of Compounds <b>2p</b>, <b>3b</b>, <b>3m</b>, and <b>3n</b><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char="±">IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char="±"><b>2p</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>3b</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>3m</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>3n</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR1</td><td class="colsep0 rowsep0" align="char" char="±">55.8 ± 3.9</td><td class="colsep0 rowsep0" align="char" char="±">16.1 ± 4.5</td><td class="colsep0 rowsep0" align="char" char="±">18.0 ± 4.9</td><td class="colsep0 rowsep0" align="char" char="±">25.2 ± 8.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR2</td><td class="colsep0 rowsep0" align="char" char="±">8.6 ± 2.0</td><td class="colsep0 rowsep0" align="char" char="±">2.0 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">1.6 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">4.7 ± 0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR3</td><td class="colsep0 rowsep0" align="char" char="±">73.1 ± 4.3</td><td class="colsep0 rowsep0" align="char" char="±">23.0 ± 8.2</td><td class="colsep0 rowsep0" align="char" char="±">27.5 ± 9.4</td><td class="colsep0 rowsep0" align="char" char="±">15.9 ± 0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR4</td><td class="colsep0 rowsep0" align="char" char="±">61.7 ± 6.4</td><td class="colsep0 rowsep0" align="char" char="±">7.4 ± 3.2</td><td class="colsep0 rowsep0" align="char" char="±">299.4 ± 34.5</td><td class="colsep0 rowsep0" align="char" char="±">93.3 ± 19.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KDR</td><td class="colsep0 rowsep0" align="char" char="±">3.7 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">0.8 ± 0.0</td><td class="colsep0 rowsep0" align="char" char="±">1.7 ± 0.0</td><td class="colsep0 rowsep0" align="char" char="±">2.6 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ret</td><td class="colsep0 rowsep0" align="char" char="±">0.7 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">0.04 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">0.2 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">0.4 ± 0.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="char" char="±">3.1 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">4.2 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">4.7 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">8.1 ± 6.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR/T790M/L858R</td><td class="colsep0 rowsep0" align="char" char="±">8.6 ± 2.5</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">6.0 ± 5.9</td><td class="colsep0 rowsep0" align="char" char="±">1.3 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DDR2</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±">0.8 ± 0.0</td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ABL</td><td class="colsep0 rowsep0" align="char" char="±">6.6 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">4.3 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">2.9 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">6.1 ± 2.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ErbB4</td><td class="colsep0 rowsep0" align="char" char="±">5.3 ± 4.4</td><td class="colsep0 rowsep0" align="char" char="±">5.0 ± 4.9</td><td class="colsep0 rowsep0" align="char" char="±">6.2 ± 3.7</td><td class="colsep0 rowsep0" align="char" char="±">2.4 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">c-Src</td><td class="colsep0 rowsep0" align="char" char="±">3.9 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">6.4 ± 4.3</td><td class="colsep0 rowsep0" align="char" char="±">5.7 ± 2.8</td><td class="colsep0 rowsep0" align="char" char="±">6.0 ± 3.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">VEGFR-1</td><td class="colsep0 rowsep0" align="char" char="±">>10</td><td class="colsep0 rowsep0" align="char" char="±">>10</td><td class="colsep0 rowsep0" align="char" char="±">1–10</td><td class="colsep0 rowsep0" align="char" char="±">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IR</td><td class="colsep0 rowsep0" align="char" char="±">91.6 ± 21.2</td><td class="colsep0 rowsep0" align="char" char="±">431.2 ± 183.2</td><td class="colsep0 rowsep0" align="char" char="±">417.5 ± 112.6</td><td class="colsep0 rowsep0" align="char" char="±">887.6 ± 163.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IGF1R</td><td class="colsep0 rowsep0" align="char" char="±">>100</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFR-α</td><td class="colsep0 rowsep0" align="char" char="±">>100</td><td class="colsep0 rowsep0" align="char" char="±">>100</td><td class="colsep0 rowsep0" align="char" char="±">>100</td><td class="colsep0 rowsep0" align="char" char="±">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFR-β</td><td class="colsep0 rowsep0" align="char" char="±">>100</td><td class="colsep0 rowsep0" align="char" char="±">1–10</td><td class="colsep0 rowsep0" align="char" char="±">>10</td><td class="colsep0 rowsep0" align="char" char="±">1–10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Mer</td><td class="colsep0 rowsep0" align="char" char="±">30.9 ± 13.7</td><td class="colsep0 rowsep0" align="char" char="±">4.4 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">36.9 ± 20.8</td><td class="colsep0 rowsep0" align="char" char="±">7.1 ± 2.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ErbB2</td><td class="colsep0 rowsep0" align="char" char="±">1–10</td><td class="colsep0 rowsep0" align="char" char="±">1–10</td><td class="colsep0 rowsep0" align="char" char="±">>10</td><td class="colsep0 rowsep0" align="char" char="±">1–10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ALK</td><td class="colsep0 rowsep0" align="char" char="±">231.1 ± 14.3</td><td class="colsep0 rowsep0" align="char" char="±">93.9 ± 27.7</td><td class="colsep0 rowsep0" align="char" char="±">101.1 ± 29.3</td><td class="colsep0 rowsep0" align="char" char="±">155.5 ± 10.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LTK</td><td class="colsep0 rowsep0" align="char" char="±">299.5 ± 123.4</td><td class="colsep0 rowsep0" align="char" char="±">45.3 ± 15.3</td><td class="colsep0 rowsep0" align="char" char="±">122.9 ± 52.4</td><td class="colsep0 rowsep0" align="char" char="±">68.5 ± 11.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ROS1</td><td class="colsep0 rowsep0" align="char" char="±">272.9 ± 101.3</td><td class="colsep0 rowsep0" align="char" char="±">168.5 ± 87.2</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EPH-A2</td><td class="colsep0 rowsep0" align="char" char="±">>10</td><td class="colsep0 rowsep0" align="char" char="±">>100</td><td class="colsep0 rowsep0" align="char" char="±">>10</td><td class="colsep0 rowsep0" align="char" char="±">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">c-Kit</td><td class="colsep0 rowsep0" align="char" char="±">>10</td><td class="colsep0 rowsep0" align="char" char="±">>10</td><td class="colsep0 rowsep0" align="char" char="±">>10</td><td class="colsep0 rowsep0" align="char" char="±">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Erk2</td><td class="colsep0 rowsep0" align="char" char="±">960.2 ± 87.4</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td><td class="colsep0 rowsep0" align="char" char="±">574.7 ± 120.1</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">c-Met</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td><td class="colsep0 rowsep0" align="char" char="±">196.1 ± 43.7</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AXL</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tyro3</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK1</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK4</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK6</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values are shown as the mean ± SD (nM) from two separate experiments.</p></div></div></div><div class="NLM_p last">Given the relatively high inhibitory potency of compounds <b>2p</b>, <b>3b</b>, <b>3m</b>, and <b>3n</b> against FGFR, RET, DDR2, EGFR, and VEGFR2, together with the fact that these kinases are important targetable oncogenes in NSCLC and the most verified targets in cancer therapy, we took these kinases as representatives to evaluate the inhibitory effects of <b>2p</b>, <b>3b</b>, <b>3m</b>, and <b>3n</b> on protein kinase-associated events. Interestingly, small structural changes may significantly alter the activity profile of the compounds. For example, compound <b>3b</b> is much more potent than <b>3m</b> on FGFR4 and EGFR inhibition, and <b>3m</b> is more active than <b>3b</b> on IR and IGF1R. Such variance in the kinase activity profile may provide an opportunity for future fine-tuning the efficacy of the compounds, suggesting that these series of compounds are usefully multitargeted instead of nonspecific promiscuous kinase inhibitors, whereas compounds <b>2p</b>, <b>3b</b>, <b>3m</b>, and <b>3n</b> displayed no obvious inhibitory activity against CDK1, CDK4, or CDK6 (IC<sub>50</sub> > 1000 nM, <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>) compared with those of 3,5-disubstituted pyridine analogues reported by Cheng et al.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Compound <b>3m</b> Blocks Protein Kinase Phosphorylation and Downstream Signaling in Cells</h3><div class="NLM_p">We then investigated the intracellular targeting activity of compound <b>3m</b>. Cell lines expressing kinase both naturally and genetically were tested (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). First, the effects of compound <b>3m</b> on FGFR phosphorylation and downstream signaling were investigated in representative FGFR-addicted cancer cells. Compound <b>3m</b> inhibited the phosphorylation of FGFRs and FGFR substrate 2α (FRS2α), the key adaptor protein largely specific to FGFR, in a dose-dependent manner in the tested cell lines. The phosphorylation of PLCγ and ERK, key downstream molecules of FGFR,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> was also inhibited upon compound <b>3m</b> treatment (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A–C). Similar results were observed in DDR2, RET, and KDR-driven NCI-H2286, Ba/F3/CCDC6-RET Ba/F3/TEL-KDR cells, respectively (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>D–F). Together, compound <b>3m</b> exhibited effective inhibition of FGFR, DDR2, RET, and KDR activation and their signaling.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/medium/jm-2017-00076u_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>3m</b> blocks tyrosine kinase phosphorylation and downstream signaling in cells. Cells including NCI-H1581(A, left), KG1(A, right), KATOIII(B), UMUC14(C), NCI-H2286(D), Ba/F3/CCDC6-RET(E), and Ba/F3/TEL-KDR (F) treated with <b>3m</b> for 2 h at the indicated concentrations were lysed and subjected to Western blot analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00076&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Compound <b>3m</b> Impairs Cancer Cell Proliferation</h3><div class="NLM_p">To further detect the antiproliferative effects of compound <b>3m</b> targeting the indicated protein kinases, we extended the panel to human cancer cells and model cell lines that harbor frequently occurring oncogenic forms of FGFRs, DDR2, EGFR, RET, and KDR (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). As expected, compound <b>3m</b> remarkably inhibited cell proliferation of FGFR-addicted cancer cells, including NCI-H1581, KG1, KATOIII, SNU16, UMUC14, and RT112, with IC<sub>50</sub> values of 391.2, 14.5, 155.7, 24.8, 128.1, and 122.5 nM, respectively. Moreover, compound <b>3m</b> significantly inhibited the proliferation of HCC827 and PC-9 cells, which feature EGFR-dependent cell growth, whereas compound <b>3m</b> inhibited the proliferation of H1975 cells with an IC<sub>50</sub> value of 447.6 nM. A similar observation was also obtained in DDR2, RET, and KDR constitutively activated NCI-H2286, Ba/F3/CCDC6-RET, and Ba/F3/TEL-KDR cells, respectively. Our results indicate that <b>3m</b> inhibits cancer cell proliferation by targeting multikinase.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Effects of <b>3m</b> on Cancer Cell Proliferation<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell Line</th><th class="colsep0 rowsep0" align="center">gene alteration</th><th class="colsep0 rowsep0" align="center" char="±"><b>3m</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>16</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCI-H1581</td><td class="colsep0 rowsep0" align="left">FGFR1 amplification</td><td class="colsep0 rowsep0" align="char" char="±">391.2 ± 14.5</td><td class="colsep0 rowsep0" align="char" char="±">62.6 ± 5.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KG1</td><td class="colsep0 rowsep0" align="left">FGFR1OP2-FGFR1</td><td class="colsep0 rowsep0" align="char" char="±">14.5 ± 4.5</td><td class="colsep0 rowsep0" align="char" char="±">16.1 ± 0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KATOIII</td><td class="colsep0 rowsep0" align="left">FGFR2 amplification</td><td class="colsep0 rowsep0" align="char" char="±">155.7 ± 21.2</td><td class="colsep0 rowsep0" align="char" char="±">14.1 ± 2.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SNU16</td><td class="colsep0 rowsep0" align="left">FGFR2 amplification</td><td class="colsep0 rowsep0" align="char" char="±">24.8 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">10.5 ± 2.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">UMUC14</td><td class="colsep0 rowsep0" align="left">FGFR3 mutation</td><td class="colsep0 rowsep0" align="char" char="±">128.1 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">27.1 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RT112</td><td class="colsep0 rowsep0" align="left">FGFR3 amplification</td><td class="colsep0 rowsep0" align="char" char="±">122.5 ± 4.1</td><td class="colsep0 rowsep0" align="char" char="±">27.0 ± 1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HCC827</td><td class="colsep0 rowsep0" align="left">EGFR Exon 19 del</td><td class="colsep0 rowsep0" align="char" char="±">0.4 ± 0.0</td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PC-9</td><td class="colsep0 rowsep0" align="left">EGFR L858R</td><td class="colsep0 rowsep0" align="char" char="±">5.3 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H1975</td><td class="colsep0 rowsep0" align="left">EGFR T790M/L858R</td><td class="colsep0 rowsep0" align="char" char="±">447.6 ± 45.7</td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCI-H2286</td><td class="colsep0 rowsep0" align="left">DDR2 I638F mutation</td><td class="colsep0 rowsep0" align="char" char="±">317.2 ± 22.1</td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ba/F3/CCDC6-RET</td><td class="colsep0 rowsep0" align="left">CCDC6-RET fusion</td><td class="colsep0 rowsep0" align="char" char="±">315.7 ± 1.7</td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ba/F3/TEL-KDR</td><td class="colsep0 rowsep0" align="left">TEL-KDR fusion</td><td class="colsep0 rowsep0" align="char" char="±">9.8 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values are shown as the mean ± SD (nM) from two separate experiments.</p></div></div></div></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> PK Profiles of Compound <b>3m</b></h3><div class="NLM_p">Pharmacokinetic (PK) profile of the candidate <b>3m</b> was assessed in Sprague–Dawley (SD) rats and CD-1 mice (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). Compound <b>3m</b> proved to be suitable for oral administration with a high area under the curve (AUC<sub>0–∞</sub> = 18705.5 ng h mL<sup>–1</sup>), long half-life (<i>t</i><sub>1/2</sub> = 8.0 h), and good oral bioavailability (<i>F</i> = 60%) in SD rats. Compound <b>3m</b> displayed a lower half-life of 2.72 h and AUC<sub>0-t</sub> of 2402 ng h mL<sup>–1</sup> at 20 mg/kg oral administration in CD-1 mice than in SD rats. The binding ratio of plasma protein to <b>3m</b> was 99.56%. Accordingly, the free <i>C</i><sub>max</sub> for <b>3m</b> in the plasma at the doses of 20 and 5 mg/kg were calculated as 10.2 and 1.1 nM, respectively.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. PK Profiles of Compound <b>3m</b> in SD Rats and CD-1 Mice</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>0–<i>t</i></sub> (ng h mL<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>0–∞</sub> (ng h mL<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">MRT (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">CLz (L h<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">rats</td><td class="colsep0 rowsep0" align="left"><b>3m</b> (po)</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">2077.4</td><td class="colsep0 rowsep0" align="char" char=".">16629.1</td><td class="colsep0 rowsep0" align="char" char=".">18705.5</td><td class="colsep0 rowsep0" align="char" char=".">6.72</td><td class="colsep0 rowsep0" align="char" char=".">8.0</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">60%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3m</b> (iv)</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td><td class="colsep0 rowsep0" align="char" char=".">6535.2</td><td class="colsep0 rowsep0" align="char" char=".">13748.4</td><td class="colsep0 rowsep0" align="char" char=".">13756.9</td><td class="colsep0 rowsep0" align="char" char=".">3.41</td><td class="colsep0 rowsep0" align="char" char=".">2.39</td><td class="colsep0 rowsep0" align="char" char=".">0.727</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">mice</td><td class="colsep0 rowsep0" align="left"><b>3m</b> (po)</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">0.42</td><td class="colsep0 rowsep0" align="char" char=".">961</td><td class="colsep0 rowsep0" align="char" char=".">2402</td><td class="colsep0 rowsep0" align="char" char=".">2409</td><td class="colsep0 rowsep0" align="char" char=".">3.59</td><td class="colsep0 rowsep0" align="char" char=".">2.72</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3m</b> (po)</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">1.50</td><td class="colsep0 rowsep0" align="char" char=".">106</td><td class="colsep0 rowsep0" align="char" char=".">289</td><td class="colsep0 rowsep0" align="char" char=".">290</td><td class="colsep0 rowsep0" align="char" char=".">3.74</td><td class="colsep0 rowsep0" align="char" char=".">2.50</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div></div></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> <i>In Vivo</i> Antitumor Efficacy</h3><div class="NLM_p">Classic FGFR-dependent H1581 lung cancer cell line-derived xenografts were used for <i>in vivo</i> efficacy evaluation; nude mice bearing NCI-H1581 tumors were randomized and treated with <b>3m</b> at doses of 5 or 20 mg/kg for 14 consecutive days. As shown in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>, compound <b>3m</b> could suppress tumor growth in a dose-dependent manner with tumor growth inhibition ratios (TGI) of 37.8 and 66.1% at doses of 5 and 20 mg/kg, respectively, indicating that compound <b>3m</b> elicited marked antitumor efficacy in the NCI-H1581 tumor model. However, because adverse reactions such as diarrhea, emaciation, and body weight loss were observed in mice dosed at 20 mg/kg, treatment with higher doses was not carried out further in this study.</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/medium/jm-2017-00076u_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>3m</b> inhibits tumor growth in NCI-H1581 xenografts. Mice were randomly assigned to control vehicle and treatment groups (<i>n</i> = 6 in treated group, <i>n</i> = 12 in vehicle group) when the tumor volume reached 100–150 mm<sup>3</sup>. The control groups were given vehicle alone, and the treatment groups received <b>3m</b> or <b>16</b> at the indicated doses via oral administration once daily for 14 days. The results are expressed as the mean ± SEM with *<i>p</i> < 0.05, **<i>p</i> < 0.01, and ***<i>p</i> < 0.001 vs control group determined using Student’s <i>t</i> test. The relative tumor volume (RTV) was measured on the final day of the study for the drug-treated mice compared with the control mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00076&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30383" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30383" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, a novel series of pyridin-3-amine derivatives were designed, synthesized, and evaluated as multitargeted protein kinase inhibitors for the treatment of NSCLC. Hit <b>1</b> was disclosed by <i>in silico</i> screening and sequentially validated by <i>in vitro</i> experiments. On the basis of the binding mode analysis of compound <b>1</b> and FGFR kinase domain, SARs focusing on the hydrophobic pocket, hinge region and P-loop region were further explored. Among them, compound <b>3m</b> showed high potency against FGFR kinase (FGFR1: IC<sub>50</sub> = 18.0 nM; FGFR2: IC<sub>50</sub> = 1.6 nM; FGFR3: IC<sub>50</sub> = 27.5 nM). Furthermore, <i>in vivo</i> pharmacology evaluations of compound <b>3m</b> showed significant antitumor activity (TGI = 66.1%) in FGFR-driven NCI-H1581 xenografts with good PK profiles in SD rats and CD-1 mice. The multikinase activity of the lead molecule may also account for the observed toxicities in the xenograft, which could be mitigated by structural optimization to remove EGFR WT activity. This novel scaffold of potent protein kinase inhibitors demonstrated a promising prospect for the discovery and development of new NSCLC agents and drugs.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73507" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73507" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Virtual Screening</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Protein Structure Preparation</h4><div class="NLM_p last">The protein structure of human FGFR1 complexed with <b>15</b> was downloaded from the Protein Data Bank (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3TT0">3TT0</a>). Protein structure was prepared with the Protein Preparation Wizard module in the Maestro program (Maestro, version 10; Schrödinger, LLC: New York, NY, 2015), which includes adding hydrogen atoms, deleting nonstructural water with less than 3 hydrogen bonds to nonwaters, optimizing the hydrogen bond assignment with exhaustive sampling, optimizing the hydrogen bond network, flip orientations, and tautomeric states of Gln, Asn, and His residues, and finally performing a restrained minimization on the ligand–protein complexes with the OPLS3 force field converged heavy atoms to RMSD of 0.3 Å. Specific parameters were set as the default.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Ligand Preparation</h4><div class="NLM_p last">Our own compound database containing 6,059 structural varieties of compounds was used as the ligand database for virtual screening. The ligand database was prepared using the LigPrep module in the Schrödinger software (LigPrep, version 3.4; Schrödinger, LLC: New York, NY, 2015) to generate accurate, energy-minimized 3D molecular structures. The parameters in LigPrep were set to retain the specific chirality of compounds and generate at most 32 conformations and one lowest energy ring conformation per ligand; in addition, the ionization of compounds were determined at pH 7.0 ± 2.0 by Epik (Epik, version 3.2; Schrödinger, LLC: New York, NY, 2015).</div></div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Molecular Docking</h4><div class="NLM_p">Molecular docking followed the standard Glide protocol. A receptor grid file was generated based on the prepared protein structure. The enclosing box centered at ligand <b>15</b> with a size of 18 Å, and extra precision molecular docking was carried out with the receptor grid file and the prepared ligand database. Epik state penalties were added to the docking score, and other parameters were used the default settings for other parameters. Virtual screening was completed with the standard Glide protocol. Altogether, 1120 of the top-ranked poses with XP GScore lower than −7.0 kcal/mol were kept. After removal of the duplicated compounds, the remaining 949 compounds were clustered with the software of BIOVIA Pipeline Pilot (Pipeline Pilot, version 7.5, BIOVIA, <a href="http://accelrys.com" class="extLink">http://accelrys.com</a>). The molecular fingerprints ECFP4 used for clustering analysis, and the average compound number of each cluster, was set to 20. For each cluster, only one or two compounds with higher docking scores were retained, and finally, 57 compounds were selected for biological evaluation. The putative binding modes of multisubstituted pyridin-3-amine derivatives were all generated using Glide in XP mode with the same procedures described above.</div><div id="sec4_2_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> Chemistry</h5><div class="NLM_p last">The reagents (chemicals) were purchased and used without further purification. Nuclear magnetic resonance (NMR) spectroscopy was performed on a Bruker AMX-400 and AMX-300 NMR (IS as TMS). Chemical shifts were reported in parts per million (ppm, δ) downfield from tetramethylsilane. Proton coupling patterns were described as singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m), and broad (br). Low- and high-resolution mass spectra (LRMS and HRMS) were given with electric, electrospray, and matrix-assisted laser desorption ionization (EI, ESI, and MALDI) produced by a Finnigan MAT-95, LCQ-DECA spectrometer and IonSpec 4.7 T. Optical rotations were measured using a 1 mL cell with a 10 mm path length on an Auto pol V PLVS matic polarimeter and were reported as follows: [α]<sup>20</sup><sub>D</sub> (<i>c</i> g/100 mL, in solvent). HPLC analysis of all final biological testing compounds was carried out on an Agilent 1260 Series HPLC with an Agilent Extend-C18 column (150 × 4.6 mm, 5 μm). All final compounds achieved a minimum of 95% purity.</div></div><div id="sec4_2_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> (<i>R</i>)-2-(6-(Furan-3-yl)-5-(3-methyl-1<i>H</i>-indazol-5-yl)pyridin-3-ylamino)-2-phenylethanol (<b>1</b>)</h5><div class="NLM_p last">To (<i>R</i>)-2-(6-chloro-5-(3-methyl-1<i>H</i>-indazol-5-yl)pyridin-3-ylamino)-2-phenylethanol <b>11a</b> (150 mg, 0.40 mmol), furan-3-ylboronic acid (66 mg, 0.59 mmol), and K<sub>2</sub>CO<sub>3</sub>(137 mg, 0.99 mmol) in a microwave tube were added 3 mL of dioxane and 300 μL of water followed by the addition of Pd(dppf)<sub>2</sub>Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub> (32 mg, 0.04 mmol). The reaction mixture was filled with argon and then heated at 120 °C for 2 h under microwave heating. TLC and LC–MS showed completion of the reaction. The resulting reaction medium was diluted with DCM (20 mL) and filtered. The filtrate was washed with water (20 mL) three times, and the aqueous layer was re-extracted by DCM (20 mL). The combined organic layer was washed by brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The crude product was purified by silica gel column chromatography (MeOH/CH<sub>2</sub>Cl<sub>2</sub>, 1/50–1/20) to afford compound <b>1</b> as a pale yellow solid (69 mg, 42% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.90 (d, <i>J</i> = 2.8 Hz, 1H), 7.47–7.41 (m, 3H), 7.39 (d, <i>J</i> = 8.7 Hz, 1H), 7.35 (t, <i>J</i> = 7.5 Hz, 2H), 7.27 (d, <i>J</i> = 7.3 Hz, 1H), 7.24 (t, <i>J</i> = 1.7 Hz, 1H), 7.12 (d, <i>J</i> = 8.6 Hz, 1H), 6.94 (dd, <i>J</i> = 1.5, 0.8 Hz, 1H), 6.92 (d, <i>J</i> = 2.8 Hz, 1H), 6.15 (dd, <i>J</i> = 1.8, 0.8 Hz, 1H), 4.53 (dd, <i>J</i> = 7.8, 4.7 Hz, 1H), 3.79 (ddd, <i>J</i> = 19.1, 11.2, 6.3 Hz, 2H), 2.51 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 142.4, 142.1, 141.4, 140.1, 139.8, 136.8, 135.7, 133.9, 131.6, 128.3 (2C), 127.4, 127.1 (2C), 127.0, 126.4, 122.3, 121.2, 119.7, 110.6, 109.9, 65.9, 59.1, 11.7. Mp 175.3–178.2 °C. [α]<sup>20</sup><sub>D</sub> −16.5 (<i>c</i> 0.085, CH<sub>3</sub>OH). LRMS [M + H]<sup>+</sup>: 411.1. HRMS (ESI) calcd for C<sub>25</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 411.1816; found: 411.1818.</div></div><div id="sec4_2_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> (<i>R</i>)-2-(6-(Furan-2-yl)-5-(3-methyl-1<i>H</i>-indazol-5-yl)pyridin-3-ylamino)-2-phenylethanol (<b>2a</b>)</h5><div class="NLM_p last">Compound <b>2a</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 41%. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 7.93 (d, <i>J</i> = 2.5 Hz, 1H), 7.45–7.39 (m, 4H), 7.36 (d, <i>J</i> = 7.3 Hz, 2H), 7.33–7.30 (m, 1H), 7.29–7.24 (m, 1H), 7.08 (dd, <i>J</i> = 8.6, 1.4 Hz, 1H), 6.89 (d, <i>J</i> = 2.7 Hz, 1H), 6.20 (dd, <i>J</i> = 3.3, 1.8 Hz, 1H), 5.66 (d, <i>J</i> = 3.1 Hz, 1H), 4.54 (dd, <i>J</i> = 7.7, 4.9 Hz, 1H), 3.79 (ddd, <i>J</i> = 19.0, 11.2, 6.3 Hz, 2H), 2.50 (s, 3H). Mp 130.8–134.1 °C. [α]<sup>20</sup><sub>D</sub> −16.5 (<i>c</i> 0.085, CH<sub>3</sub>OH). LRMS: [M + H]<sup>+</sup>: 411.1. HRMS (ESI) calcd for C<sub>25</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 411.1821; found: 411.1814.</div></div><div id="sec4_2_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> (<i>R</i>)-2-(5-(3-Methyl-1<i>H</i>-indazol-5-yl)-6-(thiophen-3-yl)pyridin-3-ylamino)-2-phenylethanol (<b>2b</b>)</h5><div class="NLM_p last">Compound <b>2b</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 44%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.92 (d, <i>J</i> = 2.7 Hz, 1H), 7.44 (d, <i>J</i> = 7.2 Hz, 2H), 7.40–7.33 (m, 3H), 7.32–7.25 (m, 2H), 7.13 (dd, <i>J</i> = 5.0, 3.0 Hz, 1H), 7.02 (dd, <i>J</i> = 4.3, 1.4 Hz, 1H), 7.00 (t, <i>J</i> = 1.3 Hz, 1H), 6.97 (d, <i>J</i> = 2.7 Hz, 1H), 6.73 (dd, <i>J</i> = 5.0, 1.2 Hz, 1H), 4.56 (dd, <i>J</i> = 7.8, 4.7 Hz, 1H), 3.80 (ddd, <i>J</i> = 19.1, 11.2, 6.3 Hz, 1H), 2.47 (s, 3H). Mp 212.7–215.4 °C. [α]<sup>20</sup><sub>D</sub> −26.7 (<i>c</i> 0.09, CH<sub>3</sub>OH). LRMS [M + H]<sup>+</sup>: 427.1. HRMS (ESI) calcd for C<sub>25</sub>H<sub>23</sub>N<sub>4</sub>OS [M + H]<sup>+</sup>: 427.1587; found: 427.1589.</div></div><div id="sec4_2_1_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> (<i>R</i>)-2-(5-(3-Methyl-1<i>H</i>-indazol-5-yl)-6-(thiophen-2-yl)pyridin-3-ylamino)-2-phenylethanol (<b>2c</b>)</h5><div class="NLM_p last">Compound <b>2c</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 46%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.90 (d, <i>J</i> = 2.7 Hz, 1H), 7.44–7.39 (m, 3H), 7.36–7.31 (m, 3H), 7.28–7.24 (m, 1H), 7.15 (dd, <i>J</i> = 5.1, 1.1 Hz, 1H), 7.07 (dd, <i>J</i> = 8.6, 1.5 Hz, 1H), 6.87 (d, <i>J</i> = 2.7 Hz, 1H), 6.68 (dd, <i>J</i> = 5.1, 3.7 Hz, 1H), 6.37 (dd, <i>J</i> = 3.7, 1.1 Hz, 1H), 4.53 (dd, <i>J</i> = 7.8, 4.7 Hz, 1H), 3.78 (ddd, <i>J</i> = 19.1, 11.2, 6.3 Hz, 2H), 2.48 (s, 3H). Mp 117.6–121.3 °C. [α]<sup>20</sup><sub>D</sub> −25.0 (<i>c</i> 0.08, CH<sub>3</sub>OH). LRMS [M + H]<sup>+</sup>: 427.1. HRMS (ESI) calcd for C<sub>25</sub>H<sub>23</sub>N<sub>4</sub>OS [M + H]<sup>+</sup>: 427.1593; found: 427.1591.</div></div><div id="sec4_2_1_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> (<i>R</i>)-2-(5-(3-Methyl-1<i>H</i>-indazol-5-yl)-6-phenylpyridin-3-ylamino)-2-phenylethanol (<b>2d</b>)</h5><div class="NLM_p last">Compound <b>2d</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 41%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.95 (d, <i>J</i> = 2.7 Hz, 1H), 7.46 (d, <i>J</i> = 7.1 Hz, 2H), 7.38 (t, <i>J</i> = 7.5 Hz, 2H), 7.34 (dd, <i>J</i> = 1.5, 0.8 Hz, 1H), 7.29 (t, <i>J</i> = 7.3 Hz, 1H), 7.20 (dd, <i>J</i> = 8.7, 0.7 Hz, 1H), 7.16–7.12 (m, 5H), 7.03 (d, <i>J</i> = 2.7 Hz, 1H), 6.93 (dd, <i>J</i> = 8.6, 1.6 Hz, 1H), 4.57 (dd, <i>J</i> = 7.9, 4.7 Hz, 1H), 3.81 (ddd, <i>J</i> = 19.0, 11.2, 6.3 Hz, 2H), 2.44 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 143.9, 143.1, 141.4, 141.2, 140.6, 139.8, 135.7, 134.0, 131.9, 129.3 (2C), 128.3 (2C), 127.9, 127.4 (2C), 127.1 (2C), 127.0, 126.2, 122.4, 121.4, 119.9, 109.5, 65.9, 59.8, 11.6. Mp 130.3–132.7 °C. [α]<sup>20</sup><sub>D</sub> −35.6 (<i>c</i> 0.09, CH<sub>3</sub>OH). LRMS [M + H]<sup>+</sup>: 421.2. HRMS (ESI) calcd for C<sub>27</sub>H<sub>25</sub>N<sub>4</sub>O [M + H]<sup>+</sup>: 421.2023; found: 421.2022.</div></div><div id="sec4_2_1_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> (<i>R</i>)-2-(3-(3-Methyl-1<i>H</i>-indazol-5-yl)-2,3′-bipyridin-5-ylamino)-2-phenylethanol (<b>2e</b>)</h5><div class="NLM_p last">Compound <b>2e</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 48%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.33–8.16 (m, 2H), 8.04 (d, <i>J</i> = 2.7 Hz, 1H), 7.67–7.58 (m, 1H), 7.45 (d, <i>J</i> = 7.3 Hz, 2H), 7.40–7.31 (m, 3H), 7.31–7.18 (m, 3H), 7.02 (d, <i>J</i> = 2.7 Hz, 1H), 6.94 (dd, <i>J</i> = 8.6, 1.5 Hz, 1H), 4.59 (dd, <i>J</i> = 7.7, 4.7 Hz, 1H), 3.81 (ddd, <i>J</i> = 19.1, 11.2, 6.3 Hz, 2H), 2.45 (s, 3H). Mp 135.0–137.2 °C. [α]<sup>20</sup><sub>D</sub> −43.5 (<i>c</i> 0.085g/100 mL, CH<sub>3</sub>OH). LRMS [M + H]<sup>+</sup>: 422.2. HRMS (ESI) calcd for C<sub>26</sub>H<sub>24</sub>N<sub>5</sub>O [M + H]<sup>+</sup>: 422.1981; found: 422.1982.</div></div><div id="sec4_2_1_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> (<i>R</i>)-2-(5-(3-Methyl-1<i>H</i>-indazol-5-yl)-6-(quinolin-8-yl)pyridin-3-ylamino)-2-phenylethanol (<b>2f</b>)</h5><div class="NLM_p last">Compound <b>2f</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 46%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.57 (s, 1H), 8.22 (d, <i>J</i> = 7.6 Hz, 1H), 8.01 (s, 1H), 7.82 (d, <i>J</i> = 7.8 Hz, 1H), 7.55–7.43 (m, 4H), 7.41–7.32 (m, 3H), 7.28 (t, <i>J</i> = 7.3 Hz, 1H), 7.21 (s, 1H), 7.17 (d, <i>J</i> = 2.1 Hz, 1H), 6.97 (d, <i>J</i> = 8.6 Hz, 1H), 6.89 (dd, <i>J</i> = 8.7, 1.4 Hz, 1H), 4.62 (dd, <i>J</i> = 7.7, 4.7 Hz, 1H), 3.83 (ddd, <i>J</i> = 19.0, 11.2, 6.3 Hz, 2H), 2.25 (s, 3H). Mp 160.9–163.7 °C. [α]<sup>20</sup><sub>D</sub> −32.2 (<i>c</i> 0.09, CH<sub>3</sub>OH). LRMS [M + H]<sup>+</sup>: 472.2. HRMS (ESI) calcd for C<sub>30</sub>H<sub>26</sub>N<sub>5</sub>O [M + H]<sup>+</sup>: 472.2137; found: 472.2126.</div></div><div id="sec4_2_1_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> (<i>R</i>)-2-(6-(1<i>H</i>-Indol-7-yl)-5-(3-methyl-1<i>H</i>-indazol-5-yl)pyridin-3-ylamino)-2-phenylethanol (<b>2g</b>)</h5><div class="NLM_p last">Compound <b>2g</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 38%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.02 (d, <i>J</i> = 2.7 Hz, 1H), 7.48 (d, <i>J</i> = 7.3 Hz, 2H), 7.42–7.33 (m, 4H), 7.29 (t, <i>J</i> = 7.3 Hz, 1H), 7.12 (d, <i>J</i> = 2.7 Hz, 1H), 7.08 (d, <i>J</i> = 3.2 Hz, 1H), 7.06 (d, <i>J</i> = 8.7 Hz, 1H), 6.90 (dd, <i>J</i> = 8.7, 1.5 Hz, 1H), 6.74 (t, <i>J</i> = 7.6 Hz, 1H), 6.64 (dd, <i>J</i> = 7.3, 0.9 Hz, 1H), 6.36 (d, <i>J</i> = 3.2 Hz, 1H), 4.60 (dd, <i>J</i> = 7.9, 4.7 Hz, 1H), 3.82 (ddd, <i>J</i> = 19.1, 11.2, 6.3 Hz, 2H), 2.37 (s, 3H). Mp 167.3–170.8 °C. [α]<sup>20</sup><sub>D</sub> −54.7 (<i>c</i> 0.075, CH<sub>3</sub>OH). LRMS [M + H]<sup>+</sup>: 460.1. HRMS (ESI) calcd for C<sub>29</sub>H<sub>26</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 460.2132; found: 460.2136.</div></div><div id="sec4_2_1_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> (<i>R</i>)-2-(6-(2-Fluorophenyl)-5-(3-methyl-1<i>H</i>-indazol-5-yl)pyridin-3-ylamino)-2-phenylethanol (<b>2h</b>)</h5><div class="NLM_p last">Compound <b>2h</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 37%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.96 (d, <i>J</i> = 2.6 Hz, 1H), 7.45 (d, <i>J</i> = 7.3 Hz, 2H), 7.36 (t, <i>J</i> = 7.5 Hz, 2H), 7.31–7.13 (m, 5H), 7.06 (t, <i>J</i> = 7.1 Hz, 1H), 7.03 (d, <i>J</i> = 2.7 Hz, 1H), 6.97 (dd, <i>J</i> = 8.7, 1.3 Hz, 1H), 6.86–6.80 (m, 1H), 4.57 (dd, <i>J</i> = 7.7, 4.6 Hz, 1H), 3.81 (ddd, <i>J</i> = 19.1, 11.2, 6.3 Hz, 2H), 2.38 (s, 3H). Mp 155.1–157.6 °C. [α]<sup>20</sup><sub>D</sub> −65.3 (<i>c</i> 0.095, CH<sub>3</sub>OH). LRMS [M + H]<sup>+</sup>: 439.1. HRMS (ESI) calcd for C<sub>27</sub>H<sub>24</sub>N<sub>4</sub>O F [M + H]<sup>+</sup>: 439.1934; found: 439.1945.</div></div><div id="sec4_2_1_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> (<i>R</i>)-2-(5-(3-Methyl-1<i>H</i>-indazol-5-yl)-6-(2-(trifluoromethyl)phenyl)pyridin-3-ylamino)-2-phenylethanol (<b>2i</b>)</h5><div class="NLM_p last">Compound <b>2i</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 51%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.94 (s, 1H), 7.62 (s, 1H), 7.46 (d, <i>J</i> = 7.3 Hz, 2H), 7.43–7.25 (m, 5H), 7.18 (d, <i>J</i> = 8.6 Hz, 2H), 7.14–6.85 (m, 3H), 4.57 (dd, <i>J</i> = 7.3, 4.8 Hz, 1H), 3.82 (ddd, <i>J</i> = 19.1, 11.2, 6.4 Hz, 2H), 2.38 (s, 3H). Mp 140.8–142.7 °C. [α]<sup>20</sup><sub>D</sub> −46.3 (<i>c</i> 0.095, CH<sub>3</sub>OH). LRMS [M + H]<sup>+</sup>: 489.1. HRMS (ESI) calcd for C<sub>28</sub>H<sub>24</sub>N<sub>4</sub>OF<sub>3</sub> [M + H]<sup>+</sup>: 489.1982; found: 489.1984.</div></div><div id="sec4_2_1_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> (<i>R</i>)-<i>N</i>-(2-(5-(2-Hydroxy-1-phenylethylamino)-3-(3-methyl-1<i>H</i>-indazol-5-yl)pyridin-2-yl)phenyl)acetamide (<b>2j</b>)</h5><div class="NLM_p last">Compound <b>2j</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 48%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.99 (d, <i>J</i> = 2.7 Hz, 1H), 7.52 (d, <i>J</i> = 8.1 Hz, 1H), 7.46 (d, <i>J</i> = 7.3 Hz, 2H), 7.36 (t, <i>J</i> = 7.5 Hz, 2H), 7.31–7.25 (m, 2H), 7.22–7.14 (m, 2H), 7.10 (dd, <i>J</i> = 7.7, 1.5 Hz, 1H), 7.06 (d, <i>J</i> = 2.7 Hz, 1H), 7.01 (t, <i>J</i> = 7.5 Hz, 1H), 6.97 (dd, <i>J</i> = 8.7, 1.5 Hz, 1H), 4.58 (dd, <i>J</i> = 7.9, 4.7 Hz, 1H), 3.81 (ddd, <i>J</i> = 19.1, 11.2, 6.3 Hz, 2H), 2.40 (s, 3H), 1.78 (s, 3H). Mp 170.3–172.9 °C. [α]<sup>20</sup><sub>D</sub> −9.0 (<i>c</i> 0.1, CH<sub>3</sub>OH). LRMS [M + H]<sup>+</sup>: 478.2. HRMS (ESI) calcd for C<sub>29</sub>H<sub>28</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 478.2243; found: 478.2232.</div></div><div id="sec4_2_1_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> (<i>R</i>)-2-(6-(2-(Hydroxymethyl)phenyl)-5-(3-methyl-1<i>H</i>-indazol-5-yl)pyridin-3-ylamino)-2-phenylethanol (<b>2k</b>)</h5><div class="NLM_p last">Compound <b>2k</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 49%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.94 (d, <i>J</i> = 2.6 Hz, 1H), 7.46 (d, <i>J</i> = 7.4 Hz, 2H), 7.42–7.34 (m, 3H), 7.31–7.25 (m, 2H), 7.21 (t, <i>J</i> = 7.5 Hz, 1H), 7.15 (d, <i>J</i> = 8.7 Hz, 1H), 7.07 (d, <i>J</i> = 2.6 Hz, 1H), 7.03 (t, <i>J</i> = 7.5 Hz, 1H), 6.96 (d, <i>J</i> = 8.7 Hz, 1H), 6.91 (d, <i>J</i> = 7.6 Hz, 1H), 4.57 (dd, <i>J</i> = 7.7, 4.7 Hz, 1H), 4.28 (s, 2H), 3.81 (ddd, <i>J</i> = 19.1, 11.2, 6.3 Hz, 2H), 2.39 (s, 3H). Mp 140.4–142.6 °C. [α]<sup>20</sup><sub>D</sub> −52.2 (<i>c</i> 0.115, CH<sub>3</sub>OH). LRMS [M + H]<sup>+</sup>: 451.2. HRMS (ESI) calcd for C<sub>28</sub>H<sub>27</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 451.2134; found: 451.2128.</div></div><div id="sec4_2_1_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> (<i>R</i>)-2-(5-(2-Hydroxy-1-phenylethylamino)-3-(3-methyl-1<i>H</i>-indazol-5-yl)pyridin-2-yl)benzamide (<b>2l</b>)</h5><div class="NLM_p last">Compound <b>2l</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 35%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.89 (d, <i>J</i> = 2.6 Hz, 1H), 7.49 (dd, <i>J</i> = 7.4, 1.5 Hz, 1H), 7.45 (d, <i>J</i> = 7.2 Hz, 2H), 7.36 (dd, <i>J</i> = 13.9, 6.6 Hz, 3H), 7.30–7.19 (m, 3H), 7.16 (d, <i>J</i> = 8.7 Hz, 1H), 7.10 (dd, <i>J</i> = 8.7, 1.5 Hz, 1H), 7.03 (d, <i>J</i> = 2.7 Hz, 1H), 7.00 (dd, <i>J</i> = 7.4, 1.5 Hz, 1H), 4.54 (dd, <i>J</i> = 7.8, 4.7 Hz, 1H), 3.79 (ddd, <i>J</i> = 19.2, 11.2, 6.3 Hz, 2H), 2.39 (s, 3H). Mp 216.5–219.8 °C. [α]<sup>20</sup><sub>D</sub> −30.5 (<i>c</i> 0.095, CH<sub>3</sub>OH). LRMS [M + H]<sup>+</sup>: 464.2. HRMS (ESI) calcd for C<sub>28</sub>H<sub>26</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 464.2087; found: 464.2078.</div></div><div id="sec4_2_1_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> (<i>R</i>)-2-(5-(2-Hydroxy-1-phenylethylamino)-3-(3-methyl-1<i>H</i>-indazol-5-yl)pyridin-2-yl)phenol (<b>2m</b>)</h5><div class="NLM_p last">Compound <b>2m</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 32%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.61 (s, 1H), 10.97 (s, 1H), 7.95 (d, <i>J</i> = 2.7 Hz, 1H), 7.48–7.40 (m, 3H), 7.34 (t, <i>J</i> = 7.5 Hz, 2H), 7.29–7.18 (m, 2H), 7.01–6.91 (m, 3H), 6.78–6.67 (m, 2H), 6.64 (d, <i>J</i> = 6.5 Hz, 1H), 6.43 (t, <i>J</i> = 7.5 Hz, 1H), 5.05 (t, <i>J</i> = 5.6 Hz, 1H), 4.55 (dd, <i>J</i> = 12.0, 6.3 Hz, 1H), 3.74–3.60 (m, 2H), 2.41 (s, 3H). Mp 239.3–241.9 °C. [α]<sup>20</sup><sub>D</sub> −26.25 (<i>c</i> 0.08, CH<sub>3</sub>OH). LRMS [M + H]<sup>+</sup>: 437.1. HRMS (ESI) calcd for C<sub>27</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 437.1972; found: 437.1971.</div></div><div id="sec4_2_1_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> (<i>R</i>)-2-(6-(2-Methoxyphenyl)-5-(3-methyl-1<i>H</i>-indazol-5-yl)pyridin-3-ylamino)-2-phenylethanol (<b>2n</b>)</h5><div class="NLM_p last">Compound <b>7n</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 49%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.90 (d, <i>J</i> = 2.7 Hz, 1H), 7.47 (d, <i>J</i> = 7.3 Hz, 2H), 7.37 (t, <i>J</i> = 7.4 Hz, 2H), 7.31–7.25 (m, 1H), 7.24–7.15 (m, 4H), 7.06–6.97 (m, 2H), 6.89 (d, <i>J</i> = 7.5 Hz, 1H), 6.69 (d, <i>J</i> = 8.2 Hz, 1H), 4.56 (dd, <i>J</i> = 7.9, 4.6 Hz, 1H), 3.81 (ddd, <i>J</i> = 19.1, 11.2, 6.3 Hz, 2H), 3.23 (s, 3H), 2.37 (s, 3H). Mp 151.2–152.5 °C. [α]<sup>20</sup><sub>D</sub> −23.3 (<i>c</i> 0.09, CH<sub>3</sub>OH). LRMS [M + H]<sup>+</sup>: 451.2. HRMS (ESI) calcd for C<sub>28</sub>H<sub>27</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 451.2129; found: 451.2127.</div></div><div id="sec4_2_1_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> (<i>R</i>)-3-(5-(2-Hydroxy-1-phenylethylamino)-3-(3-methyl-1<i>H</i>-indazol-5-yl)pyridin-2-yl)phenol (<b>2o</b>)</h5><div class="NLM_p last">Compound <b>2o</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 38%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.60 (s, 1H), 9.10 (s, 1H), 7.99 (d, <i>J</i> = 2.7 Hz, 1H), 7.46–7.40 (m, 3H), 7.33 (t, <i>J</i> = 7.5 Hz, 2H), 7.25 (d, <i>J</i> = 7.3 Hz, 1H), 7.22 (d, <i>J</i> = 8.3 Hz, 1H), 6.89–6.81 (m, 3H), 6.66–6.61 (m, 1H), 6.53–6.43 (m, 3H), 5.02 (t, <i>J</i> = 5.6 Hz, 1H), 4.53 (dd, <i>J</i> = 12.1, 6.4 Hz, 1H), 3.71–3.59 (m, 2H), 2.43 (s, 3H). Mp 173.8–175.1 °C. [α]<sup>20</sup><sub>D</sub> −40.0 (<i>c</i> 0.085, CH<sub>3</sub>OH). LRMS [M + H]<sup>+</sup>: 437.1. HRMS (ESI) calcd for C<sub>27</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 437.1972; found: 437.1975.</div></div><div id="sec4_2_1_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> (<i>R</i>)-4-Chloro-2-(5-(2-hydroxy-1-phenylethylamino)-3-(3-methyl-1<i>H</i>-indazol-5-yl)pyridin-2-yl)phenol (<b>2p</b>)</h5><div class="NLM_p last">Compound <b>2p</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 47%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.93 (d, <i>J</i> = 2.7 Hz, 1H), 7.45 (d, <i>J</i> = 7.2 Hz, 2H), 7.40–7.38 (m, 1H), 7.36 (t, <i>J</i> = 7.5 Hz, 2H), 7.30–7.25 (m, 2H), 7.06–7.01 (m, 2H), 6.96 (dd, <i>J</i> = 8.7, 2.6 Hz, 1H), 6.79 (d, <i>J</i> = 2.6 Hz, 1H), 6.65 (d, <i>J</i> = 8.7 Hz, 1H), 4.57 (dd, <i>J</i> = 7.8, 4.7 Hz, 1H), 3.81 (ddd, <i>J</i> = 19.1, 11.2, 6.3 Hz, 2H), 2.45 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 154.7, 143.4, 141.3, 141.3, 140.9, 139.9, 137.0, 132.0, 131.6, 130.0, 128.4, 127.7, 127.1, 127.0, 122.4, 121.9, 121.4, 119.6, 117.6, 109.6, 65.9, 59.1, 11.7. Mp 138.7–140.1 °C. [α]<sup>20</sup><sub>D</sub> −32.0 (<i>c</i> 0.075, CH<sub>3</sub>OH). LRMS [M + H]<sup>+</sup>: 471.1. HRMS (ESI) calcd for C<sub>27</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub>Cl [M + H]<sup>+</sup>: 471.1582; found: 471.1580.</div></div><div id="sec4_2_1_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> (<i>R</i>)-4-Chloro-2-(5-(2-hydroxy-1-phenylethylamino)-3-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-5-yl)pyridin-2-yl)phenol (<b>3a</b>)</h5><div class="NLM_p last">Compound <b>3a</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 50%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.14 (d, <i>J</i> = 1.9 Hz, 1H), 7.99 (d, <i>J</i> = 2.7 Hz, 1H), 7.86 (d, <i>J</i> = 2.0 Hz, 1H), 7.49–7.44 (m, 2H), 7.36 (t, <i>J</i> = 7.5 Hz, 2H), 7.28 (t, <i>J</i> = 7.3 Hz, 1H), 7.06–7.00 (m, 3H), 6.57 (dd, <i>J</i> = 7.4, 1.6 Hz, 1H), 4.59 (dd, <i>J</i> = 7.8, 4.8 Hz, 1H), 3.82 (ddd, <i>J</i> = 19.1, 11.2, 6.3 Hz, 2H), 2.46 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 153.7, 151.3, 148.6, 143.5, 141.3, 141.2, 141.0, 134.0, 133.4, 130.5, 128.5, 128.4, 128.3 (2C), 128.0, 127.1 (3C), 121.8, 120.8, 117.2, 113.5, 65.9, 59.0, 12.1. Mp 142.9–145.0 °C. [α]<sup>20</sup><sub>D</sub> −21.3 (<i>c</i> 0.075, CH<sub>3</sub>OH). LRMS [M + H]<sup>+</sup>: 472.1. HRMS (ESI) calcd for C<sub>26</sub>H<sub>23</sub>N<sub>5</sub>O<sub>2</sub>Cl [M + H]<sup>+</sup>: 472.1535; found: 472.1538.</div></div><div id="sec4_2_1_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> (<i>R</i>)-4-Chloro-2-(5-(2-hydroxy-1-phenylethylamino)-3-(isoquinolin-6-yl)pyridin-2-yl)phenol (<b>3b</b>)</h5><div class="NLM_p last">Compound <b>3b</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 53%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 9.15 (s, 1H), 8.38 (d, <i>J</i> = 5.8 Hz, 1H), 8.00 (d, <i>J</i> = 2.7 Hz, 1H), 7.92 (d, <i>J</i> = 8.6 Hz, 1H), 7.68 (d, <i>J</i> = 6.8 Hz, 2H), 7.49–7.42 (m, 2H), 7.40–7.32 (m, 3H), 7.27 (t, <i>J</i> = 7.3 Hz, 1H), 7.08 (d, <i>J</i> = 2.7 Hz, 1H), 6.98 (dd, <i>J</i> = 8.7, 2.6 Hz, 1H), 6.91 (d, <i>J</i> = 2.6 Hz, 1H), 6.59 (d, <i>J</i> = 8.7 Hz, 1H), 4.63–4.57 (m, 1H), 3.81 (ddd, <i>J</i> = 19.1, 1.2, 6.3 Hz, 2H). Mp 124.9–127.5 °C. [α]<sup>20</sup><sub>D</sub> −48.0 (<i>c</i> 0.075, CH<sub>3</sub>OH). LRMS [M + H]<sup>+</sup>: 468.1. HRMS (ESI) calcd for C<sub>28</sub>H<sub>23</sub>N<sub>3</sub>O<sub>2</sub>Cl [M + H]<sup>+</sup>: 468.1473; found: 468.1477.</div></div><div id="sec4_2_1_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> (<i>R</i>)-5-(2-(5-Chloro-2-hydroxyphenyl)-5-(2-hydroxy-1-phenylethylamino)pyridin-3-yl)indolin-2-one (<b>3c</b>)</h5><div class="NLM_p last">Compound <b>3c</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 46%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.75 (s, 1H), 10.40 (s, 1H), 7.94 (d, <i>J</i> = 2.4 Hz, 1H), 7.42 (d, <i>J</i> = 7.4 Hz, 2H), 7.33 (t, <i>J</i> = 7.5 Hz, 2H), 7.23 (t, <i>J</i> = 7.1 Hz, 1H), 7.02 (dd, <i>J</i> = 8.7, 2.6 Hz, 1H), 6.97 (s, 1H), 6.86 (d, <i>J</i> = 2.8 Hz, 2H), 6.82 (d, <i>J</i> = 2.6 Hz, 1H), 6.72–6.62 (m, 3H), 5.03 (t, <i>J</i> = 5.5 Hz, 1H), 4.53 (dd, <i>J</i> = 12.1, 6.3 Hz, 1H), 3.70–3.59 (m, 2H), 3.40 (s, 2H). Mp 126.1–128.5 °C. [α]<sup>20</sup><sub>D</sub> −15.2 (<i>c</i> 0.105, CH<sub>3</sub>OH). LRMS [M + H]<sup>+</sup>: 472.1. HRMS (ESI) calcd for C<sub>27</sub>H<sub>23</sub>N<sub>3</sub>O<sub>3</sub>Cl [M + H]<sup>+</sup>: 472.1422; found: 472.1420.</div></div><div id="sec4_2_1_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> (<i>R</i>)-<i>N</i>-(4-(2-(5-Chloro-2-hydroxyphenyl)-5-(2-hydroxy-1-phenylethylamino)pyridin-3-yl)phenyl)acetamide (<b>3d</b>)</h5><div class="NLM_p last">Compound <b>3d</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 61%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.90 (d, <i>J</i> = 2.7 Hz, 1H), 7.46–7.41 (m, 4H), 7.35 (t, <i>J</i> = 7.5 Hz, 2H), 7.27 (t, <i>J</i> = 7.3 Hz, 1H), 7.04–6.97 (m, 3H), 6.95 (d, <i>J</i> = 2.7 Hz, 1H), 6.82 (d, <i>J</i> = 2.6 Hz, 1H), 6.67 (d, <i>J</i> = 8.7 Hz, 1H), 4.55 (dd, <i>J</i> = 7.9, 4.7 Hz, 1H), 3.79 (ddd, <i>J</i> = 19.1, 11.2, 6.3 Hz, 2H), 2.11 (s, 3H). Mp 129.0–130.2 °C. [α]<sup>20</sup><sub>D</sub> −28.0 (<i>c</i> 0.1, CH<sub>3</sub>OH). LRMS [M-H]<sup>+</sup>: 472.1. HRMS (ESI) calcd for C<sub>27</sub>H<sub>23</sub>N<sub>3</sub>O<sub>3</sub>Cl [M – H]<sup>+</sup>: 472.1433; found: 472.1442.</div></div><div id="sec4_2_1_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> (<i>R</i>)-4-Chloro-2-(5-(2-hydroxy-1-phenylethylamino)-3-(1<i>H</i>-indol-5-yl)pyridin-2-yl)phenol (<b>3e</b>)</h5><div class="NLM_p last">Compound <b>3e</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 53%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.88 (d, <i>J</i> = 2.7 Hz, 1H), 7.44 (d, <i>J</i> = 7.2 Hz, 2H), 7.35 (t, <i>J</i> = 7.5 Hz, 2H), 7.31 (d, <i>J</i> = 1.2 Hz, 1H), 7.29–7.22 (m, 2H), 7.22 (d, <i>J</i> = 3.1 Hz, 1H), 7.04 (d, <i>J</i> = 2.7 Hz, 1H), 6.91 (dd, <i>J</i> = 8.7, 2.6 Hz, 1H), 6.78 (dd, <i>J</i> = 8.4, 1.6 Hz, 1H), 6.73 (d, <i>J</i> = 2.6 Hz, 1H), 6.67 (d, <i>J</i> = 8.7 Hz, 1H), 6.38 (dd, <i>J</i> = 3.1, 0.7 Hz, 1H), 4.56 (dd, <i>J</i> = 7.7, 4.8 Hz, 1H), 3.80 (ddd, <i>J</i> = 19.1, 11.2, 6.3 Hz, 2H). Mp 116.7–121.5 °C. [α]<sup>20</sup><sub>D</sub> −37.0 (<i>c</i> 0.1, CH<sub>3</sub>OH). LRMS [M + H]<sup>+</sup>: 456.1. HRMS (ESI) calcd for C<sub>27</sub>H<sub>23</sub>N<sub>3</sub>O<sub>2</sub>Cl [M + H]<sup>+</sup>: 456.1473; found: 456.1470.</div></div><div id="sec4_2_1_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> (<i>S</i>)-4-Chloro-2-(5-(2-hydroxy-1-phenylethylamino)-3-(3-methyl-1<i>H</i>-indazol-5-yl)pyridin-2-yl)phenol (<b>3f</b>)</h5><div class="NLM_p last">Compound <b>3f</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 46%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.93 (d, <i>J</i> = 2.7 Hz, 1H), 7.45 (d, <i>J</i> = 7.7 Hz, 2H), 7.42–7.32 (m, 3H), 7.31–7.23 (m, 2H), 7.03 (dd, <i>J</i> = 10.5, 2.1 Hz, 2H), 6.96 (dd, <i>J</i> = 8.7, 2.6 Hz, 1H), 6.79 (d, <i>J</i> = 2.6 Hz, 1H), 6.64 (d, <i>J</i> = 8.7 Hz, 1H), 4.56 (dd, <i>J</i> = 7.7, 4.8 Hz, 1H), 3.80 (ddd, <i>J</i> = 19.1, 11.2, 6.3 Hz, 2H), 2.45 (s, 3H). Mp 136.5–139.1 °C. [α]<sup>20</sup><sub>D</sub> +28.3 (<i>c</i> 0.06, CH<sub>3</sub>OH). LRMS [M + H]<sup>+</sup>: 471.1. HRMS (ESI) calcd for C<sub>27</sub>H<sub>24</sub>N<sub>4</sub>O <sub>2</sub>Cl [M + H]<sup>+</sup>: 471.1588; found: 471.1578.</div></div><div id="sec4_2_1_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> (<i>S</i>)-4-Chloro-2-(3-(3-methyl-1<i>H</i>-indazol-5-yl)-5-(1-phenylethylamino)pyridin-2-yl)phenol (<b>3g</b>)</h5><div class="NLM_p last">Compound <b>8g</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 52%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.87 (d, <i>J</i> = 2.7 Hz, 1H), 7.40 (d, <i>J</i> = 7.2 Hz, 2H), 7.36 (d, <i>J</i> = 0.6 Hz, 1H), 7.32 (t, <i>J</i> = 7.6 Hz, 2H), 7.26 (dd, <i>J</i> = 8.6, 0.6 Hz, 1H), 7.22 (t, <i>J</i> = 7.3 Hz, 1H), 7.01 (dd, <i>J</i> = 8.7, 1.6 Hz, 1H), 6.97–6.90 (m, 2H), 6.77 (d, <i>J</i> = 2.6 Hz, 1H), 6.64 (d, <i>J</i> = 8.7 Hz, 1H), 4.56 (q, <i>J</i> = 6.7 Hz, 1H), 2.44 (s, 3H), 1.54 (d, <i>J</i> = 6.8 Hz, 3H). Mp 107.3–109.0 °C. [α]<sup>20</sup><sub>D</sub> +23.2 (<i>c</i> 0.095, CH<sub>3</sub>OH). LRMS [M + H]<sup>+</sup>: 455.1. HRMS (ESI) calcd for C<sub>27</sub>H<sub>24</sub>N<sub>4</sub>OCl [M + H]<sup>+</sup>: 455.1639; found: 455.1627.</div></div><div id="sec4_2_1_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> (<i>R</i>)-4-Chloro-2-(5-(2-hydroxyethylamino)-3-(3-methyl-1<i>H</i>-indazol-5-yl)pyridin-2-yl)phenol (<b>3h</b>)</h5><div class="NLM_p last">Compound <b>3h</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 52%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.01 (d, <i>J</i> = 2.7 Hz, 1H), 7.62 (s, 1H), 7.34 (d, <i>J</i> = 8.6 Hz, 1H), 7.19 (d, <i>J</i> = 8.7 Hz, 1H), 7.15 (d, <i>J</i> = 2.7 Hz, 1H), 6.75 (td, <i>J</i> = 8.4, 3.0 Hz, 1H), 6.69 (dd, <i>J</i> = 8.8, 5.0 Hz, 1H), 6.57 (dd, <i>J</i> = 9.8, 3.0 Hz, 1H), 3.78 (t, <i>J</i> = 5.7 Hz, 2H), 3.35 (t, <i>J</i> = 5.7 Hz, 2H), 2.50 (s, 3H). Mp 226.5–227.8 °C. LRMS:[M + H]<sup>+</sup>: 379. HRMS (ESI) calcd for C<sub>21</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub>F [M + H]<sup>+</sup>: 379.1565; found: 379.1566.</div></div><div id="sec4_2_1_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> (<i>R</i>)-4-Chloro-2-(5-(3-hydroxypropylamino)-3-(3-methyl-1<i>H</i>-indazol-5-yl)pyridin-2-yl)phenol (<b>3i</b>)</h5><div class="NLM_p last">Compound <b>3i</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 54%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.99 (d, <i>J</i> = 2.8 Hz, 1H), 7.62 (s, 1H), 7.35 (d, <i>J</i> = 8.6 Hz, 1H), 7.19 (dd, <i>J</i> = 8.6, 1.5 Hz, 1H), 7.11 (d, <i>J</i> = 2.8 Hz, 1H), 6.74 (dd, <i>J</i> = 8.0, 3.1 Hz, 1H), 6.72–6.66 (m, 1H), 6.56 (dd, <i>J</i> = 9.8, 3.0 Hz, 1H), 3.72 (t, <i>J</i> = 6.2 Hz, 2H), 2.50 (s, 3H), 1.89 (dd, <i>J</i> = 13.1, 6.6 Hz, 2H). Mp 249.6–252.3 °C. LRMS [M + H]<sup>+</sup>: 393.2. HRMS (ESI) calcd for C<sub>22</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub>F [M + H]<sup>+</sup>: 393.1721; found: 393.1721.</div></div><div id="sec4_2_1_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> (<i>R</i>)-4-Chloro-2-(5-(2-hydroxy-2-phenylethylamino)-3-(3-methyl-1<i>H</i>-indazol-5-yl)pyridin-2-yl)phenol (<b>3j</b>)</h5><div class="NLM_p last">Compound <b>3j</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 44%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.98 (d, <i>J</i> = 2.7 Hz, 1H), 7.57 (s, 1H), 7.44 (d, <i>J</i> = 7.2 Hz, 2H), 7.34 (t, <i>J</i> = 7.6 Hz, 3H), 7.26 (s, 1H), 7.14 (dd, <i>J</i> = 8.6, 1.5 Hz, 1H), 7.08 (d, <i>J</i> = 2.7 Hz, 1H), 6.97 (dd, <i>J</i> = 8.7, 2.6 Hz, 1H), 6.82 (d, <i>J</i> = 2.6 Hz, 1H), 6.67 (d, <i>J</i> = 8.7 Hz, 1H), 3.50–3.39 (m, 2H), 2.49 (s, 3H). Mp 156.7–159.3 °C. [α]<sup>20</sup><sub>D</sub> +20.9 (<i>c</i> 0.11, CH<sub>3</sub>OH). LRMS [M + H]<sup>+</sup>: 471.1. HRMS (ESI) calcd for C<sub>27</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub>Cl [M + H]<sup>+</sup>: 471.1588; found: 471.1586.</div></div><div id="sec4_2_1_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> (<i>R</i>)-2-(5-(2-Hydroxy-1-phenylethylamino)-3-(3-methyl-1<i>H</i>-indazol-5-yl)pyridin-2-yl)-4-methylphenol (<b>3k</b>)</h5><div class="NLM_p last">Compound <b>3k</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 42%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.91 (d, <i>J</i> = 2.7 Hz, 1H), 7.45 (d, <i>J</i> = 7.4 Hz, 2H), 7.41–7.32 (m, 3H), 7.27 (t, <i>J</i> = 7.3 Hz, 1H), 7.22 (d, <i>J</i> = 8.6 Hz, 1H), 7.07–7.00 (m, 2H), 6.81 (dd, <i>J</i> = 8.2, 2.2 Hz, 1H), 6.63 (d, <i>J</i> = 1.9 Hz, 1H), 6.57 (d, <i>J</i> = 8.2 Hz, 1H), 4.56 (dd, <i>J</i> = 7.8, 4.7 Hz, 1H), 3.80 (ddd, <i>J</i> = 19.1, 11.2, 6.3 Hz, 2H), 2.43 (s, 3H), 1.92 (s, 3H). Mp 93.2–95.0 °C. [α]<sup>20</sup><sub>D</sub> −15.6 (<i>c</i> 0.09, CH<sub>3</sub>OH). LRMS [M + H]<sup>+</sup>: 451.2. HRMS (ESI) calcd for C<sub>28</sub>H<sub>27</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 451.2134; found: 451.2123.</div></div><div id="sec4_2_1_30" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> (<i>R</i>)-2-(5-(2-Hydroxy-1-phenylethylamino)-3-(3-methyl-1<i>H</i>-indazol-5-yl)pyridin-2-yl)-4-isopropylphenol (<b>3l</b>)</h5><div class="NLM_p last">Compound <b>3l</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 31%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.92 (d, <i>J</i> = 2.1 Hz, 1H), 7.45 (d, <i>J</i> = 7.4 Hz, 2H), 7.38–7.33 (m, 3H), 7.28 (d, <i>J</i> = 8.1 Hz, 2H), 7.08–7.01 (m, 2H), 6.82 (d, <i>J</i> = 8.0 Hz, 1H), 6.63 (d, <i>J</i> = 8.3 Hz, 1H), 6.58 (s, 1H), 4.56 (dd, <i>J</i> = 7.3, 4.8 Hz, 1H), 3.80 (ddd, <i>J</i> = 19.0, 11.1, 6.4 Hz, 2H), 2.44–2.35 (m, 4H), 0.73 (dd, <i>J</i> = 6.7, 4.0 Hz, 6H). Mp 128.6–131.6 °C. [α]<sup>20</sup><sub>D</sub> −18.8 (<i>c</i> 0.08, CH<sub>3</sub>OH). LRMS [M + H]<sup>+</sup>: 479.2. HRMS (ESI) calcd for C<sub>30</sub>H<sub>31</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 479.2442; found: 479.2443.</div></div><div id="sec4_2_1_31" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> (<i>R</i>)-4-Fluoro-2-(5-(2-hydroxy-1-phenylethylamino)-3-(3-methyl-1<i>H</i>-indazol-5-yl)pyridin-2-yl)phenol (<b>3m</b>)</h5><div class="NLM_p last">Compound <b>3m</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 46%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.65 (s, 1H), 10.73 (s, 1H), 7.99–7.92 (m, 1H), 7.44 (d, <i>J</i> = 7.2 Hz, 3H), 7.34 (t, <i>J</i> = 7.5 Hz, 2H), 7.29 (d, <i>J</i> = 8.7 Hz, 1H), 7.25 (t, <i>J</i> = 7.3 Hz, 1H), 6.99–6.94 (m, 2H), 6.80 (td, <i>J</i> = 8.5, 3.2 Hz, 1H), 6.70 (d, <i>J</i> = 6.5 Hz, 1H), 6.65 (dd, <i>J</i> = 8.9, 5.1 Hz, 1H), 6.49 (dd, <i>J</i> = 10.2, 3.1 Hz, 1H), 5.05 (t, <i>J</i> = 5.6 Hz, 1H), 4.56 (dd, <i>J</i> = 12.1, 6.4 Hz, 1H), 3.67 (dt, <i>J</i> = 12.0, 6.0 Hz, 2H), 2.42 (s, 3H). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD) δ 157.8, 155.9, 153.3, 145.0, 143.7, 143.4 141.7, 139.1, 133.5, 133.4, 129.8, 129.5, 128.6, 128.2, 127.1 (d, <i>J</i> = 7.5 Hz), 124.2, 123.5, 121.3, 118.0 (d, <i>J</i> = 12.1 Hz), 117.9 (d, <i>J</i> = 3.7 Hz), 115.8 (d, <i>J</i> = 23.1 Hz), 110.7, 67.7, 61.2, 11.6. Mp 144.5–147.9 °C. [α]<sup>20</sup><sub>D</sub> −27.4 (<i>c</i> 0.095, CH<sub>3</sub>OH). LRMS [M + H]<sup>+</sup>: 455.2. HRMS (ESI) calcd for C<sub>27</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub>F [M + H]<sup>+</sup>: 455.1878; found: 455.1877.</div></div><div id="sec4_2_1_32" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> (<i>R</i>)-5-Fluoro-2-(5-(2-hydroxy-1-phenylethylamino)-3-(3-methyl-1<i>H</i>-indazol-5-yl)pyridin-2-yl)phenol (<b>3n</b>)</h5><div class="NLM_p last">Compound <b>3n</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 44%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.92 (d, <i>J</i> = 2.7 Hz, 1H), 7.46 (d, <i>J</i> = 7.4 Hz, 2H), 7.40–7.34 (m, 3H), 7.31–7.24 (m, 2H), 7.07–7.01 (m, 2H), 6.78 (dd, <i>J</i> = 8.2, 7.1 Hz, 1H), 6.43 (dd, <i>J</i> = 10.6, 2.6 Hz, 1H), 6.25 (td, <i>J</i> = 8.6, 2.2 Hz, 1H), 4.57 (dd, <i>J</i> = 7.8, 4.7 Hz, 1H), 3.81 (ddd, <i>J</i> = 19.1, 11.2, 6.3 Hz, 2H), 2.46 (s, 3H). Mp 140.8–143.1 °C. [α]<sup>20</sup><sub>D</sub> −25.5 (<i>c</i> 0.11, CH<sub>3</sub>OH). LRMS [M + H]<sup>+</sup>: 455.1. HRMS (ESI) calcd for C<sub>27</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub>F [M + H]<sup>+</sup>: 455.1878; found: 455.1883.</div></div><div id="sec4_2_1_33" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> (<i>R</i>)-2-Fluoro-6-(5-(2-hydroxy-1-phenylethylamino)-3-(3-methyl-1<i>H</i>-indazol-5-yl)pyridin-2-yl)phenol (<b>3o</b>)</h5><div class="NLM_p last">Compound <b>3o</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 39%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.94 (d, <i>J</i> = 2.7 Hz, 1H), 7.46 (d, <i>J</i> = 7.2 Hz, 2H), 7.40–7.35 (m, 3H), 7.29 (d, <i>J</i> = 7.3 Hz, 1H), 7.25 (d, <i>J</i> = 8.6 Hz, 1H), 7.07–7.01 (m, 2H), 6.87 (ddd, <i>J</i> = 10.8, 8.1, 1.5 Hz, 1H), 6.62 (d, <i>J</i> = 7.8 Hz, 1H), 6.48 (td, <i>J</i> = 8.0, 5.0 Hz, 1H), 4.58 (dd, <i>J</i> = 7.8, 4.7 Hz, 1H), 3.81 (ddd, <i>J</i> = 19.1, 11.2, 6.3 Hz, 2H), 2.45 (s, 3H). Mp 135.6–138.3 °C. [α]<sup>20</sup><sub>D</sub> −32.3 (<i>c</i> 0.065, CH<sub>3</sub>OH). LRMS [M – H]<sup>+</sup>: 453.2. HRMS (ESI) calcd for C<sub>27</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub>F [M – H]<sup>+</sup>: 453.1732; found: 453.1739.</div></div><div id="sec4_2_1_34" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> (<i>R</i>)-4,5-Difluoro-2-(5-(2-hydroxy-1-phenylethylamino)-3-(3-methyl-1<i>H</i>-indazol-5-yl)pyridin-2-yl)phenol (<b>3p</b>)</h5><div class="NLM_p last">Compound <b>3p</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 40%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.93 (d, <i>J</i> = 2.7 Hz, 1H), 7.48–7.40 (m, 3H), 7.37 (t, <i>J</i> = 7.6 Hz, 2H), 7.34–7.26 (m, 2H), 7.04 (dd, <i>J</i> = 8.6, 1.5 Hz, 1H), 7.02 (d, <i>J</i> = 2.7 Hz, 1H), 6.65 (dd, <i>J</i> = 11.9, 9.3 Hz, 1H), 6.55 (dd, <i>J</i> = 12.1, 7.1 Hz, 1H), 4.57 (dd, <i>J</i> = 7.8, 4.7 Hz, 1H), 3.81 (ddd, <i>J</i> = 19.1, 11.3, 6.3 Hz, 2H), 2.48 (s, 3H). Mp 146.8–149.2 °C. [α]<sup>20</sup><sub>D</sub> −23.8 (<i>c</i> 0.08, CH<sub>3</sub>OH). LRMS [M + H]<sup>+</sup>: 473.2. HRMS (ESI) calcd for C<sub>27</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub>F<sub>2</sub> [M + H]<sup>+</sup>: 473.1784; found: 473.1781.</div></div><div id="sec4_2_1_35" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> (<i>R</i>)-2,4-Difluoro-6-(5-(2-hydroxy-1-phenylethylamino)-3-(3-methyl-1<i>H</i>-indazol-5-yl)pyridin-2-yl)phenol (<b>3q</b>)</h5><div class="NLM_p last">Compound <b>3q</b> was prepared in a similar manner as described for compound <b>1</b>. Yield: 37%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.97 (d, <i>J</i> = 2.7 Hz, 1H), 7.51–7.46 (m, 2H), 7.43 (dd, <i>J</i> = 1.5, 0.8 Hz, 1H), 7.39 (t, <i>J</i> = 7.5 Hz, 2H), 7.34–7.28 (m, 2H), 7.07 (dd, <i>J</i> = 8.6, 1.6 Hz, 1H), 7.05 (d, <i>J</i> = 2.7 Hz, 1H), 6.80–6.73 (m, 1H), 6.41 (ddd, <i>J</i> = 9.6, 3.0, 1.9 Hz, 1H), 4.60 (dd, <i>J</i> = 7.9, 4.8 Hz, 1H), 3.83 (ddd, <i>J</i> = 19.1, 11.2, 6.3 Hz, 2H), 2.49 (s, 3H). Mp 143.5–145.2 °C. [α]<sup>20</sup><sub>D</sub> −24.3(<i>c</i> 0.09, CH<sub>3</sub>OH). LRMS [M – H]<sup>+</sup>: 471.1. HRMS (ESI) calcd for C<sub>27</sub>H<sub>21</sub>N<sub>4</sub>O<sub>2</sub>F<sub>2</sub> [M – H]<sup>+</sup>: 471.1638; found: 471.1646.</div></div><div id="sec4_2_1_36" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> 1-(5-Bromo-2-fluorophenyl)ethanone (<b>5a</b>)</h5><div class="NLM_p last">To a stirred solution of 5-bromo-2-fluoro-benzaldehyde (8.00 g, 39.4 mmol) in anhydrous ether (150 mL) under argon atmosphere at 0 °C was added MeMgBr (17.1 mL, 3.0 M solution in ether, 51.2 mmol) slowly. After 1 h, water was slowly added to the reaction mixture, followed by 1 M HCl in an ice bath. The mixture was extracted with EA (200 mL) three times. The combined organic layer was washed by brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The obtained oil was mixed with dioxane (100 mL), followed by the addition of manganese dioxide (17.13 g, 197.0 mmol). The reaction mixture was heated at reflux for 4 h. The resulting mixture was cooled to room temperature and filtered. The filtrate was concentrated under vacuum and purified by silica gel column chromatography (EA/PE, 1/20–1/10) to afford <b>5a</b> (6.32g, 74%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.92 (dd, <i>J</i> = 6.4, 2.7 Hz, 1H), 7.72 (ddd, <i>J</i> = 8.7, 4.2, 2.7 Hz, 1H), 7.19 (dd, <i>J</i> = 10.7, 8.8 Hz, 1H), 2.59 (d, <i>J</i> = 4.7 Hz, 3H). LRMS [M + H]<sup>+</sup>: 217.0.</div></div><div id="sec4_2_1_37" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> 1-(5-Bromo-2-fluoropyridin-3-yl)ethanone (<b>5b</b>)</h5><div class="NLM_p last">Compound <b>5b</b> was prepared in a similar manner as described for compound <b>10a</b>. Yield: 71%. LRMS [M + H]<sup>+</sup>: 218.1.</div></div><div id="sec4_2_1_38" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> 5-Bromo-3-methyl-1<i>H</i>-indazole (<b>6a</b>)</h5><div class="NLM_p last">To a solution of hydrazine monohydrate (15 mL) was added 1-(5-bromo-2-fluorophenyl)ethanone <b>10a</b> (3.0 g, 13.82 mmol). The resulting mixture was refluxed for 24h and then cooled to room temperature. The mixture was poured over ice, and a pale brown solid was precipitated. The solid was collected by filtration and purified by silica gel column chromatography (EA/PE, 1/4–1/2) to afford <b>11a</b> (1.89 g, 65%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.87 (s, 1H), 7.44 (dd, <i>J</i> = 8.8, 1.3 Hz, 1H), 7.39 (d, <i>J</i> = 8.7 Hz, 1H), 2.52 (s, 3H). LRMS [M + H]<sup>+</sup>: 211.1.</div></div><div id="sec4_2_1_39" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> 5-Bromo-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine (<b>6b</b>)</h5><div class="NLM_p last">Compound <b>6b</b> was prepared in a similar manner as described for compound <b>6a</b>. Yield: 59%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.50 (d, <i>J</i> = 2.1 Hz, 1H), 8.37 (d, <i>J</i> = 2.1 Hz, 1H), 2.52 (s, 3H). LRMS [M + H]<sup>+</sup>: 212.1.</div></div><div id="sec4_2_1_40" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> <i>tert</i>-Butyl 3-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-indazole-1-carboxylate (<b>7a</b>)</h5><div class="NLM_p last">To a stirred mixture of 5-bromo-3-methyl-1<i>H</i>-indazole <b>6a</b> (2.0 g, 9.48 mmol) and triethylamine (2.0 mL, 14.21 mmol) in THF (20 mL) were added Boc<sub>2</sub>O (3.10 g, 14.21 mmol) and DMAP (116 mg, 0.95 mmol) at room temperature. After 4 h, TLC showed completion of the reaction. The resulting mixture was diluted with EA (40 mL) and washed by saturated aqueous citric acid (40 mL) two times. The organic phase was washed by brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The obtained solid was added to a mixture of 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (3.61 g, 14.21 mmol) and KOAc (2.33 g, 23.69 mmol) in dioxane (20 mL). The reaction vessel was evacuated and refilled with nitrogen (3 times), followed by the addition of Pd(dppf)<sub>2</sub>Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub> (32 mg, 0.04 mmol). The resulting mixture was stirred at 80 °C for 6 h and then cooled to room temperature. The mixture was diluted with EA (30 mL) and filtered. The filtrate was sequentially washed by water and brine and dried over anhydrous Na<sub>2</sub>SO<sub>4.</sub> The obtained organic solution was concentrated under vacuum and purified by silica gel column chromatography (EA/PE, 1/15–1/10) to afford compound <b>7a</b> as a white solid (2.17g, 64% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.15 (s, 1H), 8.09 (d, <i>J</i> = 8.3 Hz, 1H), 7.93 (dd, <i>J</i> = 8.4, 0.9 Hz, 1H), 2.61 (s, 3H), 1.71 (s, 9H), 1.37 (s, 12H). LRMS [M + H]<sup>+</sup>: 359.2.</div></div><div id="sec4_2_1_41" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> <i>tert</i>-Butyl 3-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine-1-carboxylate (<b>7b</b>)</h5><div class="NLM_p last">Compound <b>7b</b> was prepared in a similar manner as described for compound <b>6a.</b> Yield: 51%. LRMS [M + H]<sup>+</sup>: 360.1.</div></div><div id="sec4_2_1_42" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> 3-Bromo-2-chloro-5-iodopyridine (<b>9</b>)</h5><div class="NLM_p last">To a solution of 5N aqueous HCl (100 mL) was added 5-bromo-6-chloropyridin-3-amine (15 g, 72.30 mmol), which was then cooled to 0 °C. An aqueous solution of NaNO<sub>2</sub> (7.48 g, 108.5 mmol) was dropwise added to the former stirred mixture in an ice bath. After 1 h, to the reaction mixture was very slowly added an aqueous solution of KI (26.41 g, 159.1 mmol) in an ice bath. The temperature was gradually restored to room temperature, followed by continuous stirring until no generation of nitrogen was observed. Thereafter, the solution was alkalized with sodium hydroxide in an ice bath until the pH reached 10–11. The aqueous layer was then extracted with EA (300 mL) two times. The organic layer was washed with saturated aqueous sodium thiosulfate and brine, which was then dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. The crude product was purified by silica gel column chromatography (EA/PE, 0–1/50) to afford compound <b>9</b> as a white solid (20.5 g, 89% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.68 (d, <i>J</i> = 2.0 Hz, 1H), 8.67 (d, <i>J</i> = 2.0 Hz, 1H). LRMS [M + H]<sup>+</sup>: 319.9.</div></div><div id="sec4_2_1_43" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> (<i>R</i>)-2-(5-Bromo-6-chloropyridin-3-ylamino)-2-phenylethanol (<b>10</b>)</h5><div class="NLM_p last">To a stirred mixture of (<i>R</i>)-2-amino-2-phenylethanol (1.24 g, 9.05 mmol) and K<sub>3</sub>PO<sub>4</sub> (3.20 g, 15.08 mmol) in isopropanol (20 mL) was added 3-bromo-2-chloro-5-iodopyridine <b>9</b> (2.4 g, 7.54 mmol) and ethane-1,2-diol (0.385 mL, 7.54 mmol). The reaction vessel was evacuated and refilled with nitrogen (3 times), followed by the addition of CuI (144 mg, 0.75 mmol). The resulting mixture was stirred at 80 °C for 18 h and then cooled to room temperature. The mixture was diluted with EA (30 mL) and filtered. The filtrate was sequentially washed by water and brine and dried over anhydrous Na<sub>2</sub>SO<sub>4.</sub> The obtained organic solution was concentrated under vacuum and purified by silica gel column chromatography (EA/PE, 1/4–1/2) to afford compound <b>10</b> as a yellow solid (1.31 g, 53% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.73 (d, <i>J</i> = 2.5 Hz, 1H), 7.37 (d, <i>J</i> = 7.2 Hz, 2H), 7.33 (t, <i>J</i> = 7.5 Hz, 2H), 7.29–7.21 (m, 2H), 6.87 (d, <i>J</i> = 6.9 Hz, 1H), 5.06 (t, <i>J</i> = 5.4 Hz, 1H), 4.47 (dd, <i>J</i> = 11.8, 7.0 Hz, 1H), 3.72–3.51 (m, 2H). LRMS [M + H]<sup>+</sup>: 328.9.</div></div><div id="sec4_2_1_44" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> (<i>R</i>)-2-(6-Chloro-5-(3-methyl-1<i>H</i>-indazol-5-yl)pyridin-3-ylamino)-2-phenylethanol (<b>11a</b>)</h5><div class="NLM_p last">To a stirred mixture of (<i>R</i>)-2-(5-bromo-6-chloropyridin-3-ylamino)-2-phenylethanol <b>15</b> (3.0 g, 9.16 mmol) and Na<sub>2</sub>CO<sub>3</sub> (2.43 g, 22.89 mmol) in dioxane (50 mL) was added <i>tert</i>-butyl 3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-indazole-1-carboxylate <b>12a</b> (4.92 g, 13.74 mmol) and 2.5 mL of water. The reaction vessel was evacuated and refilled with nitrogen (3 times), followed by the addition of Pd(dppf)<sub>2</sub>Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub> (748 mg, 0.92 mmol). The resulting mixture was stirred at 80 °C overnight and then cooled to room temperature. The mixture was diluted with EA (30 mL) and filtered. The filtrate was sequentially washed by water and brine and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The obtained organic solution was concentrated under vacuum. The obtained solid was redissolved in DCM (30 mL). To the stirred mixture was added 15 mL of TFA. After 6 h, the mixture was concentrated under vacuum and neutralized with 1 M aqueous sodium hydroxide under ice bath. The mixture was extracted with DCM (65 mL) three times. The combined organic layer was washed with brine and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The obtained solution was concentrated under vacuum and purified by silica gel column chromatography (MeOH/DCM, 1/100–1/50) to afford compound <b>11a</b> as a yellow solid (1.89 g, 55% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.66 (d, <i>J</i> = 2.9 Hz, 1H), 7.53 (d, <i>J</i> = 0.6 Hz, 1H), 7.45 (d, <i>J</i> = 8.6 Hz, 1H), 7.42–7.37 (m, 2H), 7.36–7.30 (m, 3H), 7.26 (t, <i>J</i> = 7.2 Hz, 1H), 6.99 (d, <i>J</i> = 2.9 Hz, 1H), 4.48 (dd, <i>J</i> = 7.8, 4.7 Hz, 1H), 3.77 (ddd, <i>J</i> = 19.1, 11.2, 6.3 Hz, 2H), 2.55 (d, <i>J</i> = 12.5 Hz, 3H). LRMS [M + H]<sup>+</sup>: 379.1.</div></div><div id="sec4_2_1_45" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> (<i>R</i>)-2-(6-Chloro-5-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-5-yl)pyridin-3-ylamino)-2-phenylethanol (<b>11b</b>)</h5><div class="NLM_p last">Yield: 48%. Compound <b>11b</b> was prepared in a similar manner as described for compound <b>11a.</b> LRMS [M + H]<sup>+</sup>: 380.1.</div></div><div id="sec4_2_1_46" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> (<i>R</i>)-2-(6-Chloro-5-(isoquinolin-6-yl)pyridin-3-ylamino)-2-phenylethanol (<b>12a</b>)</h5><div class="NLM_p last">To a stirred mixture of (<i>R</i>)-2-(5-bromo-6-chloropyridin-3-ylamino)-2-phenylethanol <b>10</b> (2.5 g, 7.63 mmol) and K<sub>2</sub>CO<sub>3</sub> (2.64 g, 19.08 mmol) in dioxane (30 mL) were added 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinoline (2.92 g, 11.45 mmol) and 1.5 mL of water. The reaction vessel was evacuated and refilled with nitrogen (3 times), followed by the addition of Pd(dppf)<sub>2</sub>Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub> (623 mg, 0.76 mmol). The resulting mixture was stirred at 90 °C overnight and then cooled to room temperature. The mixture was diluted with EA (30 mL) and filtered. The filtrate was sequentially washed by water and brine and dried over anhydrous Na<sub>2</sub>SO<sub>4.</sub> The organic layer was concentrated under vacuum and purified by silica gel column chromatography (MeOH/DCM, 1/100–1/50) to afford compound <b>12a</b> as a white solid (1.97 g, 69% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 9.25 (s, 1H), 8.45 (d, <i>J</i> = 5.8 Hz, 1H), 8.11 (d, <i>J</i> = 8.5 Hz, 1H), 7.81 (d, <i>J</i> = 5.6 Hz, 2H), 7.74 (d, <i>J</i> = 2.7 Hz, 1H), 7.63 (d, <i>J</i> = 8.3 Hz, 1H), 7.40 (d, <i>J</i> = 7.4 Hz, 2H), 7.34 (t, <i>J</i> = 7.4 Hz, 2H), 7.26 (t, <i>J</i> = 7.1 Hz, 1H), 7.05 (d, <i>J</i> = 2.7 Hz, 1H), 4.51 (dd, <i>J</i> = 7.3, 4.7 Hz, 1H), 3.78 (ddd, <i>J</i> = 18.8, 11.1, 6.2 Hz, 2H). LRMS [M + H]<sup>+</sup>: 376.1.</div></div><div id="sec4_2_1_47" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> (<i>R</i>)-5-(2-Chloro-5-(2-hydroxy-1-phenylethylamino)pyridin-3-yl)indolin-2-one (<b>12b</b>)</h5><div class="NLM_p last">Compound <b>12b</b> was prepared in a similar manner as described for compound <b>12a</b>. Yield: 64%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.63 (d, <i>J</i> = 2.9 Hz, 1H), 7.39 (d, <i>J</i> = 7.2 Hz, 2H), 7.34 (t, <i>J</i> = 7.5 Hz, 2H), 7.26 (t, <i>J</i> = 7.2 Hz, 1H), 7.20 (s, 1H), 7.14 (d, <i>J</i> = 8.0 Hz, 1H), 6.92 (t, <i>J</i> = 6.0 Hz, 2H), 4.47 (dd, <i>J</i> = 7.8, 4.6 Hz, 1H), 3.76 (ddd, <i>J</i> = 19.1, 11.2, 6.3 Hz, 2H), 3.55 (s, 2H). LRMS [M + H]<sup>+</sup>: 380.1.</div></div><div id="sec4_2_1_48" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> (<i>R</i>)-<i>N</i>-(4-(2-Chloro-5-(2-hydroxy-1-phenylethylamino)pyridin-3-yl)phenyl)acetamide (<b>12c</b>)</h5><div class="NLM_p last">Compound <b>12c</b> was prepared in a similar manner as described for compound <b>12a</b>. Yield: 68%. LRMS [M + H]<sup>+</sup>: 382.1.</div></div><div id="sec4_2_1_49" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> (<i>R</i>)-2-(6-Chloro-5-(1<i>H</i>-indol-5-yl)pyridin-3-ylamino)-2-phenylethanol (<b>12d</b>)</h5><div class="NLM_p last">Compound <b>12d</b> was prepared in a similar manner as described for compound <b>12a</b>. Yield: 72%. LRMS [M + H]<sup>+</sup>: 364.0.</div></div><div id="sec4_2_1_50" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> (S)-2-(5-Bromo-6-chloropyridin-3-ylamino)-2-phenylethanol (<b>13a</b>)</h5><div class="NLM_p last">Compound <b>13a</b> was prepared in a similar manner as described for compound <b>10</b>. Yield: 51%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.66 (d, <i>J</i> = 2.7 Hz, 1H), 7.40–7.32 (m, 4H), 7.26 (t, <i>J</i> = 6.8 Hz, 1H), 7.21 (d, <i>J</i> = 2.7 Hz, 1H), 4.42 (dd, <i>J</i> = 7.8, 4.6 Hz, 1H), 3.74 (ddd, <i>J</i> = 19.1, 11.3, 6.3 Hz, 2H). LRMS [M + H]<sup>+</sup>: 328.9.</div></div><div id="sec4_2_1_51" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> (<i>R</i>)-2-(5-Bromo-6-chloropyridin-3-ylamino)ethanol (<b>13b</b>)</h5><div class="NLM_p last">Compound <b>13b</b> was prepared in a similar manner as described for compound <b>15</b>. Yield: 48%. LRMS [M + H]<sup>+</sup>: 253.0.</div></div><div id="sec4_2_1_52" class="NLM_sec NLM_sec_level_4"><div id="ac_i79" class="anchor-spacer"></div><h5 class="article-section__title" id="_i79"> (<i>R</i>)-3-(5-Bromo-6-chloropyridin-3-ylamino)propan-1-ol (<b>13c</b>)</h5><div class="NLM_p last">Compound <b>13c</b> was prepared in a similar manner as described for compound <b>15</b>. Yield: 45%. LRMS [M + H]<sup>+</sup>: 267.0.</div></div><div id="sec4_2_1_53" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80"> (<i>S</i>)-2-(6-Chloro-5-(3-methyl-1<i>H</i>-indazol-5-yl)pyridin-3-ylamino)-2-phenylethanol (<b>14a</b>)</h5><div class="NLM_p last">Compound <b>14a</b> was prepared in a similar manner as described for compound <b>16a</b>. Yield: 53%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.67 (d, <i>J</i> = 2.9 Hz, 1H), 7.55–7.51 (m, 1H), 7.46(d, <i>J</i> = 8.6 Hz, 1H), 7.43–7.37 (m, 2H), 7.36–7.31 (m, 3H), 7.30–7.22 (m, 1H), 6.97 (d, <i>J</i> = 2.9 Hz, 1H), 4.49 (dd, <i>J</i> = 7.8, 4.8 Hz, 1H), 3.82 (dd, <i>J</i> = 11.2, 4.8 Hz, 1H), 3.73 (dd, <i>J</i> = 11.2, 7.9 Hz, 1H), 2.56 (d, <i>J</i> = 12.6 Hz, 3H). LRMS [M + H]<sup>+</sup>: 379.1.</div></div><div id="sec4_2_1_54" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81"> (<i>R</i>)-2-(6-Chloro-5-(3-methyl-1<i>H</i>-indazol-5-yl)pyridin-3-ylamino)ethanol (<b>14b</b>)</h5><div class="NLM_p last">Compound <b>14b</b> was prepared in a similar manner as described for compound <b>16a</b>. Yield: 42%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.76 (s, 1H), 7.79 (d, <i>J</i> = 2.9 Hz, 1H), 7.74 (s, 1H), 7.52 (d, <i>J</i> = 8.5 Hz, 1H), 7.39 (dd, <i>J</i> = 8.6, 1.4 Hz, 1H), 7.06 (d, <i>J</i> = 2.9 Hz, 1H), 6.11 (t, <i>J</i> = 5.8 Hz, 1H), 4.76 (t, <i>J</i> = 5.3 Hz, 1H), 3.57 (q, <i>J</i> = 5.7 Hz, 2H), 3.17 (dd, <i>J</i> = 11.4, 5.7 Hz, 2H), 2.51 (s, 3H). LRMS [M + H]<sup>+</sup>: 303.0.</div></div><div id="sec4_2_1_55" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82"> (<i>R</i>)-2-(6-Chloro-5-(3-methyl-1<i>H</i>-indazol-5-yl)pyridin-3-ylamino)ethanol (<b>14c</b>)</h5><div class="NLM_p last">Compound <b>14c</b> was prepared in a similar manner as described for compound <b>16a</b>. Yield: 48%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.75 (s, 1H), 7.75 (d, <i>J</i> = 2.7 Hz, 2H), 7.52 (d, <i>J</i> = 8.6 Hz, 1H), 7.39 (dd, <i>J</i> = 8.6, 1.4 Hz, 1H), 7.01 (d, <i>J</i> = 2.9 Hz, 1H), 6.10 (t, <i>J</i> = 5.4 Hz, 1H), 4.52 (t, <i>J</i> = 5.1 Hz, 1H), 3.51 (dd, <i>J</i> = 11.5, 6.1 Hz, 2H), 3.13 (dd, <i>J</i> = 12.7, 6.7 Hz, 2H), 2.51 (s, 3H), 1.71 (p, <i>J</i> = 6.5 Hz, 2H). LRMS [M + H]<sup>+</sup>: 317.1.</div></div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> Kinase Profiling</h3><div class="NLM_p">The kinase profiling of compounds was used by various methods: the kinase of Erk was tested by a fluorescence resonance energy transfer (FRET)-based assay with Z′-LYTE Kinase Assay Kit (Invitrogen, Grand Island, NY); the kinases of CDK1, CDK4, and CDK6 were detected by a FRET-based assay with LANCE Ultra Kinase Assay Kit (PerkinElmer, Waltham, Massachusetts), and other kinases used an ELISA kinase assay as described below.</div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> ELISA Kinase Assay</h4><div class="NLM_p last">The effects of indicated compound on the activities of various tyrosine kinases were determined using enzyme-linked immunosorbent assays (ELISAs) with purified recombinant proteins. Briefly, 20 μg/mL of poly(Glu, Tyr) 4:1 (Sigma, St. Louis, MO, USA) was precoated on 96-well plates as a substrate. A 50 μL aliquot of 10 μM ATP solution diluted in kinase reaction buffer (50 mM HEPES [pH 7.4], 50 mM MgCl<sub>2</sub>, 0.5 mM MnCl<sub>2</sub>, 0.2 mM Na<sub>3</sub>VO<sub>4</sub>, and 1 mM DTT) was added to each well; 1 μL of the indicated compound diluted in 1% DMSO (v/v) (Sigma, St. Louis, MO, USA) was then added to each reaction well. DMSO (1%, v/v) was used as the negative control. The kinase reaction was initiated by the addition of purified tyrosine kinase proteins diluted in 49 μL of kinase reaction buffer. After incubation for 60 min at 37 °C, the plate was washed three times with phosphate-buffered saline (PBS) containing 0.1% Tween 20 (T-PBS). Antiphosphotyrosine (PY99) antibody (100 μL; 1:500, diluted in 5 mg/mL of BSA T-PBS) was then added. After a 30 min incubation at 37 °C, the plate was washed three times, and 100 μL of horseradish peroxidase-conjugated goat antimouse IgG (1:1000, diluted in 5 mg/mL of BSA T-PBS) was added. The plate was then incubated at 37 °C for 30 min and washed 3 times. A 100 μL aliquot of a solution containing 0.03% H<sub>2</sub>O<sub>2</sub> and 2 mg/mL of <i>o</i>-phenylenediamine in 0.1 M citrate buffer (pH 5.5) was added. The reaction was terminated by the addition of 50 μL of 2 M H<sub>2</sub>SO<sub>4</sub> as the color changed, and the plate was analyzed using a multiwell spectrophotometer (SpectraMAX190, from Molecular Devices, Palo Alto, CA, USA) at 490 nm. The inhibition ratio (%) was calculated using the equation: [1 – (A490/A490 control)] × 100%. The IC<sub>50</sub> values were calculated from the inhibition curves in two separate experiments.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> Western Blot Analysis</h4><div class="NLM_p last">NCI-H1581, KG1, SNU16, KATOIII, UMUC14, RT112, HCC827, PC-9, Ba/F3/CCDC6-RET, and Ba/F3/TEL-KDR cells were treated with the indicated dose of <b>3m</b> for 2 h at 37 °C and then lysed in 1× SDS sample buffer. The cell lysates were subsequently resolved by 10% SDS-PAGE and transferred to nitrocellulose membranes. The membranes were probed with the appropriate primary antibodies [phospho-FGFR1, FGFR1, phospho-FGFR2, FGFR2, phospho-FGFR3, FGFR3, phospho-DDR2, DDR2, phospho-RET, RET, phospho-KDR, KDR, phospho-FRS2, FRS2, phosphor-ERK, ERK, PLCγ, phosphor-PLCγ, phospho-SRC, SRC, phospho-STAT3, STAT3, phospho-AKT, AKT, Tubulin, GAPDH (all from Cell Signaling Technology, Beverly, MA, USA)] and then with horseradish peroxidase-conjugated antirabbit or anti-mouse IgG. The immune reactive proteins were detected using an enhanced chemilluminescense detection reagent (Thermo Fisher Scientific, Rockford, IL, USA)</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> Cell Proliferation Assay</h4><div class="NLM_p last">Cells were seeded in 96-well cell culture plates. On the day when seeding, the cells were exposed to various concentrations of compounds and further cultured for 72 h at 37 °C. Cell proliferation was then determined using Cell Counts Kit-8 (CCK8). The IC<sub>50</sub> values were calculated by concentration–response curve fitting using the four-parameter method.</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> <i>In Vivo</i> Antitumor Activity Assay</h4><div class="NLM_p">Female nude mice (4–6 weeks) were housed at five or six mice per cage in a specific pathogen-free room with a 12 h light/dark schedule at 25 ± 1 °C; the animals were fed an autoclaved chow diet and water ad libitum. All animal experiments were performed according to the institutional ethical guidelines of animal care.</div><div class="NLM_p last">NCI-H1581 cells at a density of 5 × 10<sup>6</sup> were first implanted subcutaneously into the right flank of each mouse and then allowed to grow to 700–800 mm<sup>3</sup>, which was defined as a well-developed tumor. The well-developed tumors were cut into 1.5 mm<sup>3</sup> fragments and transplanted subcutaneously into the right flank of nude mice using a tracer. When the tumor volume reached 100–150 mm<sup>3</sup>, the mice were randomly assigned into control vehicle and treatment groups (<i>n</i> = 6 in treated group, <i>n</i> = 12 in vehicle group). The control groups were given vehicle alone, and the treatment groups received <b>3m</b> at the indicated doses via oral administration once daily for 14 days. Compound <b>16</b> was a positive control drug. The sizes of the tumors were measured twice per week using microcalipers. The tumor volume (TV) was calculated as follows: TV = (length × width<sup>2</sup>)/2. The tumor volume shown was obtained on the indicated days as the median tumor volume ± SEM for indicated groups of mice. The relative tumor volume (RTV) values were measured on the final day of the study for the drug-treated mice compared with the vehicle-treated mice and were calculated as RTV = <i>V</i><sub>t</sub>/<i>V</i><sub>0</sub>, where <i>V</i><sub>0</sub> is the tumor volume at day 0 and <i>V</i><sub>t</sub> is the tumor volume measured at each time point. The percentage of tumor volume inhibition values (TGI) was also measured. Significant differences between the treated versus the control groups (<i>p</i> ≤ 0.05) were determined using Student’s <i>t</i> test.</div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> Pharmacokinetic Profiles in SD Rats and CD-1 Mice</h4><div class="NLM_p last">Compound <b>3m</b> (5% DMSO + 5% Tween-80 in 90% saline) was subjected to PK studies in SD rats and CD-1 mice. Compound <b>3m</b> was administered via the oral route at 20 mg/kg and administered via the intravenous route at 10 mg/kg in SD rats. Compound <b>3m</b> was administered via the oral route at 20 mg/kg and iv route at 5 mg/kg in CD-1 mice. After oral and intravenous administration, blood samples were collected. The blood samples were centrifuged to obtain the plasma fraction. The plasma samples were deproteinized with methanol containing an internal standard. After centrifugation, the supernatant was diluted with methanol and centrifuged again. The compound concentrations in the supernatant were measured by LC/MS/MS.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i89"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00076">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03101" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03101" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00076" class="ext-link">10.1021/acs.jmedchem.7b00076</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">HPLC analysis data of all final compounds, illustration of the potential internal H-bond of compound <b>2m</b>, and the putative binding mode of <b>3m</b> with FGFR1 protein (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00076/suppl_file/jm7b00076_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">SMILES strings of 57 candidate compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00076/suppl_file/jm7b00076_si_003.xlsx" class="ext-link">XLSX</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00076/suppl_file/jm7b00076_si_001.pdf">jm7b00076_si_001.pdf (223.49 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00076/suppl_file/jm7b00076_si_003.xlsx">jm7b00076_si_003.xlsx (20.03 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b00076" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56524" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56524" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing Ai</span> - <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#bfd5ded6ffccd6d2d291dedc91dcd1"><span class="__cf_email__" data-cfemail="1a707b735a69737777347b79347974">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mingyue Zheng</span> - <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3323-3092" title="Orcid link">http://orcid.org/0000-0002-3323-3092</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e78a9e9d8f828980a7948e8a8ac98684c98489"><span class="__cf_email__" data-cfemail="80edf9fae8e5eee7c0f3e9ededaee1e3aee3ee">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Liu</span> - <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0863-7853" title="Orcid link">http://orcid.org/0000-0002-0863-7853</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#680004011d281b01050546090b460b06"><span class="__cf_email__" data-cfemail="cda5a1a4b88dbea4a0a0e3acaee3aea3">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Zhu</span> - <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hui Chen</span> - <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yulan Wang</span> - <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiang Wang</span> - <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xia Peng</span> - <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xianjie Chen</span> - <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yinglei Gao</span> - <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chunpu Li</span> - <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yulong He</span> - <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Meiyu Geng</span> - <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>W.Z., H.C., and Y.W. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d96e6913-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i91">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03542" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03542" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We gratefully acknowledge financial support from the National Natural Science Foundation of China Grants (21632008, 81620108027, and 81473243), NSFC-Shandong Joint Fund for Marine Science Research Centers (U1406402), Major Project of Chinese National Programs for Fundamental Research and Development (2015CB910304), and the Strategic Priority Research Program of the Chinese Academy of Sciences (XDA12050201).</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i92" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i92"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i93" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i93"> Abbreviations</h2><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">nonsmall cell lung cancer</p></td></tr><tr><td class="NLM_term">FGFR</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptors</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">TKIs</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitors</p></td></tr><tr><td class="NLM_term">VEGFR</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor</p></td></tr><tr><td class="NLM_term">CSF1R</td><td class="NLM_def"><p class="first last">colony-stimulating factor 1 receptor</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i94">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04465" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04465" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 40 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Jemal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thun, M. J.</span><span> </span><span class="NLM_article-title">Cancer statistics, 2007</span> <span class="citation_source-journal">Ca-Cancer J. Clin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">43</span><span class="NLM_x">–</span> <span class="NLM_lpage">66</span><span class="refDoi"> DOI: 10.3322/canjclin.57.1.43</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.3322%2Fcanjclin.57.1.43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=17237035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FjvVKmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2007&pages=43-66&author=A.+Jemalauthor=R.+Siegelauthor=E.+Wardauthor=T.+Murrayauthor=J.+Xuauthor=M.+J.+Thun&title=Cancer+statistics%2C+2007&doi=10.3322%2Fcanjclin.57.1.43"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer statistics, 2007</span></div><div class="casAuthors">Jemal Ahmedin; Siegel Rebecca; Ward Elizabeth; Murray Taylor; Xu Jiaquan; Thun Michael J</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-66</span>
        ISSN:<span class="NLM_cas:issn">0007-9235</span>.
    </div><div class="casAbstract">Each year, the American Cancer Society (ACS) estimates the number of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics.  This report considers incidence data through 2003 and mortality data through 2004.  Incidence and death rates are age-standardized to the 2000 US standard million population.  A total of 1,444,920 new cancer cases and 559,650 deaths for cancers are projected to occur in the United States in 2007.  Notable trends in cancer incidence and mortality rates include stabilization of the age-standardized, delay-adjusted incidence rates for all cancers combined in men from 1995 through 2003; a continuing increase in the incidence rate by 0.3% per year in women; and a 13.6% total decrease in age-standardized cancer death rates among men and women combined between 1991 and 2004.  This report also examines cancer incidence, mortality, and survival by site, sex, race/ethnicity, geographic area, and calendar year, as well as the proportionate contribution of selected sites to the overall trends.  While the absolute number of cancer deaths decreased for the second consecutive year in the United States (by more than 3,000 from 2003 to 2004) and much progress has been made in reducing mortality rates and improving survival, cancer still accounts for more deaths than heart disease in persons under age 85 years.  Further progress can be accelerated by supporting new discoveries and by applying existing cancer control knowledge across all segments of the population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRpAWCsxi_XOhBrI9DTGjC0fW6udTcc2eb_BENBCeGxzbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FjvVKmtA%253D%253D&md5=d82aa6c2ef180df91cec1814833c9004</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcanjclin.57.1.43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcanjclin.57.1.43%26sid%3Dliteratum%253Aachs%26aulast%3DJemal%26aufirst%3DA.%26aulast%3DSiegel%26aufirst%3DR.%26aulast%3DWard%26aufirst%3DE.%26aulast%3DMurray%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DThun%26aufirst%3DM.%2BJ.%26atitle%3DCancer%2520statistics%252C%25202007%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2007%26volume%3D57%26spage%3D43%26epage%3D66%26doi%3D10.3322%2Fcanjclin.57.1.43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span> </span><span class="NLM_article-title">The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">8629</span><span class="refDoi"> DOI: 10.1038/srep08629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1038%2Fsrep08629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=25720956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVCrtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=8629&author=Y.+Zhouauthor=Y.+Zhangauthor=H.+Zouauthor=N.+Caiauthor=X.+Chenauthor=L.+Xuauthor=X.+Kongauthor=P.+Liu&title=The+multi-targeted+tyrosine+kinase+inhibitor+vandetanib+plays+a+bifunctional+role+in+non-small+cell+lung+cancer+cells&doi=10.1038%2Fsrep08629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells</span></div><div class="casAuthors">Zhou, Yan; Zhang, Yuanliang; Zou, Hanbing; Cai, Ning; Chen, Xiaojing; Xu, Longmei; Kong, Xianming; Liu, Peifeng</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8629</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Vandetanib, a multikinase inhibitor, is a target of drug treatments for non-small cell lung cancer (NSCLC).  However, phase II and III clin. trials have not conclusively demonstrated the curative effects of vandetanib for NSCLC, and the reasons for this are unknown.  In the present study, we use the NSCLC cell line Calu-6 as a model to det. the cellular and biol. effects of vandetanib.  Our results demonstrate that vandetanib impairs Calu-6 cell migration and invasion.  We find that vandetanib can directly inhibit RET activity, which influences the Rho-JNK pathway.  Overexpression of a constitutively active Rho GTPase antagonizes the inhibitory effects of vandetanib on Calu-6 cells invasion and JNK pathway activation.  In addn., vandetanib induces autophagy by increasing the level of reactive oxygen species (ROS) in Calu-6 cells, and blockade of autophagy or ROS effectively enhances the cell death effect of vandetanib.  In this study, we find vandetanib is of a double effect in some NSCLC cells, presenting new possibilities for the pharmacol. treatment of NSCLC and introducing a novel role for vandetanib in treatment options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMuZHNy56DYLVg90H21EOLACvtfcHk0lh9eV8nVRlYQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVCrtbk%253D&md5=20e56ddafc18a905ca4bd2031515805c</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fsrep08629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep08629%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DCai%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DP.%26atitle%3DThe%2520multi-targeted%2520tyrosine%2520kinase%2520inhibitor%2520vandetanib%2520plays%2520a%2520bifunctional%2520role%2520in%2520non-small%2520cell%2520lung%2520cancer%2520cells%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D8629%26doi%3D10.1038%2Fsrep08629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Lin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, H.</span><span> </span><span class="NLM_article-title">EGFR-TKI resistance in NSCLC patients: mechanisms and strategies</span> <span class="citation_source-journal">Am. J. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">411</span><span class="NLM_x">–</span> <span class="NLM_lpage">435</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=25232485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVOqsr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=411-435&author=Y.+Linauthor=X.+Wangauthor=H.+Jin&title=EGFR-TKI+resistance+in+NSCLC+patients%3A+mechanisms+and+strategies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR-TKI resistance in NSCLC patients: mechanisms and strategies</span></div><div class="casAuthors">Lin, Yuxin; Wang, Xian; Jin, Hongchuan</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">411-435, 25 pp.</span>CODEN:
                <span class="NLM_cas:coden">AJCRFT</span>;
        ISSN:<span class="NLM_cas:issn">2156-6976</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) is a kind of receptor tyrosine kinase (RTK) that plays a crit. role in the initiation and development of malignant tumors via modulating downstream signaling pathways.  In non-small cell lung cancer (NSCLC), the activating mutations located in the tyrosine kinase domains of EGFR have been demonstrated in multiple researches as the "Achilles' heel" of this deadly disease since they could be well-targeted by epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).  However, it's still too early to celebrate since the first-generation EGFR-TKIs such as gefitinib and erlotinib have only achieved limited clin. benefits and acquired resistance to this kind of drugs occurred inevitably in almost all the NSCLC patients.  In order to make the most of EGFR-TKIs and develop more effective regimens for the NSCLC patients, researchers majoring in different aspects start a battle against EGFR-TKI resistance.  Challenging as it is, we still progress stably and step firmly toward the final victory.  This review will summarize the major mechanisms of acquired resistance to EGFR-TKIs, and then discuss the development of rationally designed mol. target drugs in accordance with each mechanism, in the hope of shedding light on the great achievements we have obtained and tough obstacles we have to overcome in the battle against this deadly disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5q1xMeLLDIrVg90H21EOLACvtfcHk0lhisdLUn0pezg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVOqsr7F&md5=021beb6a44d84bbf6b2c5002921bb448</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DJin%26aufirst%3DH.%26atitle%3DEGFR-TKI%2520resistance%2520in%2520NSCLC%2520patients%253A%2520mechanisms%2520and%2520strategies%26jtitle%3DAm.%2520J.%2520Cancer%2520Res.%26date%3D2014%26volume%3D4%26spage%3D411%26epage%3D435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Shea, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rangachari, D.</span><span> </span><span class="NLM_article-title">Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches</span> <span class="citation_source-journal">Ther. Adv. Respir. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">129</span><span class="refDoi"> DOI: 10.1177/1753465815617871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1177%2F1753465815617871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=26620497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntFOrtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=113-129&author=M.+Sheaauthor=D.+B.+Costaauthor=D.+Rangachari&title=Management+of+advanced+non-small+cell+lung+cancers+with+known+mutations+or+rearrangements%3A+latest+evidence+and+treatment+approaches&doi=10.1177%2F1753465815617871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches</span></div><div class="casAuthors">Shea, Meghan; Costa, Daniel B.; Rangachari, Deepa</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Respiratory Disease</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-129</span>CODEN:
                <span class="NLM_cas:coden">TARDCZ</span>;
        ISSN:<span class="NLM_cas:issn">1753-4658</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Precision oncol. is now the evidence-based std. of care for the management of many advanced non-small cell lung cancers (NSCLCs).  Expert consensus has defined min. requirements for routine testing and identification of epidermal growth factor (EGFR) mutations (15% of tumors harbor EGFR exon 19 deletions or exon 21 L858R substitutions) and anaplastic lymphoma kinase (ALK) rearrangements (5% of tumors) in advanced lung adenocarcinomas (ACs).  Application of palliative targeted therapies with oral tyrosine kinase inhibitors (TKIs) in advanced/metastatic lung ACs harboring abnormalities in EGFR (gefitinib, erlotinib, afatinib) and ALK/ROS1/MET (crizotinib) has consistently led to more favorable outcomes compared with traditional cytotoxic agents.  In addn., mutations leading to resistance to first-line EGFR and ALK TKIs can now be successfully inhibited by soon to be approved third-generation EGFR TKIs (osimertinib, rociletinib) and second-generation ALK TKIs (ceritinib, alectinib).  Notably, increasing feasibility, accessibility, and application of mol. profiling technologies has permitted dynamic growth in the identification of actionable driver oncogenes.  Emerging genomic aberrations for which TKIs have shown impressive results in clin. trials and expansion of drug labels for approved agents are awaited include ROS1 rearrangements (1-2% of tumors, drug: crizotinib) and BRAF-V600E mutations (1-3% of tumors, drugs: vemurafenib, dafrafenib + trametinib).  Evolving genomic events in which TKI responses have been reported in smaller series include MET exon 14 skipping mutations (2-4% of tumors, drug: crizotinib); high-level MET amplification (1-2% of tumors, drug: crizotinib); RET rearrangements (1% of tumors, drug: cabozantinib); and ERBB2 mutations (2-3% of tumors, drug: afatinib), among others.  Unfortunately, the most common genomic event in NSCLC, KRAS mutations (25-30% of tumors), is not targetable with approved or in development small mol. inhibitors.  Here, we review currently approved, emerging, and evolving systemic precision therapies matched with their driver oncogenes for the management of advanced NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoNtXAJ4imrLVg90H21EOLACvtfcHk0lhisdLUn0pezg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntFOrtbw%253D&md5=1ff6692d5cbef3da8a1e628f8b33cda9</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1177%2F1753465815617871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1753465815617871%26sid%3Dliteratum%253Aachs%26aulast%3DShea%26aufirst%3DM.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DRangachari%26aufirst%3DD.%26atitle%3DManagement%2520of%2520advanced%2520non-small%2520cell%2520lung%2520cancers%2520with%2520known%2520mutations%2520or%2520rearrangements%253A%2520latest%2520evidence%2520and%2520treatment%2520approaches%26jtitle%3DTher.%2520Adv.%2520Respir.%2520Dis.%26date%3D2016%26volume%3D10%26spage%3D113%26epage%3D129%26doi%3D10.1177%2F1753465815617871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Beenken, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammadi, M.</span><span> </span><span class="NLM_article-title">The FGF family: biology, pathophysiology and therapy</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">253</span><span class="refDoi"> DOI: 10.1038/nrd2792</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1038%2Fnrd2792" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=19247306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVShur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=235-253&author=A.+Beenkenauthor=M.+Mohammadi&title=The+FGF+family%3A+biology%2C+pathophysiology+and+therapy&doi=10.1038%2Fnrd2792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The FGF family: biology, pathophysiology and therapy</span></div><div class="casAuthors">Beenken, Andrew; Mohammadi, Moosa</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">235-253</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The family of fibroblast growth factors (FGFs) regulates a plethora of developmental processes, including brain patterning, branching morphogenesis and limb development.  Several mitogenic, cytoprotective and angiogenic therapeutic applications of FGFs are already being explored, and the recent discovery of the crucial roles of the endocrine-acting FGF19 subfamily in bile acid, glucose and phosphate homeostasis has sparked renewed interest in the pharmacol. potential of this family.  This review discusses traditional applications of recombinant FGFs and small-mol. FGF receptor kinase inhibitors in the treatment of cancer and cardiovascular disease and their emerging potential in the treatment of metabolic syndrome and hypophosphatemic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmidKyrdG0lbVg90H21EOLACvtfcHk0lhisdLUn0pezg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVShur4%253D&md5=4789ed4cb521a92114063a400a138645</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd2792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2792%26sid%3Dliteratum%253Aachs%26aulast%3DBeenken%26aufirst%3DA.%26aulast%3DMohammadi%26aufirst%3DM.%26atitle%3DThe%2520FGF%2520family%253A%2520biology%252C%2520pathophysiology%2520and%2520therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D235%26epage%3D253%26doi%3D10.1038%2Fnrd2792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Turner, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grose, R.</span><span> </span><span class="NLM_article-title">Fibroblast growth factor signalling: from development to cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">116</span><span class="NLM_x">–</span> <span class="NLM_lpage">129</span><span class="refDoi"> DOI: 10.1038/nrc2780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1038%2Fnrc2780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=20094046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Gktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=116-129&author=N.+Turnerauthor=R.+Grose&title=Fibroblast+growth+factor+signalling%3A+from+development+to+cancer&doi=10.1038%2Fnrc2780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factor signalling: from development to cancer</span></div><div class="casAuthors">Turner, Nicholas; Grose, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">116-129</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Fibroblast growth factors (FGFs) and their receptors control a wide range of biol. functions, regulating cellular proliferation, survival, migration and differentiation.  Although targeting FGF signalling as a cancer therapeutic target has lagged behind that of other receptor tyrosine kinases, there is now substantial evidence for the importance of FGF signalling in the pathogenesis of diverse tumor types, and clin. reagents that specifically target the FGFs or FGF receptors are being developed.  Although FGF signalling can drive tumorigenesis, in different contexts FGF signalling can mediate tumor protective functions; the identification of the mechanisms that underlie these differential effects will be important to understand how FGF signalling can be most appropriately therapeutically targeted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUBfz6uAu97bVg90H21EOLACvtfcHk0lhisdLUn0pezg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Gktg%253D%253D&md5=7963bc75c149981560dffc8d91b4aaf1</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrc2780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2780%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DGrose%26aufirst%3DR.%26atitle%3DFibroblast%2520growth%2520factor%2520signalling%253A%2520from%2520development%2520to%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D116%26epage%3D129%26doi%3D10.1038%2Fnrc2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Weiss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peifer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zander, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soltermann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagener, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heynck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schöttle, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leenders, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabler, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dabow, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Querings, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heukamp, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balke-Want, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ansén, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baessmann, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altmüller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wainer, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conron, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brambilla, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brambilla, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorimier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sollberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brustugun, O. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel-Riedel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petersen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sänger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clement, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timens, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sietsma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thunnissen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smit, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heideman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ligorio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damiani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beroukhim, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buettner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernestus, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoelben, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nürnberg, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span> </span><span class="NLM_article-title">Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">62ra93</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3001451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1126%2Fscitranslmed.3001451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=21160078" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=62ra93&author=J.+Weissauthor=M.+L.+Sosauthor=D.+Seidelauthor=M.+Peiferauthor=T.+Zanderauthor=J.+M.+Heuckmannauthor=R.+T.+Ullrichauthor=R.+Menonauthor=S.+Maierauthor=A.+Soltermannauthor=H.+Mochauthor=P.+Wagenerauthor=F.+Fischerauthor=S.+Heynckauthor=M.+Kokerauthor=J.+Sch%C3%B6ttleauthor=F.+Leendersauthor=F.+Gablerauthor=I.+Dabowauthor=S.+Queringsauthor=L.+C.+Heukampauthor=H.+Balke-Wantauthor=S.+Ans%C3%A9nauthor=D.+Rauhauthor=I.+Baessmannauthor=J.+Altm%C3%BCllerauthor=Z.+Wainerauthor=M.+Conronauthor=G.+Wrightauthor=P.+Russellauthor=B.+Solomonauthor=E.+Brambillaauthor=C.+Brambillaauthor=P.+Lorimierauthor=S.+Sollbergauthor=O.+T.+Brustugunauthor=W.+Engel-Riedelauthor=C.+Ludwigauthor=I.+Petersenauthor=J.+S%C3%A4ngerauthor=J.+Clementauthor=H.+Groenauthor=W.+Timensauthor=H.+Sietsmaauthor=E.+Thunnissenauthor=E.+Smitauthor=D.+Heidemanauthor=F.+Cappuzzoauthor=C.+Ligorioauthor=S.+Damianiauthor=M.+Hallekauthor=R.+Beroukhimauthor=W.+Paoauthor=B.+Kleblauthor=M.+Baumannauthor=R.+Buettnerauthor=K.+Ernestusauthor=E.+Stoelbenauthor=J.+Wolfauthor=P.+N%C3%BCrnbergauthor=S.+Pernerauthor=R.+K.+Thomas&title=Frequent+and+focal+FGFR1+amplification+associates+with+therapeutically+tractable+FGFR1+dependency+in+squamous+cell+lung+cancer&doi=10.1126%2Fscitranslmed.3001451"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3001451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3001451%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DSeidel%26aufirst%3DD.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DZander%26aufirst%3DT.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DUllrich%26aufirst%3DR.%2BT.%26aulast%3DMenon%26aufirst%3DR.%26aulast%3DMaier%26aufirst%3DS.%26aulast%3DSoltermann%26aufirst%3DA.%26aulast%3DMoch%26aufirst%3DH.%26aulast%3DWagener%26aufirst%3DP.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DSch%25C3%25B6ttle%26aufirst%3DJ.%26aulast%3DLeenders%26aufirst%3DF.%26aulast%3DGabler%26aufirst%3DF.%26aulast%3DDabow%26aufirst%3DI.%26aulast%3DQuerings%26aufirst%3DS.%26aulast%3DHeukamp%26aufirst%3DL.%2BC.%26aulast%3DBalke-Want%26aufirst%3DH.%26aulast%3DAns%25C3%25A9n%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DBaessmann%26aufirst%3DI.%26aulast%3DAltm%25C3%25BCller%26aufirst%3DJ.%26aulast%3DWainer%26aufirst%3DZ.%26aulast%3DConron%26aufirst%3DM.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DRussell%26aufirst%3DP.%26aulast%3DSolomon%26aufirst%3DB.%26aulast%3DBrambilla%26aufirst%3DE.%26aulast%3DBrambilla%26aufirst%3DC.%26aulast%3DLorimier%26aufirst%3DP.%26aulast%3DSollberg%26aufirst%3DS.%26aulast%3DBrustugun%26aufirst%3DO.%2BT.%26aulast%3DEngel-Riedel%26aufirst%3DW.%26aulast%3DLudwig%26aufirst%3DC.%26aulast%3DPetersen%26aufirst%3DI.%26aulast%3DS%25C3%25A4nger%26aufirst%3DJ.%26aulast%3DClement%26aufirst%3DJ.%26aulast%3DGroen%26aufirst%3DH.%26aulast%3DTimens%26aufirst%3DW.%26aulast%3DSietsma%26aufirst%3DH.%26aulast%3DThunnissen%26aufirst%3DE.%26aulast%3DSmit%26aufirst%3DE.%26aulast%3DHeideman%26aufirst%3DD.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DLigorio%26aufirst%3DC.%26aulast%3DDamiani%26aufirst%3DS.%26aulast%3DHallek%26aufirst%3DM.%26aulast%3DBeroukhim%26aufirst%3DR.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DBuettner%26aufirst%3DR.%26aulast%3DErnestus%26aufirst%3DK.%26aulast%3DStoelben%26aufirst%3DE.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DN%25C3%25BCrnberg%26aufirst%3DP.%26aulast%3DPerner%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26atitle%3DFrequent%2520and%2520focal%2520FGFR1%2520amplification%2520associates%2520with%2520therapeutically%2520tractable%2520FGFR1%2520dependency%2520in%2520squamous%2520cell%2520lung%2520cancer%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2010%26volume%3D2%26spage%3D62ra93%26doi%3D10.1126%2Fscitranslmed.3001451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Oxnard, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binder, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">New targetable oncogenes in non-small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1097</span><span class="NLM_x">–</span> <span class="NLM_lpage">1104</span><span class="refDoi"> DOI: 10.1200/JCO.2012.42.9829</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1200%2FJCO.2012.42.9829" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=23401445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltl2murw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1097-1104&author=G.+R.+Oxnardauthor=A.+Binderauthor=P.+A.+J%C3%A4nne&title=New+targetable+oncogenes+in+non-small-cell+lung+cancer&doi=10.1200%2FJCO.2012.42.9829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">New targetable oncogenes in non-small-cell lung cancer</span></div><div class="casAuthors">Oxnard, Geoffrey R.; Binder, Adam; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1097-1104</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The identification of oncogenic driver mutations underlying sensitivity to epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors has led to a surge of interest in identifying addnl. targetable oncogenes in non-small-cell lung cancer.  A no. of new potentially oncogenic gene alterations have been characterized in recent years, including BRAF mutations, HER2 insertions, PIK3CA mutations, FGFR1 amplifications, DDR2 mutations, ROS1 rearrangements, and RET rearrangements.  In this review, we will discuss the techniques used to discover each of these candidate oncogenes, the prevalence of each in non-small-cell lung cancer, the preclin. data supporting their role in lung cancer, and data on small mol. inhibitors in development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9d7dOluS9lLVg90H21EOLACvtfcHk0ljmK76UhYjaOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltl2murw%253D&md5=4b40537217169227893de4f37f43f9df</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.42.9829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.42.9829%26sid%3Dliteratum%253Aachs%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DBinder%26aufirst%3DA.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DNew%2520targetable%2520oncogenes%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D1097%26epage%3D1104%26doi%3D10.1200%2FJCO.2012.42.9829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Zhao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henry, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zia-Ebrahimi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloem, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huss, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCann, D. J.</span><span> </span><span class="NLM_article-title">A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2200</span><span class="NLM_x">–</span> <span class="NLM_lpage">2210</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1158%2F1535-7163.MCT-11-0306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=21900693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVeltb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2200-2210&author=G.+Zhaoauthor=W.+Y.+Liauthor=D.+Chenauthor=J.+R.+Henryauthor=H.+Y.+Liauthor=Z.+Chenauthor=M.+Zia-Ebrahimiauthor=L.+Bloemauthor=Y.+Zhaiauthor=K.+Hussauthor=S.+B.+Pengauthor=D.+J.+McCann&title=A+novel%2C+selective+inhibitor+of+fibroblast+growth+factor+receptors+that+shows+a+potent+broad+spectrum+of+antitumor+activity+in+several+tumor+xenograft+models&doi=10.1158%2F1535-7163.MCT-11-0306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models</span></div><div class="casAuthors">Zhao, Genshi; Li, Wei-ying; Chen, Daohong; Henry, James R.; Li, Hong-Yu; Chen, Zhaogen; Zia-Ebrahimi, Mohammad; Bloem, Laura; Zhai, Yan; Huss, Karen; Peng, Sheng-bin; McCann, Denis J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2200-2210</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The fibroblast growth factor receptors (FGFR) are tyrosine kinases that are present in many types of endothelial and tumor cells and play an important role in tumor cell growth, survival, and migration as well as in maintaining tumor angiogenesis.  Overexpression of FGFRs or aberrant regulation of their activities has been implicated in many forms of human malignancies.  Therefore, targeting FGFRs represents an attractive strategy for development of cancer treatment options by simultaneously inhibiting tumor cell growth, survival, and migration as well as tumor angiogenesis.  Here, we describe a potent, selective, small-mol. FGFR inhibitor, (R)-(E)-2-(4-(2-(5-(1-(3,5-Dichloropyridin-4-yl)ethoxy)-1H-indazol-3yl)vinyl)-1H-pyrazol-1-yl)ethanol, designated as LY2874455.  This mol. is active against all 4 FGFRs, with a similar potency in biochem. assays.  It exhibits a potent activity against FGF/FGFR-mediated signaling in several cancer cell lines and shows an excellent broad spectrum of antitumor activity in several tumor xenograft models representing the major FGF/FGFR relevant tumor histologies including lung, gastric, and bladder cancers and multiple myeloma, and with a well-defined pharmacokinetic/pharmacodynamic relationship.  LY2874455 also exhibits a 6- to 9-fold in vitro and in vivo selectivity on inhibition of FGF- over VEGF-mediated target signaling in mice.  Furthermore, LY2874455 did not show VEGF receptor 2-mediated toxicities such as hypertension at efficacious doses.  Currently, this mol. is being evaluated for its potential use in the clinic.  Mol Cancer Ther; 10(11); 2200-10.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLrzAyZQK_grVg90H21EOLACvtfcHk0ljmK76UhYjaOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVeltb7N&md5=eaf08fd213a836f48da2055e01bd9c29</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0306%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DW.%2BY.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DHenry%26aufirst%3DJ.%2BR.%26aulast%3DLi%26aufirst%3DH.%2BY.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZia-Ebrahimi%26aufirst%3DM.%26aulast%3DBloem%26aufirst%3DL.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DHuss%26aufirst%3DK.%26aulast%3DPeng%26aufirst%3DS.%2BB.%26aulast%3DMcCann%26aufirst%3DD.%2BJ.%26atitle%3DA%2520novel%252C%2520selective%2520inhibitor%2520of%2520fibroblast%2520growth%2520factor%2520receptors%2520that%2520shows%2520a%2520potent%2520broad%2520spectrum%2520of%2520antitumor%2520activity%2520in%2520several%2520tumor%2520xenograft%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2200%26epage%3D2210%26doi%3D10.1158%2F1535-7163.MCT-11-0306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Inoue, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masuda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koga, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sata, M.</span><span> </span><span class="NLM_article-title">Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3924</span><span class="NLM_x">–</span> <span class="NLM_lpage">2933</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-2041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1158%2F1078-0432.CCR-11-2041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=22611027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVelur3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=3924-2933&author=K.+Inoueauthor=T.+Torimuraauthor=T.+Nakamuraauthor=H.+Iwamotoauthor=H.+Masudaauthor=M.+Abeauthor=O.+Hashimotoauthor=H.+Kogaauthor=T.+Uenoauthor=H.+Yanoauthor=M.+Sata&title=Vandetanib%2C+an+inhibitor+of+VEGF+receptor-2+and+EGF+receptor%2C+suppresses+tumor+development+and+improves+prognosis+of+liver+cancer+in+mice&doi=10.1158%2F1078-0432.CCR-11-2041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Vandetanib, an Inhibitor of VEGF Receptor-2 and EGF Receptor, Suppresses Tumor Development and Improves Prognosis of Liver Cancer in Mice</span></div><div class="casAuthors">Inoue, Kinya; Torimura, Takuji; Nakamura, Toru; Iwamoto, Hideki; Masuda, Hiroshi; Abe, Mitsuhiko; Hashimoto, Osamu; Koga, Hironori; Ueno, Takato; Yano, Hirohisa; Sata, Michio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3924-3933</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: VEGF, EGF, and TGF-α are expressed in hepatocellular carcinomas (HCC) and play a role in its growth.  Vandetanib, a multikinase inhibitor, suppresses the phosphorylation of VEGF receptor 2 (VEGFR-2) and EGF receptor (EGFR).  The aim of this study was to clarify the antitumor effect of vandetanib in mouse HCCs.  Exptl. Design: We evaluated the effects of vandetanib on proliferation of human umbilical vein endothelial cells (HUVEC) and three hepatoma cell lines, as well as the phosphorylation of VEGFR-2 and EGFR in these cells.  Mice were implanted with hepatoma cells s.c. or orthotopically in the liver and treated with 50 or 75 mg/kg vandetanib.  We analyzed the effects of treatment on tumor cell proliferation and apoptosis, vessel d., phosphorylation of VEGFR-2 and EGFR, and prodn. of VEGF, TGF-α, and EGF in tumor tissues.  Adverse events on vandetanib administration were also investigated.  Results: Vandetanib suppressed phosphorylation of VEGFR-2 in HUVECs and EGFR in hepatoma cells and inhibited cell proliferation.  In tumor-bearing mice, vandetanib suppressed phosphorylation of VEGFR-2 and EGFR in tumor tissues, significantly reduced tumor vessel d., enhanced tumor cell apoptosis, suppressed tumor growth, improved survival, reduced no. of intrahepatic metastases, and upregulated VEGF, TGF-α, and EGF in tumor tissues.  Treatment with vandetanib was not assocd. with serious adverse events, including alanine aminotransferase abnormality, bone marrow suppression, or body wt. loss.  Conclusions: The antitumor effects of vandetanib in mice suggest that it is a potentially suitable and safe chemotherapeutic agent for HCCs.  Clin Cancer Res; 18(14); 3924-33. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonGLsy-nYGHbVg90H21EOLACvtfcHk0lixQZZoJISOug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVelur3J&md5=5fd21f90672f2a8f92e4d473e2d6f26f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2041%26sid%3Dliteratum%253Aachs%26aulast%3DInoue%26aufirst%3DK.%26aulast%3DTorimura%26aufirst%3DT.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DIwamoto%26aufirst%3DH.%26aulast%3DMasuda%26aufirst%3DH.%26aulast%3DAbe%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DO.%26aulast%3DKoga%26aufirst%3DH.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DSata%26aufirst%3DM.%26atitle%3DVandetanib%252C%2520an%2520inhibitor%2520of%2520VEGF%2520receptor-2%2520and%2520EGF%2520receptor%252C%2520suppresses%2520tumor%2520development%2520and%2520improves%2520prognosis%2520of%2520liver%2520cancer%2520in%2520mice%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D3924%26epage%3D2933%26doi%3D10.1158%2F1078-0432.CCR-11-2041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Matsui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funahashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruoka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakabayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uenaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asada, M.</span><span> </span><span class="NLM_article-title">E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">664</span><span class="NLM_x">–</span> <span class="NLM_lpage">671</span><span class="refDoi"> DOI: 10.1002/ijc.23131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1002%2Fijc.23131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=17943726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A280%3ADC%252BD2sjhvVGnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2008&pages=664-671&author=J.+Matsuiauthor=Y.+Yamamotoauthor=Y.+Funahashiauthor=A.+Tsuruokaauthor=T.+Watanabeauthor=T.+Wakabayashiauthor=T.+Uenakaauthor=M.+Asada&title=E7080%2C+a+novel+inhibitor+that+targets+multiple+kinases%2C+has+potent+antitumor+activities+against+stem+cell+factor+producing+human+small+cell+lung+cancer+H146%2C+based+on+angiogenesis+inhibition&doi=10.1002%2Fijc.23131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition</span></div><div class="casAuthors">Matsui Junji; Yamamoto Yuji; Funahashi Yasuhiro; Tsuruoka Akihiko; Watanabe Tatsuo; Wakabayashi Toshiaki; Uenaka Toshimitsu; Asada Makoto</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">664-71</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">E7080 is an orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors.  In this study, we show the inhibitory activity of E7080 against SCF-induced angiogenesis in vitro and tumor growth of SCF-producing human small cell lung carcinoma H146 cells in vivo.  E7080 inhibits SCF-driven tube formation of HUVEC, which express SCF receptor, KIT at the IC(50) value of 5.2 nM and it was almost identical for VEGF-driven one (IC(50) = 5.1 nM).  To assess the role of SCF/KIT signaling in tumor angiogenesis, we evaluated the effect of imatinib, a selective KIT kinase inhibitor, on tumor growth of H146 cells in nude mice.  Imatinib did not show the potent antitumor activity in vitro (IC(50) = 2,200 nM), because H146 cells did not express KIT.  However, oral administration of imatinib at 160 mg/kg clearly slowed tumor growth of H146 cells in nude mice, accompanied by decreased microvessel density.  Oral administration of E7080 inhibited tumor growth of H146 cells at doses of 30 and 100 mg/kg in a dose-dependent manner and caused tumor regression at 100 mg/kg.  While anti-VEGF antibody also slowed tumor growth, it did not cause tumor regression.  These results indicate that KIT signaling has a role in tumor angiogenesis of SCF-producing H146 cells, and E7080 causes regression of H146 tumors as a result of antiangiogenic activity mediated by inhibition of both KIT and VEGF receptor signaling.  E7080 may provide therapeutic benefits in the treatment of SCF-producing tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQxatmtwSKaDe98rul4nhSdfW6udTcc2eaeOI7y4FDh8bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sjhvVGnsA%253D%253D&md5=cfa467e773fd98d6f95b0dded62d31ef</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fijc.23131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.23131%26sid%3Dliteratum%253Aachs%26aulast%3DMatsui%26aufirst%3DJ.%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DFunahashi%26aufirst%3DY.%26aulast%3DTsuruoka%26aufirst%3DA.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DWakabayashi%26aufirst%3DT.%26aulast%3DUenaka%26aufirst%3DT.%26aulast%3DAsada%26aufirst%3DM.%26atitle%3DE7080%252C%2520a%2520novel%2520inhibitor%2520that%2520targets%2520multiple%2520kinases%252C%2520has%2520potent%2520antitumor%2520activities%2520against%2520stem%2520cell%2520factor%2520producing%2520human%2520small%2520cell%2520lung%2520cancer%2520H146%252C%2520based%2520on%2520angiogenesis%2520inhibition%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2008%26volume%3D122%26spage%3D664%26epage%3D671%26doi%3D10.1002%2Fijc.23131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Roth, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heckel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colbatzky, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Handschuh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann-Lintz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lotz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tontsch-Grunt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilberg, F.</span><span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">4466</span><span class="NLM_x">–</span> <span class="NLM_lpage">4480</span><span class="refDoi"> DOI: 10.1021/jm900431g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900431g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntFygsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4466-4480&author=G.+J.+Rothauthor=A.+Heckelauthor=F.+Colbatzkyauthor=S.+Handschuhauthor=J.+Kleyauthor=T.+Lehmann-Lintzauthor=R.+Lotzauthor=U.+Tontsch-Gruntauthor=R.+Walterauthor=F.+Hilberg&title=Design%2C+synthesis%2C+and+evaluation+of+indolinones+as+triple+angiokinase+inhibitors+and+the+discovery+of+a+highly+specific+6-methoxycarbonyl-substituted+indolinone+%28BIBF+1120%29&doi=10.1021%2Fjm900431g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of Indolinones as Triple Angiokinase Inhibitors and the Discovery of a Highly Specific 6-Methoxycarbonyl-Substituted Indolinone (BIBF 1120)</span></div><div class="casAuthors">Roth, Gerald J.; Heckel, Armin; Colbatzky, Florian; Handschuh, Sandra; Kley, Jorg; Lehmann-Lintz, Thorsten; Lotz, Ralf; Tontsch-Grunt, Ulrike; Walter, Rainer; Hilberg, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4466-4480</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of tumor angiogenesis through blockade of the vascular endothelial growth factor (VEGF) signaling pathway is a new treatment modality in oncol.  Preclin. findings suggest that blockade of addnl. pro-angiogenic kinases, such as fibroblast and platelet-derived growth factor receptors (FGFR and PDGFR), may improve the efficacy of pharmacol. cancer treatment.  Indolinones substituted in position 6 were identified as selective inhibitors of VEGF-, PDGF-, and FGF-receptor kinases.  In particular, 6-methoxycarbonyl-substituted indolinones showed a highly favorable selectivity profile.  Optimization identified potent inhibitors of VEGF-related endothelial cell proliferation with addnl. efficacy on pericyctes and smooth muscle cells.  In contrast, no direct inhibition of tumor cell proliferation was obsd.  Compds. 2 (BIBF 1000) and 3 (BIBF 1120) are orally available and display encouraging efficacy in in vivo tumor models while being well tolerated.  The triple angiokinase inhibitor 3 (I) is currently in phase III clin. trials for the treatment of nonsmall cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvvcX-_HYCS7Vg90H21EOLACvtfcHk0lgoR_xh9J38Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntFygsL4%253D&md5=1b8af461631ae3117520fc4811130bb3</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm900431g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900431g%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DG.%2BJ.%26aulast%3DHeckel%26aufirst%3DA.%26aulast%3DColbatzky%26aufirst%3DF.%26aulast%3DHandschuh%26aufirst%3DS.%26aulast%3DKley%26aufirst%3DJ.%26aulast%3DLehmann-Lintz%26aufirst%3DT.%26aulast%3DLotz%26aufirst%3DR.%26aulast%3DTontsch-Grunt%26aufirst%3DU.%26aulast%3DWalter%26aufirst%3DR.%26aulast%3DHilberg%26aufirst%3DF.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520indolinones%2520as%2520triple%2520angiokinase%2520inhibitors%2520and%2520the%2520discovery%2520of%2520a%2520highly%2520specific%25206-methoxycarbonyl-substituted%2520indolinone%2520%2528BIBF%25201120%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4466%26epage%3D4480%26doi%3D10.1021%2Fjm900431g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Gozgit, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loriaux, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohemmad, Q. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narasimhan, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span> </span><span class="NLM_article-title">Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1028</span><span class="NLM_x">–</span> <span class="NLM_lpage">1035</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-10-1044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1158%2F1535-7163.MCT-10-1044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=21482694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnt1anurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=1028-1035&author=J.+M.+Gozgitauthor=M.+J.+Wongauthor=S.+Wardwellauthor=J.+W.+Tynerauthor=M.+M.+Loriauxauthor=Q.+K.+Mohemmadauthor=N.+I.+Narasimhanauthor=W.+C.+Shakespeareauthor=F.+Wangauthor=B.+J.+Drukerauthor=T.+Clacksonauthor=V.+M.+Rivera&title=Potent+activity+of+ponatinib+%28AP24534%29+in+models+of+FLT3-driven+acute+myeloid+leukemia+and+other+hematologic+malignancies&doi=10.1158%2F1535-7163.MCT-10-1044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies</span></div><div class="casAuthors">Gozgit, Joseph M.; Wong, Matthew J.; Wardwell, Scott; Tyner, Jeffrey W.; Loriaux, Marc M.; Mohemmad, Qurish K.; Narasimhan, Narayana I.; Shakespeare, William C.; Wang, Frank; Druker, Brian J.; Clackson, Tim; Rivera, Victor M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1028-1035</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Ponatinib (AP24534) is a novel multitargeted kinase inhibitor that potently inhibits native and mutant BCR-ABL at clin. achievable drug levels.  Ponatinib also has in vitro inhibitory activity against a discrete set of kinases implicated in the pathogenesis of other hematol. malignancies, including FLT3, KIT, fibroblast growth factor receptor 1 (FGFR1), and platelet derived growth factor receptor α (PDGFRα).  Here, using leukemic cell lines contg. activated forms of each of these receptors, we show that ponatinib potently inhibits receptor phosphorylation and cellular proliferation with IC50 values comparable to those required for inhibition of BCR-ABL (0.3 to 20 nmol/L).  The activity of ponatinib against the FLT3-ITD mutant, found in up to 30% of acute myeloid leukemia (AML) patients, was particularly notable.  In MV4-11 (FLT3-ITD+/+) but not RS4;11 (FLT3-ITD-/-) AML cells, ponatinib inhibited FLT3 signaling and induced apoptosis at concns. of less than 10 nmol/L.  In an MV4-11 mouse xenograft model, once daily oral dosing of ponatinib led to a dose-dependent inhibition of signaling and tumor regression.  Ponatinib inhibited viability of primary leukemic blasts from a FLT3-ITD pos. AML patient (IC50 4 nmol/L) but not those isolated from 3 patients with AML expressing native FLT3.  Overall, these results support the investigation of ponatinib in patients with FLT3-ITD-driven AML and other hematol. malignancies driven by KIT, FGFR1, or PDGFRα.  Mol Cancer Ther; 10(6); 1028-35.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9zB1-MfOsuLVg90H21EOLACvtfcHk0lgoR_xh9J38Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnt1anurw%253D&md5=3448caf6ca749c1bdd49355fa48ee1d2</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-1044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-1044%26sid%3Dliteratum%253Aachs%26aulast%3DGozgit%26aufirst%3DJ.%2BM.%26aulast%3DWong%26aufirst%3DM.%2BJ.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26atitle%3DPotent%2520activity%2520of%2520ponatinib%2520%2528AP24534%2529%2520in%2520models%2520of%2520FLT3-driven%2520acute%2520myeloid%2520leukemia%2520and%2520other%2520hematologic%2520malignancies%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D1028%26epage%3D1035%26doi%3D10.1158%2F1535-7163.MCT-10-1044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, Y.</span><span> </span><span class="NLM_article-title">Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors</span> <span class="citation_source-journal">J. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">105</span><span class="refDoi"> DOI: 10.1186/s13045-016-0332-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1186%2Fs13045-016-0332-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=27716285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVajsbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=105&author=Y.+Sunauthor=W.+Niuauthor=F.+Duauthor=C.+Duauthor=S.+Liauthor=J.+Wangauthor=L.+Liauthor=F.+Wangauthor=Y.+Haoauthor=C.+Liauthor=Y.+Chi&title=Safety%2C+pharmacokinetics%2C+and+antitumor+properties+of+anlotinib%2C+an+oral+multi-target+tyrosine+kinase+inhibitor%2C+in+patients+with+advanced+refractory+solid+tumors&doi=10.1186%2Fs13045-016-0332-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors</span></div><div class="casAuthors">Sun, Yongkun; Niu, Wei; Du, Feng; Du, Chunxia; Li, Shuting; Wang, Jinwan; Li, Li; Wang, Fengqing; Hao, Yu; Li, Chuan; Chi, Yihebali</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">105/1-105/9</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Anlotinib is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit VEGFR2/3, FGFR1-4, PDGFR α/β, c-Kit, and Ret.  We aimed to evaluate the safety, pharmacokinetics, and antitumor activity of anlotinib in patients with advanced refractory solid tumors.  Methods: Anlotinib (5-16 mg) was orally administered in patients with solid tumor once a day on two schedules: (1) four consecutive weeks (4/0) or (2) 2-wk on/1-wk off (2/1).  Pharmacokinetic sampling was performed in all patients.  Twenty-one patients were further enrolled in an expanded cohort study on the recommended dose and schedule.  Preliminary tumor response was also assessed.  Results: On the 4/0 schedule, dose-limiting toxicity (DLT) was grade 3 hypertension at 10 mg.  On the 2/1 schedule, DLT was grade 3 hypertension and grade 3 fatigue at 16 mg.  Pharmacokinetic assessment indicated that anlotinib had long elimination half-lives and significant accumulation during multiple oral doses.  The 2/1 schedule was selected, with 12 mg once daily as the max. tolerated dose for the expanding study.  Twenty of the 21 patients (with colon adenocarcinoma, non-small cell lung cancer, renal clear cell cancer, medullary thyroid carcinoma, and soft tissue sarcoma) were assessable for antitumor activity of anlotinib: 3 patients had partial response, 14 patients had stable disease including 12 tumor burden shrinkage, and 3 had disease progression.  The main serious adverse effects were hypertension, triglyceride elevation, hand-foot skin reaction, and lipase elevation.  Conclusions: At the dose of 12 mg once daily at the 2/1 schedule, anlotinib displayed manageable toxicity, long circulation, and broad-spectrum antitumor potential, justifying the conduct of further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDNQUtYXwHILVg90H21EOLACvtfcHk0lgoR_xh9J38Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVajsbjN&md5=38e37bd976e43f78f9d2ddae6fe61c97</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0332-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0332-8%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%26aulast%3DNiu%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DF.%26aulast%3DDu%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DHao%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DChi%26aufirst%3DY.%26atitle%3DSafety%252C%2520pharmacokinetics%252C%2520and%2520antitumor%2520properties%2520of%2520anlotinib%252C%2520an%2520oral%2520multi-target%2520tyrosine%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520refractory%2520solid%2520tumors%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D105%26doi%3D10.1186%2Fs13045-016-0332-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Morton, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keir, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorlick, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolb, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billups, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, P. J.</span><span> </span><span class="NLM_article-title">Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program</span> <span class="citation_source-journal">Pediatr. Blood Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">566</span><span class="NLM_x">–</span> <span class="NLM_lpage">571</span><span class="refDoi"> DOI: 10.1002/pbc.23159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1002%2Fpbc.23159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=21538824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A280%3ADC%252BC383is1CqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2012&pages=566-571&author=C.+L.+Mortonauthor=J.+M.+Marisauthor=S.+T.+Keirauthor=R.+Gorlickauthor=E.+A.+Kolbauthor=C.+A.+Billupsauthor=J.+Wuauthor=M.+A.+Smithauthor=P.+J.+Houghton&title=Combination+testing+of+cediranib+%28AZD2171%29+against+childhood+cancer+models+by+the+pediatric+preclinical+testing+program&doi=10.1002%2Fpbc.23159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program</span></div><div class="casAuthors">Morton Christopher L; Maris John M; Keir Stephen T; Gorlick Richard; Kolb E Anders; Billups Catherine A; Wu Jianrong; Smith Malcolm A; Houghton Peter J</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric blood & cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">566-71</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Cediranib (AZD2171) is a potent small molecule inhibitor of vascular endothelial growth factor (VEGF) receptors.  Cediranib has demonstrated single agent activity in several adult cancers and is being studied in combination with standard cytotoxic agents in multiple disease settings.  PROCEDURES:  Cediranib was tested in vivo against six childhood tumor xenograft models (four sarcomas, one glioblastoma, one neuroblastoma) alone or combined with cyclophosphamide (two models), vincristine (three models) or cisplatin (one model), each administered at its maximum tolerated dose, or rapamycin (six models).  RESULTS:  The combination of cediranib with standard cytotoxic agents was superior to the cytotoxic agent used alone for a single xenograft (one of the three xenografts evaluated for the vincristine-cediranib combination).  The cediranib-cyclophosphamide combination was inferior to single agent cyclophosphamide in time to event for both models studied and was significantly inferior for one of the models.  Cediranib combined with rapamycin was superior to each of the agents used alone in two of the six models and was determined to be additive or supra-additive with rapamycin in four models, although the effects were not large.  CONCLUSIONS:  Cediranib combined with cytotoxic chemotherapy agents demonstrated little or no benefit (and in one case was significantly inferior) compared to chemotherapy alone for the six pediatric cancer xenografts studied.  By contrast, the combination of cediranib with rapamycin was additive or supra-additive in four of the six models in terms of prolongation of time to event, though tumor regressions were not observed for this combination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR9RI-zRIITRJdYoSR9eyvsfW6udTcc2ebKmj5tQRjqVbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383is1CqtQ%253D%253D&md5=69e1a1c566f37b84974332b76e3cc761</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fpbc.23159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpbc.23159%26sid%3Dliteratum%253Aachs%26aulast%3DMorton%26aufirst%3DC.%2BL.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26aulast%3DKeir%26aufirst%3DS.%2BT.%26aulast%3DGorlick%26aufirst%3DR.%26aulast%3DKolb%26aufirst%3DE.%2BA.%26aulast%3DBillups%26aufirst%3DC.%2BA.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DM.%2BA.%26aulast%3DHoughton%26aufirst%3DP.%2BJ.%26atitle%3DCombination%2520testing%2520of%2520cediranib%2520%2528AZD2171%2529%2520against%2520childhood%2520cancer%2520models%2520by%2520the%2520pediatric%2520preclinical%2520testing%2520program%26jtitle%3DPediatr.%2520Blood%2520Cancer%26date%3D2012%26volume%3D58%26spage%3D566%26epage%3D571%26doi%3D10.1002%2Fpbc.23159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Bello, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarlato, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliva, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berndt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valbusa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serra, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Incalci, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalletti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giavazzi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camboni, G.</span><span> </span><span class="NLM_article-title">E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">1396</span><span class="NLM_x">–</span> <span class="NLM_lpage">1405</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-2700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1158%2F0008-5472.CAN-10-2700" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=1396-1405&author=E.+Belloauthor=G.+Colellaauthor=V.+Scarlatoauthor=P.+Olivaauthor=A.+Berndtauthor=G.+Valbusaauthor=S.+C.+Serraauthor=M.+D%E2%80%99Incalciauthor=E.+Cavallettiauthor=R.+Giavazziauthor=G.+Damiaauthor=G.+Camboni&title=E-3810+is+a+potent+dual+inhibitor+of+VEGFR+and+FGFR+that+exerts+antitumor+activity+in+multiple+preclinical+models&doi=10.1158%2F0008-5472.CAN-10-2700"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2700%26sid%3Dliteratum%253Aachs%26aulast%3DBello%26aufirst%3DE.%26aulast%3DColella%26aufirst%3DG.%26aulast%3DScarlato%26aufirst%3DV.%26aulast%3DOliva%26aufirst%3DP.%26aulast%3DBerndt%26aufirst%3DA.%26aulast%3DValbusa%26aufirst%3DG.%26aulast%3DSerra%26aufirst%3DS.%2BC.%26aulast%3DD%25E2%2580%2599Incalci%26aufirst%3DM.%26aulast%3DCavalletti%26aufirst%3DE.%26aulast%3DGiavazzi%26aufirst%3DR.%26aulast%3DDamia%26aufirst%3DG.%26aulast%3DCamboni%26aufirst%3DG.%26atitle%3DE-3810%2520is%2520a%2520potent%2520dual%2520inhibitor%2520of%2520VEGFR%2520and%2520FGFR%2520that%2520exerts%2520antitumor%2520activity%2520in%2520multiple%2520preclinical%2520models%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D1396%26epage%3D1405%26doi%3D10.1158%2F0008-5472.CAN-10-2700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Bhide, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, L. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leavitt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leith, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wautlet, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortillo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeyaseelan, R.,  Sr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukral, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Arienzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derbin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span> </span><span class="NLM_article-title">Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an <i>in vivo</i> active potent VEGFR-2 inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">2143</span><span class="NLM_x">–</span> <span class="NLM_lpage">2146</span><span class="refDoi"> DOI: 10.1021/jm051106d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm051106d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=2143-2146&author=R.+S.+Bhideauthor=Z.+W.+Caiauthor=Y.+Z.+Zhangauthor=L.+Qianauthor=D.+Weiauthor=S.+Barbosaauthor=L.+J.+Lombardoauthor=R.+M.+Borzilleriauthor=X.+Zhengauthor=L.+I.+Wuauthor=J.+C.+Barrishauthor=S.+H.+Kimauthor=K.+Leavittauthor=A.+Mathurauthor=L.+Leithauthor=S.+Chaoauthor=B.+Wautletauthor=S.+Mortilloauthor=R.+Jeyaseelanauthor=D.+Kukralauthor=J.+T.+Huntauthor=A.+Kamathauthor=A.+Furaauthor=V.+Vyasauthor=P.+Maratheauthor=C.+D%E2%80%99Arienzoauthor=G.+Derbinauthor=J.+Fargnoli&title=Discovery+and+preclinical+studies+of+%28R%29-1-%284-%284-fluoro-2-methyl-1H-indol-5-yloxy%29-5-+methylpyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazin-6-yloxy%29propan-+2-ol+%28BMS-540215%29%2C+an+in+vivo+active+potent+VEGFR-2+inhibitor&doi=10.1021%2Fjm051106d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm051106d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm051106d%26sid%3Dliteratum%253Aachs%26aulast%3DBhide%26aufirst%3DR.%2BS.%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DZhang%26aufirst%3DY.%2BZ.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DBarbosa%26aufirst%3DS.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DL.%2BI.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DLeavitt%26aufirst%3DK.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DLeith%26aufirst%3DL.%26aulast%3DChao%26aufirst%3DS.%26aulast%3DWautlet%26aufirst%3DB.%26aulast%3DMortillo%26aufirst%3DS.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DKukral%26aufirst%3DD.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DVyas%26aufirst%3DV.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DDerbin%26aufirst%3DG.%26aulast%3DFargnoli%26aufirst%3DJ.%26atitle%3DDiscovery%2520and%2520preclinical%2520studies%2520of%2520%2528R%2529-1-%25284-%25284-fluoro-2-methyl-1H-indol-5-yloxy%2529-5-%2520methylpyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazin-6-yloxy%2529propan-%25202-ol%2520%2528BMS-540215%2529%252C%2520an%2520in%2520vivo%2520active%2520potent%2520VEGFR-2%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D2143%26epage%3D2146%26doi%3D10.1021%2Fjm051106d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Fei, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidhuber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moll, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groffen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heisterkamp, N.</span><span> </span><span class="NLM_article-title">Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib)</span> <span class="citation_source-journal">Mol. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">42</span><span class="refDoi"> DOI: 10.1186/1476-4598-11-42</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1186%2F1476-4598-11-42" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=22721004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVSrsbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=42&author=F.+Feiauthor=M.+Limauthor=S.+Schmidhuberauthor=J.+Mollauthor=J.+Groffenauthor=N.+Heisterkamp&title=Treatment+of+human+pre-B+acute+lymphoblastic+leukemia+with+the+Aurora+kinase+inhibitor+PHA-739358+%28Danusertib%29&doi=10.1186%2F1476-4598-11-42"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib)</span></div><div class="casAuthors">Fei, Fei; Lim, Min; Schmidhuber, Sabine; Moll, Jurgen; Groffen, John; Heisterkamp, Nora</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Treatment of Philadelphia chromosome-pos. acute lymphoblastic leukemias (Ph-pos. ALL) with clin. approved inhibitors of the Bcr/Abl tyrosine kinase frequently results in the emergence of a leukemic clone carrying the T315I mutation in Bcr/Abl, which confers resistance to these drugs.  PHA-739358, an Aurora kinase inhibitor, was reported to inhibit the Bcr/Abl T315I mutant in CML cells but no preclin. studies have examd. this in detail in human ALL.  Results: We compared the sensitivity of human Bcr/Abl T315I, Bcr/Abl wild type and non-Bcr/Abl ALL cells to this drug.  PHA-739358 inhibited proliferation and induced apoptosis independently of Bcr/Abl, the T315I mutation, or presence of the tumor suppressor p53, but the degree of effectiveness varied between different ALL samples.  Since short-term treatment with a single dose of drug only transiently inhibited proliferation, we tested combination treatments of PHA-739358 with the farnesyltransferase inhibitor Lonafarnib, with vincristine and with dasatinib.  All combinations reduced viability and cell nos. compared to treatment with a single drug.  Clonogenic assays showed that 25 nM PHA-739358 significantly reduced the colony growth potential of Ph-pos. ALL cells, and combined treatment with a second drug abrogated colony growth in this assay.  PHA-739358 further effectively blocked Bcr/Abl tyrosine kinase activity and Aurora kinase B in vivo, and mice transplanted with human Bcr/Abl T315I ALL cells treated with a 3 × 7-day cycle of PHA-739358 as mono-treatment had significantly longer survival.  Conclusions: PHA-739358 represents an alternative drug for the treatment of both Ph-pos. and neg. ALL, although combined treatment with a second drug may be needed to eradicate the leukemic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-u39qxs0SR7Vg90H21EOLACvtfcHk0lgY94tiv_LcSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVSrsbvM&md5=41d906feb25050fe9e5ad7745088192a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-11-42&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-11-42%26sid%3Dliteratum%253Aachs%26aulast%3DFei%26aufirst%3DF.%26aulast%3DLim%26aufirst%3DM.%26aulast%3DSchmidhuber%26aufirst%3DS.%26aulast%3DMoll%26aufirst%3DJ.%26aulast%3DGroffen%26aufirst%3DJ.%26aulast%3DHeisterkamp%26aufirst%3DN.%26atitle%3DTreatment%2520of%2520human%2520pre-B%2520acute%2520lymphoblastic%2520leukemia%2520with%2520the%2520Aurora%2520kinase%2520inhibitor%2520PHA-739358%2520%2528Danusertib%2529%26jtitle%3DMol.%2520Cancer%26date%3D2012%26volume%3D11%26spage%3D42%26doi%3D10.1186%2F1476-4598-11-42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Cohen, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hainsworth, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madajewicz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosgriff, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liau, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healey, D.</span><span> </span><span class="NLM_article-title">A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">89</span><span class="refDoi"> DOI: 10.1007/s00280-006-0352-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1007%2Fs00280-006-0352-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=17031646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksVOgsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2007&pages=81-89&author=R.+B.+Cohenauthor=C.+J.+Langerauthor=G.+R.+Simonauthor=P.+D.+Eisenbergauthor=J.+D.+Hainsworthauthor=S.+Madajewiczauthor=T.+M.+Cosgriffauthor=K.+Pierceauthor=H.+Xuauthor=K.+Liauauthor=D.+Healey&title=A+phase+I%2Frandomized+phase+II%2C+non-comparative%2C+multicenter%2C+open+label+trial+of+CP-547%2C632+in+combination+with+paclitaxel+and+carboplatin+or+paclitaxel+and+carboplatin+alone+as+first-line+treatment+for+advanced+non-small+cell+lung+cancer+%28NSCLC%29&doi=10.1007%2Fs00280-006-0352-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)</span></div><div class="casAuthors">Cohen, Roger B.; Langer, Corey J.; Simon, George Rajan; Eisenberg, Peter David; Hainsworth, John Daniel; Madajewicz, Stefan; Cosgriff, Thomas Michael; Pierce, Kristen; Xu, Huiping; Liau, Katherine; Healey, Diane</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">81-89</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: To evaluate the toxicity profile and pharmacol. properties of oral CP-547,632 alone and in combination with paclitaxel and carboplatin administered every 3 wk, and to assess efficacy as measured by the objective response and progressive disease rates of oral CP-547,632 administered in combination with paclitaxel and carboplatin.  Patients and methods: Patients with stage IIIB/IV or recurrent non-small cell lung cancer receiving first-line chemotherapy were treated with oral daily CP-547,632 in combination with paclitaxel 225 mg/m2 and carboplatin AUC = 6 every 3 wk.  Pharmacokinetics parameters for CP-547,632 and paclitaxel were detd. independently and during co-administration.  Results: Seventy patients were enrolled and 68 patients were treated, 37 in phase 1 and 31 in phase 2 (14 with the combination and 17 with chemotherapy alone).  Dose-limiting toxicity of CP-547,632 250 mg by mouth daily in combination with paclitaxel and carboplatin was grade 3 rash and grade 3 diarrhea despite medical intervention.  CP-547,632 did not significantly affect the pharmacol. profiles of paclitaxel and carboplatin.  No subject had CR.  In phase I, seven subjects (22.6%) had a confirmed partial response.  In phase II, four subjects (28.6%) receiving CP-547,632 plus chemotherapy had a confirmed partial response.  In the phase II chemotherapy alone group, four subjects (25%) had a confirmed partial response.  Conclusion: The combination of CP-547,632 and paclitaxel and carboplatin was well-tolerated at doses up to 200 mg by mouth daily.  Dose-limiting toxicity of CP-547,632 at 250 mg consisted of diarrhea and rash.  CP-547,632 did not increase the objective response rate to chemotherapy alone in patients with advanced non-small cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopzOmygcNSSLVg90H21EOLACvtfcHk0lgY94tiv_LcSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksVOgsLY%253D&md5=82853265274c80dc446731445b0c7707</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs00280-006-0352-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-006-0352-0%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DR.%2BB.%26aulast%3DLanger%26aufirst%3DC.%2BJ.%26aulast%3DSimon%26aufirst%3DG.%2BR.%26aulast%3DEisenberg%26aufirst%3DP.%2BD.%26aulast%3DHainsworth%26aufirst%3DJ.%2BD.%26aulast%3DMadajewicz%26aufirst%3DS.%26aulast%3DCosgriff%26aufirst%3DT.%2BM.%26aulast%3DPierce%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DLiau%26aufirst%3DK.%26aulast%3DHealey%26aufirst%3DD.%26atitle%3DA%2520phase%2520I%252Frandomized%2520phase%2520II%252C%2520non-comparative%252C%2520multicenter%252C%2520open%2520label%2520trial%2520of%2520CP-547%252C632%2520in%2520combination%2520with%2520paclitaxel%2520and%2520carboplatin%2520or%2520paclitaxel%2520and%2520carboplatin%2520alone%2520as%2520first-line%2520treatment%2520for%2520advanced%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2007%26volume%3D60%26spage%3D81%26epage%3D89%26doi%3D10.1007%2Fs00280-006-0352-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Moreno, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morland, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell-Hewson, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halford, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazmi-Stokes, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lock, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boddy, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yule, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargrave, D.</span><span> </span><span class="NLM_article-title">A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">267</span><span class="NLM_x">–</span> <span class="NLM_lpage">273</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-1592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1158%2F1078-0432.CCR-14-1592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=25370467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlGrsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=267-273&author=L.+Morenoauthor=L.+V.+Marshallauthor=A.+D.+Pearsonauthor=B.+Morlandauthor=M.+Elliottauthor=Q.+Campbell-Hewsonauthor=G.+Makinauthor=S.+E.+Halfordauthor=G.+Actonauthor=P.+Rossauthor=S.+Kazmi-Stokesauthor=V.+Lockauthor=A.+Rodriguezauthor=J.+F.+Lyonsauthor=A.+V.+Boddyauthor=M.+J.+Griffinauthor=M.+Yuleauthor=D.+Hargrave&title=A+phase+I+trial+of+AT9283+%28a+selective+inhibitor+of+aurora+kinases%29+in+children+and+adolescents+with+solid+tumors%3A+a+Cancer+Research+UK+study&doi=10.1158%2F1078-0432.CCR-14-1592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study</span></div><div class="casAuthors">Moreno, Lucas; Marshall, Lynley V.; Pearson, Andrew D. J.; Morland, Bruce; Elliott, Martin; Campbell-Hewson, Quentin; Makin, Guy; Halford, Sarah E. R.; Acton, Gary; Ross, Philip; Kazmi-Stokes, Shamim; Lock, Victoria; Rodriguez, Ana; Lyons, John F.; Boddy, Alan V.; Griffin, Melanie J.; Yule, Murray; Hargrave, Darren</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">267-273</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: A phase I trial of AT9283 (a multitargeted inhibitor of Aurora kinases A and B) was conducted in children and adolescents with solid tumors, to identify max.-tolerated dose (MTD), safety, efficacy, pharmacokinetics, and pharmacodynamic (PD) activity.  Exptl. Design: AT9283 was administered as a 72-h continuous i.v. infusion every 3 wk.  A rolling-six design, explored six dose levels (7, 9, 11.5, 14.5, 18.5, and 23 mg/m2/d).  Pharmacokinetic and PD assessments, included inhibition of phospho-histone 3 (pHH3) in paired skin punch biopsies.  Results: Thirty-three patients were evaluable for toxicity.  There were six dose-limiting toxicities and the MTD was 18.5 mg/m2/d.  Most common drug-related toxicities were hematol. (neutropenia, anemia, and thrombocytopenia in 36.4%, 18.2%, and 21.2% of patients), which were grade ≥3 in 30.3%, 6.1%, and 3% of patients.  Nonhematol. toxicities included fatigue, infections, febrile neutropenia and ALT elevation.  One patient with central nervous system-primitive neuroectodermal tumor (CNS-PNET) achieved a partial response after 16 cycles and 3 cases were stable for four or more cycles.  Plasma concns. were comparable with those in adults at the same dose level, clearance was similar although half-life was shorter (4.9 ± 1.5 h, compared with 8.4 ± 3.7 h in adults).  Inhibition of Aurora kinase B was shown by redn. in pHH3 in 17 of 18 patients treated at ≥11.5 mg/m2/d.  Conclusion: AT9283 was well tolerated in children and adolescents with solid tumors with manageable hematol. toxicity.  Target inhibition was demonstrated.  Disease stabilization was documented in intracranial and extracranial pediatric solid tumors and a phase II dose detd.  Clin Cancer Res; 21(2); 267-73. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxp9EKAjYXabVg90H21EOLACvtfcHk0lgY94tiv_LcSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlGrsrk%253D&md5=f1277d4edd2b7e36c542ce5e19fece8d</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-1592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-1592%26sid%3Dliteratum%253Aachs%26aulast%3DMoreno%26aufirst%3DL.%26aulast%3DMarshall%26aufirst%3DL.%2BV.%26aulast%3DPearson%26aufirst%3DA.%2BD.%26aulast%3DMorland%26aufirst%3DB.%26aulast%3DElliott%26aufirst%3DM.%26aulast%3DCampbell-Hewson%26aufirst%3DQ.%26aulast%3DMakin%26aufirst%3DG.%26aulast%3DHalford%26aufirst%3DS.%2BE.%26aulast%3DActon%26aufirst%3DG.%26aulast%3DRoss%26aufirst%3DP.%26aulast%3DKazmi-Stokes%26aufirst%3DS.%26aulast%3DLock%26aufirst%3DV.%26aulast%3DRodriguez%26aufirst%3DA.%26aulast%3DLyons%26aufirst%3DJ.%2BF.%26aulast%3DBoddy%26aufirst%3DA.%2BV.%26aulast%3DGriffin%26aufirst%3DM.%2BJ.%26aulast%3DYule%26aufirst%3DM.%26aulast%3DHargrave%26aufirst%3DD.%26atitle%3DA%2520phase%2520I%2520trial%2520of%2520AT9283%2520%2528a%2520selective%2520inhibitor%2520of%2520aurora%2520kinases%2529%2520in%2520children%2520and%2520adolescents%2520with%2520solid%2520tumors%253A%2520a%2520Cancer%2520Research%2520UK%2520study%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D267%26epage%3D273%26doi%3D10.1158%2F1078-0432.CCR-14-1592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Wesche, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haglund, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haugsten, E. M.</span><span> </span><span class="NLM_article-title">Fibroblast growth factors and their receptors in cancer</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">437</span><span class="NLM_x">, </span> <span class="NLM_fpage">199</span><span class="NLM_x">–</span> <span class="NLM_lpage">213</span><span class="refDoi"> DOI: 10.1042/BJ20101603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1042%2FBJ20101603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=21711248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotFSmtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=437&publication_year=2011&pages=199-213&author=J.+Wescheauthor=K.+Haglundauthor=E.+M.+Haugsten&title=Fibroblast+growth+factors+and+their+receptors+in+cancer&doi=10.1042%2FBJ20101603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factors and their receptors in cancer</span></div><div class="casAuthors">Wesche, Jorgen; Haglund, Kaisa; Haugsten, Ellen Margrethe</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">437</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-213</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  FGFs (fibroblast growth factors) and their receptors (FGFRs) play essential roles in tightly regulating cell proliferation, survival, migration and differentiation during development and adult life.  Deregulation of FGFR signaling, on the other hand, was assocd. with many developmental syndromes, and with human cancer.  In cancer, FGFRs were found to become overactivated by several mechanisms, including gene amplification, chromosomal translocation and mutations.  FGFR alterations are detected in a variety of human cancers, such as breast, bladder, prostate, endometrial and lung cancers, as well as haematol. malignancies.  Accumulating evidence indicates that FGFs and FGFRs may act in an oncogenic fashion to promote multiple steps of cancer progression by inducing mitogenic and survival signals, as well as promoting epithelial-mesenchymal transition, invasion and tumor angiogenesis.  Therapeutic strategies targeting FGFs and FGFRs in human cancer are therefore currently being explored.  In the present review we will give an overview of FGF signaling, the main FGFR alterations found in human cancer to date, how they may contribute to specific cancer types and strategies for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkZsZJgfVo0rVg90H21EOLACvtfcHk0li_ZU3H9QiHwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotFSmtbc%253D&md5=9b5249fe623e39e0445dedfc38537075</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1042%2FBJ20101603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20101603%26sid%3Dliteratum%253Aachs%26aulast%3DWesche%26aufirst%3DJ.%26aulast%3DHaglund%26aufirst%3DK.%26aulast%3DHaugsten%26aufirst%3DE.%2BM.%26atitle%3DFibroblast%2520growth%2520factors%2520and%2520their%2520receptors%2520in%2520cancer%26jtitle%3DBiochem.%2520J.%26date%3D2011%26volume%3D437%26spage%3D199%26epage%3D213%26doi%3D10.1042%2FBJ20101603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Turner, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharpe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambros, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geyer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Garcia, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natrajan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iorns, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillett, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grigoriadis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis-Filho, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">2085</span><span class="NLM_x">–</span> <span class="NLM_lpage">2094</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-3746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1158%2F0008-5472.CAN-09-3746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=20179196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFWis7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=2085-2094&author=N.+Turnerauthor=A.+Pearsonauthor=R.+Sharpeauthor=M.+Lambrosauthor=F.+Geyerauthor=M.+A.+Lopez-Garciaauthor=R.+Natrajanauthor=C.+Marchioauthor=E.+Iornsauthor=A.+Mackayauthor=C.+Gillettauthor=A.+Grigoriadisauthor=A.+Tuttauthor=J.+S.+Reis-Filhoauthor=A.+Ashworth&title=FGFR1+amplification+drives+endocrine+therapy+resistance+and+is+a+therapeutic+target+in+breast+cancer&doi=10.1158%2F0008-5472.CAN-09-3746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer</span></div><div class="casAuthors">Turner, Nicholas; Pearson, Alex; Sharpe, Rachel; Lambros, Maryou; Geyer, Felipe; Lopez-Garcia, Maria A.; Natrajan, Rachael; Marchio, Caterina; Iorns, Elizabeth; Mackay, Alan; Gillett, Cheryl; Grigoriadis, Anita; Tutt, Andrew; Reis-Filho, Jorge S.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2085-2094</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Amplification of fibroblast growth factor receptor 1 (FGFR1) occurs in ∼10% of breast cancers and is assocd. with poor prognosis.  However, it is uncertain whether overexpression of FGFR1 is causally linked to the poor prognosis of amplified cancers.  Here, we show that FGFR1 overexpression is robustly assocd. with FGFR1 amplification in two independent series of breast cancers.  Breast cancer cell lines with FGFR1 overexpression and amplification show enhanced ligand-dependent signaling, with increased activation of the mitogen-activated protein kinase and phosphoinositide 3-kinase-AKT signaling pathways in response to FGF2, but also show basal ligand-independent signaling, and are dependent on FGFR signaling for anchorage-independent growth.  FGFR1-amplified cell lines show resistance to 4-hydroxytamoxifen, which is reversed by small interfering RNA silencing of FGFR1, suggesting that FGFR1 overexpression also promotes endocrine therapy resistance.  FGFR1 signaling suppresses progesterone receptor (PR) expression in vitro, and likewise, amplified cancers are frequently PR neg., identifying a potential biomarker for FGFR1 activity.  Furthermore, we show that amplified cancers have a high proliferative rate assessed by Ki67 staining and that FGFR1 amplification is found in 16% to 27% of luminal B-type breast cancers.  Our data suggest that amplification and overexpression of FGFR1 may be a major contributor to poor prognosis in luminal-type breast cancers, driving anchorage-independent proliferation and endocrine therapy resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbsQ_wPmoftLVg90H21EOLACvtfcHk0li_ZU3H9QiHwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFWis7s%253D&md5=d14ce3b47614b090c4f7bfa7e4ce8a38</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3746%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DPearson%26aufirst%3DA.%26aulast%3DSharpe%26aufirst%3DR.%26aulast%3DLambros%26aufirst%3DM.%26aulast%3DGeyer%26aufirst%3DF.%26aulast%3DLopez-Garcia%26aufirst%3DM.%2BA.%26aulast%3DNatrajan%26aufirst%3DR.%26aulast%3DMarchio%26aufirst%3DC.%26aulast%3DIorns%26aufirst%3DE.%26aulast%3DMackay%26aufirst%3DA.%26aulast%3DGillett%26aufirst%3DC.%26aulast%3DGrigoriadis%26aufirst%3DA.%26aulast%3DTutt%26aufirst%3DA.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DFGFR1%2520amplification%2520drives%2520endocrine%2520therapy%2520resistance%2520and%2520is%2520a%2520therapeutic%2520target%2520in%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D2085%26epage%3D2094%26doi%3D10.1158%2F0008-5472.CAN-09-3746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Dutt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvesen, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramos, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onofrio, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatton, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoletti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winckler, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grewal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyhs, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziaugra, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trovik, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelsen, I. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefansson, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fennell, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cibulskis, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zody, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akslen, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span> </span><span class="NLM_article-title">Drug-sensitive FGFR2 mutations in endometrial carcinoma</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">8713</span><span class="NLM_x">–</span> <span class="NLM_lpage">8717</span><span class="refDoi"> DOI: 10.1073/pnas.0803379105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1073%2Fpnas.0803379105" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=8713-8717&author=A.+Duttauthor=H.+B.+Salvesenauthor=T.+H.+Chenauthor=A.+H.+Ramosauthor=R.+C.+Onofrioauthor=C.+Hattonauthor=R.+Nicolettiauthor=W.+Wincklerauthor=R.+Grewalauthor=M.+Hannaauthor=N.+Wyhsauthor=L.+Ziaugraauthor=D.+J.+Richterauthor=J.+Trovikauthor=I.+B.+Engelsenauthor=I.+M.+Stefanssonauthor=T.+Fennellauthor=K.+Cibulskisauthor=M.+C.+Zodyauthor=L.+A.+Akslenauthor=S.+Gabrielauthor=K.+K.+Wongauthor=W.+R.+Sellersauthor=M.+Meyersonauthor=H.+Greulich&title=Drug-sensitive+FGFR2+mutations+in+endometrial+carcinoma&doi=10.1073%2Fpnas.0803379105"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0803379105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0803379105%26sid%3Dliteratum%253Aachs%26aulast%3DDutt%26aufirst%3DA.%26aulast%3DSalvesen%26aufirst%3DH.%2BB.%26aulast%3DChen%26aufirst%3DT.%2BH.%26aulast%3DRamos%26aufirst%3DA.%2BH.%26aulast%3DOnofrio%26aufirst%3DR.%2BC.%26aulast%3DHatton%26aufirst%3DC.%26aulast%3DNicoletti%26aufirst%3DR.%26aulast%3DWinckler%26aufirst%3DW.%26aulast%3DGrewal%26aufirst%3DR.%26aulast%3DHanna%26aufirst%3DM.%26aulast%3DWyhs%26aufirst%3DN.%26aulast%3DZiaugra%26aufirst%3DL.%26aulast%3DRichter%26aufirst%3DD.%2BJ.%26aulast%3DTrovik%26aufirst%3DJ.%26aulast%3DEngelsen%26aufirst%3DI.%2BB.%26aulast%3DStefansson%26aufirst%3DI.%2BM.%26aulast%3DFennell%26aufirst%3DT.%26aulast%3DCibulskis%26aufirst%3DK.%26aulast%3DZody%26aufirst%3DM.%2BC.%26aulast%3DAkslen%26aufirst%3DL.%2BA.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DGreulich%26aufirst%3DH.%26atitle%3DDrug-sensitive%2520FGFR2%2520mutations%2520in%2520endometrial%2520carcinoma%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D8713%26epage%3D8717%26doi%3D10.1073%2Fpnas.0803379105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Shoichet, B. K.</span><span> </span><span class="NLM_article-title">Virtual screening of chemical libraries</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">432</span><span class="NLM_x">, </span> <span class="NLM_fpage">862</span><span class="NLM_x">–</span> <span class="NLM_lpage">865</span><span class="refDoi"> DOI: 10.1038/nature03197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1038%2Fnature03197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=15602552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVOht7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=432&publication_year=2004&pages=862-865&author=B.+K.+Shoichet&title=Virtual+screening+of+chemical+libraries&doi=10.1038%2Fnature03197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Virtual screening of chemical libraries</span></div><div class="casAuthors">Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">432</span>
        (<span class="NLM_cas:issue">7019</span>),
    <span class="NLM_cas:pages">862-865</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Virtual screening uses computer-based methods to discover new ligands on the basis of biol. structures.  Although widely heralded in the 1970s and 1980s, the technique has since struggled to meet its initial promise, and drug discovery remains dominated by empirical screening.  Recent successes in predicting new ligands and their receptor-bound structures, and better rates of ligand discovery compared to empirical screening, have reignited interest in virtual screening, which is now widely used in drug discovery, albeit on a more limited scale than empirical screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSY9IbbFldkrVg90H21EOLACvtfcHk0li2_ZLG_zoanQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVOht7jK&md5=e351e226e8985d7c304a05fb67dfdc60</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnature03197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03197%26sid%3Dliteratum%253Aachs%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DVirtual%2520screening%2520of%2520chemical%2520libraries%26jtitle%3DNature%26date%3D2004%26volume%3D432%26spage%3D862%26epage%3D865%26doi%3D10.1038%2Fnature03197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span> </span><span class="NLM_article-title">Rapid generation of privileged substructure-based compound libraries with structural diversity and drug-likeness</span> <span class="citation_source-journal">ACS Comb. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">184</span><span class="NLM_x">–</span> <span class="NLM_lpage">191</span><span class="refDoi"> DOI: 10.1021/co4001309</span> </span><div class="citationLinks">[<a href="/doi/10.1021/co4001309" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFKht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=184-191&author=L.+Zhangauthor=M.+Y.+Zhengauthor=F.+Zhaoauthor=Y.+Zhaiauthor=H.+Liu&title=Rapid+generation+of+privileged+substructure-based+compound+libraries+with+structural+diversity+and+drug-likeness&doi=10.1021%2Fco4001309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid Generation of Privileged Substructure-Based Compound Libraries with Structural Diversity and Drug-Likeness</span></div><div class="casAuthors">Zhang, Lei; Zheng, Mingyue; Zhao, Fei; Zhai, Yun; Liu, Hong</div><div class="citationInfo"><span class="NLM_cas:title">ACS Combinatorial Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">184-191</span>CODEN:
                <span class="NLM_cas:coden">ACSCCC</span>;
        ISSN:<span class="NLM_cas:issn">2156-8944</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A library of privileged-substructure-based, heterocyclic compds. was constructed by a sequence of Ugi four-component reactions incorporating the indole motif and microwave-assisted cyclizations in branched pathways.  Cheminformatic anal. confirmed that the library exhibited a high degree of structural diversity and good drug-likeness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs3GfYzj0NNbVg90H21EOLACvtfcHk0li2_ZLG_zoanQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFKht70%253D&md5=43ed67ba33c8765f1ebc3fa0ad4fd033</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fco4001309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fco4001309%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DM.%2BY.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DRapid%2520generation%2520of%2520privileged%2520substructure-based%2520compound%2520libraries%2520with%2520structural%2520diversity%2520and%2520drug-likeness%26jtitle%3DACS%2520Comb.%2520Sci.%26date%3D2014%26volume%3D16%26spage%3D184%26epage%3D191%26doi%3D10.1021%2Fco4001309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Drewry, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macarron, R.</span><span> </span><span class="NLM_article-title">Enhancements of screening collections to address areas of unmet medical need: an industry perspective</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">289</span><span class="NLM_x">–</span> <span class="NLM_lpage">298</span><span class="refDoi"> DOI: 10.1016/j.cbpa.2010.03.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1016%2Fj.cbpa.2010.03.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=20413343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmvVWqs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=289-298&author=D.+H.+Drewryauthor=R.+Macarron&title=Enhancements+of+screening+collections+to+address+areas+of+unmet+medical+need%3A+an+industry+perspective&doi=10.1016%2Fj.cbpa.2010.03.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancements of screening collections to address areas of unmet medical need: an industry perspective</span></div><div class="casAuthors">Drewry, David H.; Macarron, Ricardo</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">289-298</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The past 20 years have witnessed an impressive expansion of the  drug space'; defined as the intersection of the Medicinal Chem. space and the Biol. Active space relevant in the quest for new treatments for disease.  Despite the success of known lead discovery tactics, areas of unmet medical need are often linked to challenging or novel targets and are poorly served by current screening collections.  A successful strategy to fill the gaps is to diversify the approaches taken in the enhancement of screening collections.  Possible strategies include investments through proven methods, exploring areas of chem. space previously neglected (e.g. hydrophilic compds., natural product mimics), and applying tactics to the lead discovery process that are complementary to HTS (e.g. fragment based screening or multidisciplinary team efforts to tackle new target classes).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG12E8gELNY7Vg90H21EOLACvtfcHk0li2_ZLG_zoanQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmvVWqs7Y%253D&md5=42466fea7e20ea8e1170303cb44e7339</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2010.03.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2010.03.024%26sid%3Dliteratum%253Aachs%26aulast%3DDrewry%26aufirst%3DD.%2BH.%26aulast%3DMacarron%26aufirst%3DR.%26atitle%3DEnhancements%2520of%2520screening%2520collections%2520to%2520address%2520areas%2520of%2520unmet%2520medical%2520need%253A%2520an%2520industry%2520perspective%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D14%26spage%3D289%26epage%3D298%26doi%3D10.1016%2Fj.cbpa.2010.03.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Bleicher, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohm, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alanine, A. I.</span><span> </span><span class="NLM_article-title">Hit and lead generation: beyond high-throughput screening</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">369</span><span class="NLM_x">–</span> <span class="NLM_lpage">378</span><span class="refDoi"> DOI: 10.1038/nrd1086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1038%2Fnrd1086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=12750740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjslamtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=369-378&author=K.+H.+Bleicherauthor=H.+J.+Bohmauthor=K.+Mullerauthor=A.+I.+Alanine&title=Hit+and+lead+generation%3A+beyond+high-throughput+screening&doi=10.1038%2Fnrd1086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A guide to drug discovery: Hit and lead generation: beyond high-throughput screening</span></div><div class="casAuthors">Bleicher, Konrad H.; Boehm, Hans-Joachim; Mueller, Klaus; Alanine, Alexander I.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">369-378</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The identification of small-mol. modulators of protein function, and the process of transforming these into high-content lead series, are key activities in modern drug discovery.  The decisions taken during this process have far-reaching consequences for success later in lead optimization and even more crucially in clin. development.  Recently, there has been an increased focus on these activities due to escalating downstream costs resulting from high clin. failure rates.  In addn., the vast emerging opportunities from efforts in functional genomics and proteomics demands a departure from the linear process of identification, evaluation and refinement activities towards a more integrated parallel process.  This calls for flexible, fast and cost-effective strategies to meet the demands of producing high-content lead series with improved prospects for clin. success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9IQCsTR8tobVg90H21EOLACvtfcHk0li2_ZLG_zoanQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjslamtb8%253D&md5=b54e55c1f0d34fbd172c8aa9b996591d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnrd1086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1086%26sid%3Dliteratum%253Aachs%26aulast%3DBleicher%26aufirst%3DK.%2BH.%26aulast%3DBohm%26aufirst%3DH.%2BJ.%26aulast%3DMuller%26aufirst%3DK.%26aulast%3DAlanine%26aufirst%3DA.%2BI.%26atitle%3DHit%2520and%2520lead%2520generation%253A%2520beyond%2520high-throughput%2520screening%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D369%26epage%3D378%26doi%3D10.1038%2Fnrd1086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Spandl, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spring, D. R.</span><span> </span><span class="NLM_article-title">Diversity-oriented synthesis; a spectrum of approaches and results</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1149</span><span class="NLM_x">–</span> <span class="NLM_lpage">1158</span><span class="refDoi"> DOI: 10.1039/b719372f</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1039%2Fb719372f" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=18362950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjs12ntbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=1149-1158&author=R.+J.+Spandlauthor=A.+Benderauthor=D.+R.+Spring&title=Diversity-oriented+synthesis%3B+a+spectrum+of+approaches+and+results&doi=10.1039%2Fb719372f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Diversity-oriented synthesis; a spectrum of approaches and results</span></div><div class="casAuthors">Spandl, Richard J.; Bender, Andreas; Spring, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1149-1158</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Since our emerging area article, diversity-oriented synthesis (DOS), which aims to prep. efficiently collections of skeletally diverse small mols., has developed in the synthetic approaches it employs.  This article describes three general strategies, highlighting some successful examples.  The utility of DOS, in the interrogation of chem. space and in the identification of novel biol. active lead compds., is also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzIOlcPxM_ybVg90H21EOLACvtfcHk0lixGm-BQIfF8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjs12ntbg%253D&md5=b5e117edf6c8e56ba42fd33cfd39f9b1</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1039%2Fb719372f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb719372f%26sid%3Dliteratum%253Aachs%26aulast%3DSpandl%26aufirst%3DR.%2BJ.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DSpring%26aufirst%3DD.%2BR.%26atitle%3DDiversity-oriented%2520synthesis%253B%2520a%2520spectrum%2520of%2520approaches%2520and%2520results%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2008%26volume%3D6%26spage%3D1149%26epage%3D1158%26doi%3D10.1039%2Fb719372f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Golebiowski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klopfenstein, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Portlock, D. E.</span><span> </span><span class="NLM_article-title">Lead compounds discovered from libraries</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">–</span> <span class="NLM_lpage">284</span><span class="refDoi"> DOI: 10.1016/S1367-5931(00)00203-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1016%2FS1367-5931%2800%2900203-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=11479119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktlShtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2001&pages=273-284&author=A.+Golebiowskiauthor=S.+R.+Klopfensteinauthor=D.+E.+Portlock&title=Lead+compounds+discovered+from+libraries&doi=10.1016%2FS1367-5931%2800%2900203-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Lead compounds discovered from libraries</span></div><div class="casAuthors">Golebiowski, Adam; Klopfenstein, Sean R.; Portlock, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">273-284</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 77 refs.  Lead compds. with the potential to progress to viable drug candidates have been identified from libraries using several strategies.  These include rapid screening of large diverse collections, thematic libraries, project-directed libraries, and three-dimensional mol. models of corporate databases.  There have been numerous success stories, including the identification of several clin. candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKddxA9JYAmLVg90H21EOLACvtfcHk0lixGm-BQIfF8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktlShtLk%253D&md5=63b8228151566795939f5b7249b62b96</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FS1367-5931%2800%2900203-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1367-5931%252800%252900203-9%26sid%3Dliteratum%253Aachs%26aulast%3DGolebiowski%26aufirst%3DA.%26aulast%3DKlopfenstein%26aufirst%3DS.%2BR.%26aulast%3DPortlock%26aufirst%3DD.%2BE.%26atitle%3DLead%2520compounds%2520discovered%2520from%2520libraries%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2001%26volume%3D5%26spage%3D273%26epage%3D284%26doi%3D10.1016%2FS1367-5931%2800%2900203-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Geysen, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoenen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, R.</span><span> </span><span class="NLM_article-title">Combinatorial compound libraries for drug discovery: An ongoing challenge</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">222</span><span class="NLM_x">–</span> <span class="NLM_lpage">230</span><span class="refDoi"> DOI: 10.1038/nrd1035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1038%2Fnrd1035" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=222-230&author=H.+M.+Geysenauthor=F.+Schoenenauthor=D.+Wagnerauthor=R.+Wagner&title=Combinatorial+compound+libraries+for+drug+discovery%3A+An+ongoing+challenge&doi=10.1038%2Fnrd1035"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnrd1035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1035%26sid%3Dliteratum%253Aachs%26aulast%3DGeysen%26aufirst%3DH.%2BM.%26aulast%3DSchoenen%26aufirst%3DF.%26aulast%3DWagner%26aufirst%3DD.%26aulast%3DWagner%26aufirst%3DR.%26atitle%3DCombinatorial%2520compound%2520libraries%2520for%2520drug%2520discovery%253A%2520An%2520ongoing%2520challenge%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D222%26epage%3D230%26doi%3D10.1038%2Fnrd1035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Orry, A. J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abagyan, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavasotto, C. N.</span><span> </span><span class="NLM_article-title">Structure-based development of target-specific compound libraries</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">266</span><span class="refDoi"> DOI: 10.1016/S1359-6446(05)03717-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1016%2FS1359-6446%2805%2903717-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=16580603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtFagsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2006&pages=261-266&author=A.+J.+W.+Orryauthor=R.+A.+Abagyanauthor=C.+N.+Cavasotto&title=Structure-based+development+of+target-specific+compound+libraries&doi=10.1016%2FS1359-6446%2805%2903717-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based development of target-specific compound libraries</span></div><div class="casAuthors">Orry, Andrew J. W.; Abagyan, Ruben A.; Cavasotto, Claudio N.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5 & 6</span>),
    <span class="NLM_cas:pages">261-266</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The success or failure of a small-mol. drug discovery project ultimately lies in the choice of the scaffolds to be screened - chosen from among the many millions of available compds.  Therefore, the methods used to design compd. screening libraries are key for the development of new drugs that target a wide range of diseases.  Currently, there is a trend towards the construction of receptor-structure-based focused libraries.  Recent advances in high-throughput computational docking, NMR and crystallog. have facilitated the development of these libraries.  A structure-based target-specific library can save time and money by reducing the no. of compds. to be exptl. tested, also improving the drug discovery success rate by identifying more-potent and specific binders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBfW1A60Omu7Vg90H21EOLACvtfcHk0lixGm-BQIfF8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtFagsbY%253D&md5=53c0a7688115e7fed06edebafe97844a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2805%2903717-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252805%252903717-7%26sid%3Dliteratum%253Aachs%26aulast%3DOrry%26aufirst%3DA.%2BJ.%2BW.%26aulast%3DAbagyan%26aufirst%3DR.%2BA.%26aulast%3DCavasotto%26aufirst%3DC.%2BN.%26atitle%3DStructure-based%2520development%2520of%2520target-specific%2520compound%2520libraries%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2006%26volume%3D11%26spage%3D261%26epage%3D266%26doi%3D10.1016%2FS1359-6446%2805%2903717-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Welsch, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stockwell, B. R.</span><span> </span><span class="NLM_article-title">Privileged scaffolds for library design and drug discovery</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">347</span><span class="NLM_x">–</span> <span class="NLM_lpage">361</span><span class="refDoi"> DOI: 10.1016/j.cbpa.2010.02.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1016%2Fj.cbpa.2010.02.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=20303320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmvVWqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=347-361&author=M.+E.+Welschauthor=S.+A.+Snyderauthor=B.+R.+Stockwell&title=Privileged+scaffolds+for+library+design+and+drug+discovery&doi=10.1016%2Fj.cbpa.2010.02.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Privileged scaffolds for library design and drug discovery</span></div><div class="casAuthors">Welsch, Matthew E.; Snyder, Scott A.; Stockwell, Brent R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-361</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This review explores the concept of using privileged scaffolds to identify biol. active compds. through building chem. libraries.  We hope to accomplish three main objectives: to provide one of the most comprehensive listings of privileged scaffolds; to reveal through four selected examples the present state of the art in privileged scaffold library synthesis (in hopes of inspiring new and even more creative approaches); and also to offer some thoughts on how new privileged scaffolds might be identified and exploited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWQPxdsWawiLVg90H21EOLACvtfcHk0lixGm-BQIfF8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmvVWqsLs%253D&md5=fd0c2a642f063fd6f42f2c34fd186f8a</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2010.02.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2010.02.018%26sid%3Dliteratum%253Aachs%26aulast%3DWelsch%26aufirst%3DM.%2BE.%26aulast%3DSnyder%26aufirst%3DS.%2BA.%26aulast%3DStockwell%26aufirst%3DB.%2BR.%26atitle%3DPrivileged%2520scaffolds%2520for%2520library%2520design%2520and%2520drug%2520discovery%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D14%26spage%3D347%26epage%3D361%26doi%3D10.1016%2Fj.cbpa.2010.02.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Lopez-Vallejo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giulianotti, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghten, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina-Franco, J. L.</span><span> </span><span class="NLM_article-title">Expanding the medicinally relevant chemical space with compound libraries</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">718</span><span class="NLM_x">–</span> <span class="NLM_lpage">726</span><span class="refDoi"> DOI: 10.1016/j.drudis.2012.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1016%2Fj.drudis.2012.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=22515962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtFektL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=718-726&author=F.+Lopez-Vallejoauthor=M.+A.+Giulianottiauthor=R.+A.+Houghtenauthor=J.+L.+Medina-Franco&title=Expanding+the+medicinally+relevant+chemical+space+with+compound+libraries&doi=10.1016%2Fj.drudis.2012.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Expanding the medicinally relevant chemical space with compound libraries</span></div><div class="casAuthors">Lopez-Vallejo, Fabian; Giulianotti, Marc A.; Houghten, Richard A.; Medina-Franco, Jose L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">13-14</span>),
    <span class="NLM_cas:pages">718-726</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Anal. of marketed drugs and com. vendor libraries used in high-throughput screening suggests that the medicinally relevant chem. space may be expanded to unexplored regions.  Novel regions of the chem. space can be conveniently explored with structurally unique mols. with increased complexity and balanced physicochem. properties.  As a case study, we discuss the chemoinformatic profile of natural products in the Traditional Chinese Medicine (TCM) database and a large collection assembled from 30 small-mol. combinatorial libraries with emphasis on assessing mol. complexity.  The herein surveyed combinatorial libraries have been successfully used over the past 20 years to identify novel bioactive compds. across different therapeutic areas.  Combinatorial libraries and natural products are suitable sources to expand the traditional relevant medicinal chem. space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhT55nczC7sbVg90H21EOLACvtfcHk0lhAMby9CtOMkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtFektL0%253D&md5=e47776f21c5f0154c37094db030b2b9a</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2012.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2012.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DLopez-Vallejo%26aufirst%3DF.%26aulast%3DGiulianotti%26aufirst%3DM.%2BA.%26aulast%3DHoughten%26aufirst%3DR.%2BA.%26aulast%3DMedina-Franco%26aufirst%3DJ.%2BL.%26atitle%3DExpanding%2520the%2520medicinally%2520relevant%2520chemical%2520space%2520with%2520compound%2520libraries%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26spage%3D718%26epage%3D726%26doi%3D10.1016%2Fj.drudis.2012.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Guagnano, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spanka, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Douget, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamm, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brueggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wartmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berghausen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drueckes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerlin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bussiere, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graus Porta, D.</span><span> </span><span class="NLM_article-title">Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7066</span><span class="NLM_x">–</span> <span class="NLM_lpage">7083</span><span class="refDoi"> DOI: 10.1021/jm2006222</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2006222" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1SrsrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7066-7083&author=V.+Guagnanoauthor=P.+Furetauthor=C.+Spankaauthor=V.+Bordasauthor=M.+Le+Dougetauthor=C.+Stammauthor=J.+Brueggenauthor=M.+R.+Jensenauthor=C.+Schnellauthor=H.+Schmidauthor=M.+Wartmannauthor=J.+Berghausenauthor=P.+Drueckesauthor=A.+Zimmerlinauthor=D.+Bussiereauthor=J.+Murrayauthor=D.+Graus+Porta&title=Discovery+of+3-%282%2C6-dichloro-3%2C5-dimethoxy-phenyl%29-1-%7B6-%5B4-%284-ethyl-piperazin-1-yl%29-phenylamin+o%5D-pyrimidin-4-yl%7D-1-methyl-urea+%28NVP-BGJ398%29%2C+a+potent+and+selective+inhibitor+of+the+fibroblast+growth+factor+receptor+family+of+receptor+tyrosine+kinase&doi=10.1021%2Fjm2006222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase</span></div><div class="casAuthors">Guagnano, Vito; Furet, Pascal; Spanka, Carsten; Bordas, Vincent; Le Douget, Mickael; Stamm, Christelle; Brueggen, Josef; Jensen, Michael R.; Schnell, Christian; Schmid, Herbert; Wartmann, Markus; Berghausen, Joerg; Drueckes, Peter; Zimmerlin, Alfred; Bussiere, Dirksen; Murray, Jeremy; Graus Porta, Diana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7066-7083</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of N-aryl-N'-pyrimidin-4-yl ureas has been optimized to afford potent and selective inhibitors of the fibroblast growth factor receptor tyrosine kinases 1, 2, and 3 by rationally designing the substitution pattern of the aryl ring.  On the basis of its in vitro profile, compd. 1h (NVP-BGJ398) was selected for in vivo evaluation and showed significant antitumor activity in RT112 bladder cancer xenografts models overexpressing wild-type FGFR3.  These results support the potential therapeutic use of 1h as a new anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSC1v0A_6I_bVg90H21EOLACvtfcHk0lhAMby9CtOMkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1SrsrvK&md5=f9a2d742294cd3814e872bdd8add1ffa</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm2006222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2006222%26sid%3Dliteratum%253Aachs%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DSpanka%26aufirst%3DC.%26aulast%3DBordas%26aufirst%3DV.%26aulast%3DLe%2BDouget%26aufirst%3DM.%26aulast%3DStamm%26aufirst%3DC.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DSchmid%26aufirst%3DH.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DBerghausen%26aufirst%3DJ.%26aulast%3DDrueckes%26aufirst%3DP.%26aulast%3DZimmerlin%26aufirst%3DA.%26aulast%3DBussiere%26aufirst%3DD.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DGraus%2BPorta%26aufirst%3DD.%26atitle%3DDiscovery%2520of%25203-%25282%252C6-dichloro-3%252C5-dimethoxy-phenyl%2529-1-%257B6-%255B4-%25284-ethyl-piperazin-1-yl%2529-phenylamin%2520o%255D-pyrimidin-4-yl%257D-1-methyl-urea%2520%2528NVP-BGJ398%2529%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520the%2520fibroblast%2520growth%2520factor%2520receptor%2520family%2520of%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7066%26epage%3D7083%26doi%3D10.1021%2Fjm2006222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Friesner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repasky, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenwood, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halgren, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanschagrin, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mainz, D. T.</span><span> </span><span class="NLM_article-title">Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6177</span><span class="NLM_x">–</span> <span class="NLM_lpage">6196</span><span class="refDoi"> DOI: 10.1021/jm051256o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm051256o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvVGmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6177-6196&author=R.+A.+Friesnerauthor=R.+B.+Murphyauthor=M.+P.+Repaskyauthor=L.+L.+Fryeauthor=J.+R.+Greenwoodauthor=T.+A.+Halgrenauthor=P.+C.+Sanschagrinauthor=D.+T.+Mainz&title=Extra+precision+glide%3A+docking+and+scoring+incorporating+a+model+of+hydrophobic+enclosure+for+protein-ligand+complexes&doi=10.1021%2Fjm051256o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein-Ligand Complexes</span></div><div class="casAuthors">Friesner, Richard A.; Murphy, Robert B.; Repasky, Matthew P.; Frye, Leah L.; Greenwood, Jeremy R.; Halgren, Thomas A.; Sanschagrin, Paul C.; Mainz, Daniel T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6177-6196</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel scoring function to est. protein-ligand binding affinities has been developed and implemented as the Glide 4.0 XP scoring function and docking protocol.  In addn. to unique water desolvation energy terms, protein-ligand structural motifs leading to enhanced binding affinity are included:(1) hydrophobic enclosure where groups of lipophilic ligand atoms are enclosed on opposite faces by lipophilic protein atoms, (2) neutral-neutral single or correlated hydrogen bonds in a hydrophobically enclosed environment, and (3) five categories of charged-charged hydrogen bonds.  The XP scoring function and docking protocol have been developed to reproduce exptl. binding affinities for a set of 198 complexes (RMSDs of 2.26 and 1.73 kcal/mol over all and well-docked ligands, resp.) and to yield quality enrichments for a set of fifteen screens of pharmaceutical importance.  Enrichment results demonstrate the importance of the novel XP mol. recognition and water scoring in sepg. active and inactive ligands and avoiding false positives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohZiwN12vaY7Vg90H21EOLACvtfcHk0lhAMby9CtOMkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvVGmurg%253D&md5=ea428c82ead0d8c27f8c1a7b694a1edf</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm051256o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm051256o%26sid%3Dliteratum%253Aachs%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DRepasky%26aufirst%3DM.%2BP.%26aulast%3DFrye%26aufirst%3DL.%2BL.%26aulast%3DGreenwood%26aufirst%3DJ.%2BR.%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26aulast%3DSanschagrin%26aufirst%3DP.%2BC.%26aulast%3DMainz%26aufirst%3DD.%2BT.%26atitle%3DExtra%2520precision%2520glide%253A%2520docking%2520and%2520scoring%2520incorporating%2520a%2520model%2520of%2520hydrophobic%2520enclosure%2520for%2520protein-ligand%2520complexes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6177%26epage%3D6196%26doi%3D10.1021%2Fjm051256o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Gavine, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooney, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilgour, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Kadhimi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rooney, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span> </span><span class="NLM_article-title">AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">2045</span><span class="NLM_x">–</span> <span class="NLM_lpage">2056</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-3034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1158%2F0008-5472.CAN-11-3034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=22369928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC38Xls1Wgsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=2045-2056&author=P.+Gavineauthor=L.+Mooneyauthor=E.+Kilgourauthor=A.+Thomasauthor=K.+Al-Kadhimiauthor=S.+Beckauthor=C.+Rooneyauthor=T.+Colemanauthor=D.+Bakerauthor=M.+Mellorauthor=A.+Brooksauthor=T.+Klinowska&title=AZD4547%3A+an+orally+bioavailable%2C+potent%2C+and+selective+inhibitor+of+the+fibroblast+growth+factor+receptor+tyrosine+kinase+family&doi=10.1158%2F0008-5472.CAN-11-3034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family</span></div><div class="casAuthors">Gavine, Paul R.; Mooney, Lorraine; Kilgour, Elaine; Thomas, Andrew P.; Al-Kadhimi, Katherine; Beck, Sarah; Rooney, Claire; Coleman, Tanya; Baker, Dawn; Mellor, Martine J.; Brooks, A. Nigel; Klinowska, Teresa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2045-2056</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The fibroblast growth factor (FGF) signaling axis is increasingly implicated in tumorigenesis and chemoresistance.  Several small-mol. FGF receptor (FGFR) kinase inhibitors are currently in clin. development; however, the predominant activity of the most advanced of these agents is against the kinase insert domain receptor (KDR), which compromises the FGFR selectivity.  Here, we report the pharmacol. profile of AZD4547, a novel and selective inhibitor of the FGFR1, 2, and 3 tyrosine kinases.  AZD4547 inhibited recombinant FGFR kinase activity in vitro and suppressed FGFR signaling and growth in tumor cell lines with deregulated FGFR expression.  In a representative FGFR-driven human tumor xenograft model, oral administration of AZD4547 was well tolerated and resulted in potent dose-dependent antitumor activity, consistent with plasma exposure and pharmacodynamic modulation of tumor FGFR.  Importantly, at efficacious doses, no evidence of anti-KDR-related effects were obsd., confirming the in vivo FGFR selectivity of AZD4547.  Taken together, our findings show that AZD4547 is a novel selective small-mol. inhibitor of FGFR with potent antitumor activity against FGFR-deregulated tumors in preclin. models.  AZD4547 is under clin. investigation for the treatment of FGFR-dependent tumors.  Cancer Res; 72(8); 2045-56.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnpExryJc9xbVg90H21EOLACvtfcHk0lgltPzCthAPcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xls1Wgsrs%253D&md5=cba90ad8f9b9e51cd10288868bbcc85e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3034%26sid%3Dliteratum%253Aachs%26aulast%3DGavine%26aufirst%3DP.%26aulast%3DMooney%26aufirst%3DL.%26aulast%3DKilgour%26aufirst%3DE.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DBeck%26aufirst%3DS.%26aulast%3DRooney%26aufirst%3DC.%26aulast%3DColeman%26aufirst%3DT.%26aulast%3DBaker%26aufirst%3DD.%26aulast%3DMellor%26aufirst%3DM.%26aulast%3DBrooks%26aufirst%3DA.%26aulast%3DKlinowska%26aufirst%3DT.%26atitle%3DAZD4547%253A%2520an%2520orally%2520bioavailable%252C%2520potent%252C%2520and%2520selective%2520inhibitor%2520of%2520the%2520fibroblast%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520family%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D2045%26epage%3D2056%26doi%3D10.1158%2F0008-5472.CAN-11-3034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Cheng, Z.; Han, X.; Jiang, M.; Wang, J.; Wang, M.; Yang, S.; Zhou, C.</span><span> </span><span class="NLM_article-title">New substituted pyridine compounds used for treating cancers e.g. glioma, colorectal and pancreatic cancers and cancers of larynx, lymphatic system, liver, and skin</span>. WO2014/090692, June 19,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=Z.+Cheng&author=X.+Han&author=M.+Jiang&author=J.+Wang&author=M.+Wang&author=S.+Yang&author=C.+Zhou&title=New+substituted+pyridine+compounds+used+for+treating+cancers+e.g.+glioma%2C+colorectal+and+pancreatic+cancers+and+cancers+of+larynx%2C+lymphatic+system%2C+liver%2C+and+skin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DZ.%26atitle%3DNew%2520substituted%2520pyridine%2520compounds%2520used%2520for%2520treating%2520cancers%2520e.g.%2520glioma%252C%2520colorectal%2520and%2520pancreatic%2520cancers%2520and%2520cancers%2520of%2520larynx%252C%2520lymphatic%2520system%252C%2520liver%252C%2520and%2520skin%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez-Rosello, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acena, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">del Pozo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorochinsky, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fustero, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soloshonok, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span> </span><span class="NLM_article-title">Fluorine in pharmaceutical industry: fluorine-containing drugs introduced to the market in the last decade (2001–2011)</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">2432</span><span class="NLM_x">–</span> <span class="NLM_lpage">2506</span><span class="refDoi"> DOI: 10.1021/cr4002879</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr4002879" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFegsb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2014&pages=2432-2506&author=J.+Wangauthor=M.+Sanchez-Roselloauthor=J.+L.+Acenaauthor=C.+del+Pozoauthor=A.+E.+Sorochinskyauthor=S.+Fusteroauthor=V.+A.+Soloshonokauthor=H.+Liu&title=Fluorine+in+pharmaceutical+industry%3A+fluorine-containing+drugs+introduced+to+the+market+in+the+last+decade+%282001%E2%80%932011%29&doi=10.1021%2Fcr4002879"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001-2011)</span></div><div class="casAuthors">Wang, Jiang; Sanchez-Rosello, Maria; Acena, Jose Luis; del Pozo, Carlos; Sorochinsky, Alexander E.; Fustero, Santos; Soloshonok, Vadim A.; Liu, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2432-2506</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A historic review.  As expected from the fluorine position on the periodic table of elements, it possesses some extreme properties, in particular, ultimate electronegativity and oxidn. potential.  Therefore,elemental fluorine can not be prepd. by chem. reaction, and its isolation in 1886 by Henri Moissan required scientific ingenuity and great personal courage.  His historic effort earned him a Noble Prize (1906), and the developed electrolysis method is still in use for industrial prodn. of fluorine gas.  However, further development of fluorine chem. was extremely sluggish, pursued by a handful of experts capable of handling the violent gas using specially designed lab. equipment.  Industrial-scale prodn. of fluorochems. dates back to late 1930s.  Currently, there are about 200 pharmaceuticals containingfluorine, including the 40 new compds. discussed in this review.  One may agree that the contribution of the past decade indicates a significant 20% increase in the no. of fluorinated drugs on the market.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQTzcNC3MEA7Vg90H21EOLACvtfcHk0lgltPzCthAPcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFegsb7I&md5=07faac419cd090503e82c6f00d05c338</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fcr4002879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr4002879%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DSanchez-Rosello%26aufirst%3DM.%26aulast%3DAcena%26aufirst%3DJ.%2BL.%26aulast%3Ddel%2BPozo%26aufirst%3DC.%26aulast%3DSorochinsky%26aufirst%3DA.%2BE.%26aulast%3DFustero%26aufirst%3DS.%26aulast%3DSoloshonok%26aufirst%3DV.%2BA.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DFluorine%2520in%2520pharmaceutical%2520industry%253A%2520fluorine-containing%2520drugs%2520introduced%2520to%2520the%2520market%2520in%2520the%2520last%2520decade%2520%25282001%25E2%2580%25932011%2529%26jtitle%3DChem.%2520Rev.%26date%3D2014%26volume%3D114%26spage%3D2432%26epage%3D2506%26doi%3D10.1021%2Fcr4002879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acena, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soloshonok, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span> </span><span class="NLM_article-title">Next generation of fluorine-containing pharmaceuticals, compounds currently in phase II-III clinical trials of major pharmaceutical companies: new structural trends and therapeutic areas</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">422</span><span class="NLM_x">–</span> <span class="NLM_lpage">518</span><span class="refDoi"> DOI: 10.1021/acs.chemrev.5b00392</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.5b00392" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVGms7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2016&pages=422-518&author=Y.+Zhouauthor=J.+Wangauthor=Z.+Guauthor=S.+Wangauthor=W.+Zhuauthor=J.+L.+Acenaauthor=V.+A.+Soloshonokauthor=K.+Izawaauthor=H.+Liu&title=Next+generation+of+fluorine-containing+pharmaceuticals%2C+compounds+currently+in+phase+II-III+clinical+trials+of+major+pharmaceutical+companies%3A+new+structural+trends+and+therapeutic+areas&doi=10.1021%2Facs.chemrev.5b00392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II-III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas</span></div><div class="casAuthors">Zhou, Yu; Wang, Jiang; Gu, Zhanni; Wang, Shuni; Zhu, Wei; Acena, Jose Luis; Soloshonok, Vadim A.; Izawa, Kunisuke; Liu, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">422-518</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  We focus herein on a new collection of 51 fluorine-contg. mols. that either were approved after 2011 by the corresponding agencies or still are on clin. development.  These compds. cover a large no. of therapeutic areas and, on this occasion, we decided to classify them according to the no. of fluorine atoms or fluorinated moieties.  In each case, the structures and modes of action of these new drugs are revised, with a particular focus on the role of fluorine in the biol. and pharmaceutical properties, when appropriate.  Finally, representative synthetic routes are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh-rq_ZyY_jrVg90H21EOLACvtfcHk0lgltPzCthAPcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVGms7o%253D&md5=e3d07d070fcf5b69a54f70bdba99acd4</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.5b00392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.5b00392%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DAcena%26aufirst%3DJ.%2BL.%26aulast%3DSoloshonok%26aufirst%3DV.%2BA.%26aulast%3DIzawa%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DNext%2520generation%2520of%2520fluorine-containing%2520pharmaceuticals%252C%2520compounds%2520currently%2520in%2520phase%2520II-III%2520clinical%2520trials%2520of%2520major%2520pharmaceutical%2520companies%253A%2520new%2520structural%2520trends%2520and%2520therapeutic%2520areas%26jtitle%3DChem.%2520Rev.%26date%3D2016%26volume%3D116%26spage%3D422%26epage%3D518%26doi%3D10.1021%2Facs.chemrev.5b00392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Guagnano, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wohrle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamm, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barys, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pornon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Douget, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaither, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borawski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monahan, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatesan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brummendorf, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graus-Porta, D.</span><span> </span><span class="NLM_article-title">FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1118</span><span class="NLM_x">–</span> <span class="NLM_lpage">1133</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1158%2F2159-8290.CD-12-0210" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=1118-1133&author=V.+Guagnanoauthor=A.+Kauffmannauthor=S.+Wohrleauthor=C.+Stammauthor=M.+Itoauthor=L.+Barysauthor=A.+Pornonauthor=Y.+Yaoauthor=F.+Liauthor=Y.+Zhangauthor=Z.+Chenauthor=C.+J.+Wilsonauthor=V.+Bordasauthor=M.+Le+Dougetauthor=L.+A.+Gaitherauthor=J.+Borawskiauthor=J.+E.+Monahanauthor=K.+Venkatesanauthor=T.+Brummendorfauthor=D.+M.+Thomasauthor=C.+Garcia-Echeverriaauthor=F.+Hofmannauthor=W.+R.+Sellersauthor=D.+Graus-Porta&title=FGFR+genetic+alterations+predict+for+sensitivity+to+NVP-BGJ398%2C+a+selective+pan-FGFR+inhibitor&doi=10.1158%2F2159-8290.CD-12-0210"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0210%26sid%3Dliteratum%253Aachs%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DKauffmann%26aufirst%3DA.%26aulast%3DWohrle%26aufirst%3DS.%26aulast%3DStamm%26aufirst%3DC.%26aulast%3DIto%26aufirst%3DM.%26aulast%3DBarys%26aufirst%3DL.%26aulast%3DPornon%26aufirst%3DA.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DWilson%26aufirst%3DC.%2BJ.%26aulast%3DBordas%26aufirst%3DV.%26aulast%3DLe%2BDouget%26aufirst%3DM.%26aulast%3DGaither%26aufirst%3DL.%2BA.%26aulast%3DBorawski%26aufirst%3DJ.%26aulast%3DMonahan%26aufirst%3DJ.%2BE.%26aulast%3DVenkatesan%26aufirst%3DK.%26aulast%3DBrummendorf%26aufirst%3DT.%26aulast%3DThomas%26aufirst%3DD.%2BM.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DGraus-Porta%26aufirst%3DD.%26atitle%3DFGFR%2520genetic%2520alterations%2520predict%2520for%2520sensitivity%2520to%2520NVP-BGJ398%252C%2520a%2520selective%2520pan-FGFR%2520inhibitor%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26spage%3D1118%26epage%3D1133%26doi%3D10.1158%2F2159-8290.CD-12-0210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 14 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Chinatsu Otake, Takuya Namba, Hidetsugu Tabata, Kosho Makino, Kiriko Hirano, Tetsuta Oshitari, Hideaki Natsugari, Takenori Kusumi, <span class="NLM_string-name hlFld-ContribAuthor">Hideyo Takahashi</span>. </span><span class="cited-content_cbyCitation_article-title">Conformational Preference of 2′-Fluoro-Substituted Acetophenone Derivatives Revealed by Through-Space 1H–19F and 13C–19F Spin–Spin Couplings. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>86 </em>
                                    (6)
                                     , 4638-4645. <a href="https://doi.org/10.1021/acs.joc.1c00051" title="DOI URL">https://doi.org/10.1021/acs.joc.1c00051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.1c00051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.1c00051%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DConformational%252BPreference%252Bof%252B2%2525E2%252580%2525B2-Fluoro-Substituted%252BAcetophenone%252BDerivatives%252BRevealed%252Bby%252BThrough-Space%252B1H%2525E2%252580%25259319F%252Band%252B13C%2525E2%252580%25259319F%252BSpin%2525E2%252580%252593Spin%252BCouplings%26aulast%3DOtake%26aufirst%3DChinatsu%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D07012021%26date%3D01032021%26volume%3D86%26issue%3D6%26spage%3D4638%26epage%3D4645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Meher Prakash, Santosh K. Gudimella, Rajni Lodhi, Soumitra Guin, <span class="NLM_string-name hlFld-ContribAuthor">Sampak Samanta</span>. </span><span class="cited-content_cbyCitation_article-title">NH4OAc-Promoted Domino Route to Hydroxyarylated Unsymmetrical Pyridines under Neat Conditions. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (4)
                                     , 2151-2167. <a href="https://doi.org/10.1021/acs.joc.9b02896" title="DOI URL">https://doi.org/10.1021/acs.joc.9b02896</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.9b02896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.9b02896%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DNH4OAc-Promoted%252BDomino%252BRoute%252Bto%252BHydroxyarylated%252BUnsymmetrical%252BPyridines%252Bunder%252BNeat%252BConditions%26aulast%3DPrakash%26aufirst%3DMeher%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D25102019%26date%3D06012020%26date%3D25122019%26volume%3D85%26issue%3D4%26spage%3D2151%26epage%3D2167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed  Elkamhawy</span>, <span class="hlFld-ContribAuthor ">Qili  Lu</span>, <span class="hlFld-ContribAuthor ">Hossam  Nada</span>, <span class="hlFld-ContribAuthor ">Jiyu  Woo</span>, <span class="hlFld-ContribAuthor ">Guofeng  Quan</span>, <span class="hlFld-ContribAuthor ">Kyeong  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">The Journey of DDR1 and DDR2 Kinase Inhibitors as Rising Stars in the Fight Against Cancer. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (12)
                                     , 6535. <a href="https://doi.org/10.3390/ijms22126535" title="DOI URL">https://doi.org/10.3390/ijms22126535</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22126535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22126535%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DThe%252BJourney%252Bof%252BDDR1%252Band%252BDDR2%252BKinase%252BInhibitors%252Bas%252BRising%252BStars%252Bin%252Bthe%252BFight%252BAgainst%252BCancer%26aulast%3DElkamhawy%26aufirst%3DAhmed%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D12%26spage%3D6535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A. S.  Chiriapkin</span>, <span class="hlFld-ContribAuthor ">I. P.  Kodonidi</span>, <span class="hlFld-ContribAuthor ">M. V.  Larsky</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Synthesis and Analysis of Biologically Active Azomethine Derivatives of 2-amino-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide. </span><span class="cited-content_cbyCitation_journal-name">Drug development & registration</span><span> <strong>2021,</strong> <em>10 </em>
                                    (2)
                                     , 25-31. <a href="https://doi.org/10.33380/2305-2066-2021-10-2-25-31" title="DOI URL">https://doi.org/10.33380/2305-2066-2021-10-2-25-31</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.33380/2305-2066-2021-10-2-25-31&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.33380%2F2305-2066-2021-10-2-25-31%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520development%2520%2526%2520registration%26atitle%3DTargeted%252BSynthesis%252Band%252BAnalysis%252Bof%252BBiologically%252BActive%252BAzomethine%252BDerivatives%252Bof%252B2-amino-4%25252C5%25252C6%25252C7-tetrahydro-1-benzothiophene-3-carboxamide%26aulast%3DChiriapkin%26aufirst%3DA.%2BS.%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D2%26spage%3D25%26epage%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nahid  Abbas</span>, <span class="hlFld-ContribAuthor ">P. M. Gurubasavaraja  Swamy</span>, <span class="hlFld-ContribAuthor ">Prasad  Dhiwar</span>, <span class="hlFld-ContribAuthor ">Shilpa  Patel</span>, <span class="hlFld-ContribAuthor ">D.  Giles</span>. </span><span class="cited-content_cbyCitation_article-title">Development of Fused and Substituted Pyrimidine Derivatives as Potent Anticancer Agents (A Review). </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutical Chemistry Journal</span><span> <strong>2021,</strong> <em>54 </em>
                                    (12)
                                     , 1215-1226. <a href="https://doi.org/10.1007/s11094-021-02346-8" title="DOI URL">https://doi.org/10.1007/s11094-021-02346-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11094-021-02346-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11094-021-02346-8%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutical%2520Chemistry%2520Journal%26atitle%3DDevelopment%252Bof%252BFused%252Band%252BSubstituted%252BPyrimidine%252BDerivatives%252Bas%252BPotent%252BAnticancer%252BAgents%252B%252528A%252BReview%252529%26aulast%3DAbbas%26aufirst%3DNahid%26date%3D2021%26date%3D2021%26volume%3D54%26issue%3D12%26spage%3D1215%26epage%3D1226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ting  Guo</span>, <span class="hlFld-ContribAuthor ">Shutao  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors as Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (4)
                                     , 600-620. <a href="https://doi.org/10.1002/cmdc.202000658" title="DOI URL">https://doi.org/10.1002/cmdc.202000658</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000658%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BDiscovery%252Bof%252BMultitargeted%252BTyrosine%252BKinase%252BInhibitors%252Bas%252BAnticancer%252BAgents%26aulast%3DGuo%26aufirst%3DTing%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D4%26spage%3D600%26epage%3D620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feng-Tao  Liu</span>, <span class="hlFld-ContribAuthor ">Nian-Guang  Li</span>, <span class="hlFld-ContribAuthor ">Yan-Min  Zhang</span>, <span class="hlFld-ContribAuthor ">Wu-Chen  Xie</span>, <span class="hlFld-ContribAuthor ">Si-Ping  Yang</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, <span class="hlFld-ContribAuthor ">Zhi-Hao  Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advance in the development of novel, selective and potent FGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>186 </em>, 111884. <a href="https://doi.org/10.1016/j.ejmech.2019.111884" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111884</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111884%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvance%252Bin%252Bthe%252Bdevelopment%252Bof%252Bnovel%25252C%252Bselective%252Band%252Bpotent%252BFGFR%252Binhibitors%26aulast%3DLiu%26aufirst%3DFeng-Tao%26date%3D2020%26volume%3D186%26spage%3D111884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giuseppe  Marseglia</span>, <span class="hlFld-ContribAuthor ">Alessio  Lodola</span>, <span class="hlFld-ContribAuthor ">Marco  Mor</span>, <span class="hlFld-ContribAuthor ">Riccardo  Castelli</span>. </span><span class="cited-content_cbyCitation_article-title">Fibroblast growth factor receptor inhibitors: patent review (2015–2019). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2019,</strong> <em>29 </em>
                                    (12)
                                     , 965-977. <a href="https://doi.org/10.1080/13543776.2019.1688300" title="DOI URL">https://doi.org/10.1080/13543776.2019.1688300</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2019.1688300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2019.1688300%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DFibroblast%252Bgrowth%252Bfactor%252Breceptor%252Binhibitors%25253A%252Bpatent%252Breview%252B%2525282015%2525E2%252580%2525932019%252529%26aulast%3DMarseglia%26aufirst%3DGiuseppe%26date%3D2019%26date%3D2019%26volume%3D29%26issue%3D12%26spage%3D965%26epage%3D977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Güneş  Çoban</span>, <span class="hlFld-ContribAuthor ">Fadime  Aydın Köse</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, biological evaluations and molecular modelling studies of novel indolin-2-ones designing as FGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Saudi Pharmaceutical Journal</span><span> <strong>2019,</strong> <em>27 </em>
                                    (7)
                                     , 952-967. <a href="https://doi.org/10.1016/j.jsps.2019.07.004" title="DOI URL">https://doi.org/10.1016/j.jsps.2019.07.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jsps.2019.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jsps.2019.07.004%26sid%3Dliteratum%253Aachs%26jtitle%3DSaudi%2520Pharmaceutical%2520Journal%26atitle%3DSynthesis%25252C%252Bbiological%252Bevaluations%252Band%252Bmolecular%252Bmodelling%252Bstudies%252Bof%252Bnovel%252Bindolin-2-ones%252Bdesigning%252Bas%252BFGFR%252Binhibitors%26aulast%3D%25C3%2587oban%26aufirst%3DG%25C3%25BCne%25C5%259F%26date%3D2019%26volume%3D27%26issue%3D7%26spage%3D952%26epage%3D967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Galyna  Volynets</span>, <span class="hlFld-ContribAuthor ">Sergiy  Lukashov</span>, <span class="hlFld-ContribAuthor ">Iryna  Borysenko</span>, <span class="hlFld-ContribAuthor ">Andrii  Gryshchenko</span>, <span class="hlFld-ContribAuthor ">Sergiy  Starosyla</span>, <span class="hlFld-ContribAuthor ">Volodymyr  Bdzhola</span>, <span class="hlFld-ContribAuthor ">Tetiana  Ruban</span>, <span class="hlFld-ContribAuthor ">Anna  Iatsyshyna</span>, <span class="hlFld-ContribAuthor ">Lyubov  Lukash</span>, <span class="hlFld-ContribAuthor ">Yaroslav  Bilokin</span>, <span class="hlFld-ContribAuthor ">Sergiy  Yarmoluk</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of protein kinase fibroblast growth factor receptor 1 (FGFR1) inhibitors among the derivatives of 5-(5,6-dimethoxybenzimidazol-1-yl)-3-hydroxythiophene-2-carboxylic acid. </span><span class="cited-content_cbyCitation_journal-name">Monatshefte für Chemie - Chemical Monthly</span><span> <strong>2019,</strong> <em>150 </em>
                                    (10)
                                     , 1801-1808. <a href="https://doi.org/10.1007/s00706-019-02493-5" title="DOI URL">https://doi.org/10.1007/s00706-019-02493-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00706-019-02493-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00706-019-02493-5%26sid%3Dliteratum%253Aachs%26jtitle%3DMonatshefte%2520f%25C3%25BCr%2520Chemie%2520-%2520Chemical%2520Monthly%26atitle%3DIdentification%252Bof%252Bprotein%252Bkinase%252Bfibroblast%252Bgrowth%252Bfactor%252Breceptor%252B1%252B%252528FGFR1%252529%252Binhibitors%252Bamong%252Bthe%252Bderivatives%252Bof%252B5-%2525285%25252C6-dimethoxybenzimidazol-1-yl%252529-3-hydroxythiophene-2-carboxylic%252Bacid%26aulast%3DVolynets%26aufirst%3DGalyna%26date%3D2019%26date%3D2019%26volume%3D150%26issue%3D10%26spage%3D1801%26epage%3D1808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Masaru  Katoh</span>. </span><span class="cited-content_cbyCitation_article-title">Fibroblast growth factor receptors as treatment targets in clinical oncology. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Clinical Oncology</span><span> <strong>2019,</strong> <em>16 </em>
                                    (2)
                                     , 105-122. <a href="https://doi.org/10.1038/s41571-018-0115-y" title="DOI URL">https://doi.org/10.1038/s41571-018-0115-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41571-018-0115-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41571-018-0115-y%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Clinical%2520Oncology%26atitle%3DFibroblast%252Bgrowth%252Bfactor%252Breceptors%252Bas%252Btreatment%252Btargets%252Bin%252Bclinical%252Boncology%26aulast%3DKatoh%26aufirst%3DMasaru%26date%3D2019%26date%3D2018%26volume%3D16%26issue%3D2%26spage%3D105%26epage%3D122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Soumitra  Guin</span>, <span class="hlFld-ContribAuthor ">Debashis  Majee</span>, <span class="hlFld-ContribAuthor ">Soumen  Biswas</span>, <span class="hlFld-ContribAuthor ">Sampak  Samanta</span>. </span><span class="cited-content_cbyCitation_article-title">Microwave-Assisted and Base-Promoted Domino Reaction of Cyclic N-Sulfonyl Ketimines with α,β-Disubstituted Nitroalkenes: A Green Access to 2-Hydroxyarylpyridines. </span><span class="cited-content_cbyCitation_journal-name">Asian Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>7 </em>
                                    (9)
                                     , 1810-1814. <a href="https://doi.org/10.1002/ajoc.201800298" title="DOI URL">https://doi.org/10.1002/ajoc.201800298</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ajoc.201800298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fajoc.201800298%26sid%3Dliteratum%253Aachs%26jtitle%3DAsian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DMicrowave-Assisted%252Band%252BBase-Promoted%252BDomino%252BReaction%252Bof%252BCyclic%252BN-Sulfonyl%252BKetimines%252Bwith%252B%2525CE%2525B1%25252C%2525CE%2525B2-Disubstituted%252BNitroalkenes%25253A%252BA%252BGreen%252BAccess%252Bto%252B2-Hydroxyarylpyridines%26aulast%3DGuin%26aufirst%3DSoumitra%26date%3D2018%26date%3D2018%26volume%3D7%26issue%3D9%26spage%3D1810%26epage%3D1814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinyun  Dong</span>, <span class="hlFld-ContribAuthor ">Qijing  Zhang</span>, <span class="hlFld-ContribAuthor ">Zengtao  Wang</span>, <span class="hlFld-ContribAuthor ">Guang  Huang</span>, <span class="hlFld-ContribAuthor ">Shaoshun  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Development of Indazole-based Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2018,</strong> <em>13 </em>
                                    (15)
                                     , 1490-1507. <a href="https://doi.org/10.1002/cmdc.201800253" title="DOI URL">https://doi.org/10.1002/cmdc.201800253</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201800253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201800253%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BDevelopment%252Bof%252BIndazole-based%252BAnticancer%252BAgents%26aulast%3DDong%26aufirst%3DJinyun%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D15%26spage%3D1490%26epage%3D1507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sonali  Kurup</span>, <span class="hlFld-ContribAuthor ">Bradley  McAllister</span>, <span class="hlFld-ContribAuthor ">Pavlina  Liskova</span>, <span class="hlFld-ContribAuthor ">Trusha  Mistry</span>, <span class="hlFld-ContribAuthor ">Anthony  Fanizza</span>, <span class="hlFld-ContribAuthor ">Dan  Stanford</span>, <span class="hlFld-ContribAuthor ">Jolanta  Slawska</span>, <span class="hlFld-ContribAuthor ">Ulrich  Keller</span>, <span class="hlFld-ContribAuthor ">Alexander  Hoellein</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological activity of
              N
              4
              -phenylsubstituted-7
              H
              -pyrrolo[2,3-
              d
              ]pyrimidin-4-amines as dual inhibitors of aurora kinase A and epidermal growth factor receptor kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2018,</strong> <em>33 </em>
                                    (1)
                                     , 74-84. <a href="https://doi.org/10.1080/14756366.2017.1376666" title="DOI URL">https://doi.org/10.1080/14756366.2017.1376666</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2017.1376666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2017.1376666%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bactivity%252Bof%252BN%252B4%252B-phenylsubstituted-7%252BH%252B-pyrrolo%25255B2%25252C3-%252Bd%252B%25255Dpyrimidin-4-amines%252Bas%252Bdual%252Binhibitors%252Bof%252Baurora%252Bkinase%252BA%252Band%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252Bkinase%26aulast%3DKurup%26aufirst%3DSonali%26date%3D2018%26date%3D2017%26volume%3D33%26issue%3D1%26spage%3D74%26epage%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/medium/jm-2017-00076u_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00076&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/medium/jm-2017-00076u_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative structures of multitargeted and selective inhibitors with FGFR inhibitory activities for the treatment of NSCLC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00076&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/medium/jm-2017-00076u_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Identification of compound <b>1</b> as a hit against FGFR. (A) Inhibitory activity of the 57 selected compounds at 50 μM. Compound <b>16</b> (black column) was used as a positive control, and the inhibition ratio of compound <b>1</b> (red column) is 76.5%. (B) Putative binding mode of compound <b>1</b> with FGFR1, where hydrogen bonds are depicted as dashed red lines and the hydrophobic pocket of FGFR1 is marked as an orange circle. (C) Superimposition of the binding mode of compound <b>1</b> (green) with the crystal structures of compounds <b>15</b> (slate) and <b>16</b> (orange), where the hydrophobic pocket of FGFR1 is marked as an orange circle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00076&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/medium/jm-2017-00076u_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. SAR Exploration of Pyridin-3-Amine Derivatives as Potent FGFR Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00076&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/medium/jm-2017-00076u_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Routes Exploited to Access Desired Compounds <b>2</b> and <b>3</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00076&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) MeMgBr, THF, 0 °C; then, MnO<sub>2</sub>, 1,4-dioxane, reflux; (b) N<sub>2</sub>H<sub>4</sub> (75% in H<sub>2</sub>O), reflux; (c) Boc<sub>2</sub>O, Et<sub>3</sub>N, DCM, rt; then, 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane), Pd(dppf)<sub>2</sub>Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, KOAc, 1,4-dioxane, 80 °C; (d) NaI, HCl (6 M), NaNO<sub>2</sub>, H<sub>2</sub>O, 0 °C – rt; (e) (<i>R</i>)-2-amino-2-phenyl-ethanol, CuI, K<sub>3</sub>PO<sub>4</sub>, ethylene glycol, <sup><i>i</i></sup>PrOH; (f) Pd(dppf)<sub>2</sub>Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, H<sub>2</sub>O, 90 °C; then TFA, DCM; (g) boronic acids, Pd(dppf)<sub>2</sub>Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, H<sub>2</sub>O, 120 °C, MW. (h) boronic acids, Pd(dppf)<sub>2</sub>Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, H<sub>2</sub>O, 90 °C; (i) 5-chloro-2-hydroxyphenylboronic acid, Pd(dppf)<sub>2</sub>Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, H<sub>2</sub>O, 120 °C, MW.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/medium/jm-2017-00076u_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Route to Desired Compounds <b>3f</b>–<b>3j</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00076&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) amines, CuI, K<sub>3</sub>PO<sub>4</sub>, ethylene glycol, <sup><i>i</i></sup>PrOH; (b) <b>7a</b>, Pd(dppf)<sub>2</sub>Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, H<sub>2</sub>O, 90 °C; then TFA, DCM; (c) boronic acids, Pd(dppf)<sub>2</sub>Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, H<sub>2</sub>O, 120 °C, MW.</p></p></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/medium/jm-2017-00076u_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Putative binding modes of pyridine-3-amine derivatives by docking in FGFR1 protein (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3TT0">3TT0</a>). (A) Binding modes of <b>1</b> (green), <b>2d</b> (yellow), and <b>2p</b> (pink) in the hydrophobic pocket of FGFR1, of which the front side of the pocket surface is clipped away for clarity and the hydrophobic pocket is depicted as a dashed orange circle. (B) Binding modes of <b>2d</b> (yellow) and <b>2p</b> (pink) with FGFR1. (C) Superimposition of the binding modes of <b>2p</b> (pink), <b>3c</b> (blue), and <b>3b</b> (green). (D) Binding modes of <b>2p</b> ((<i>R</i>)<i>-</i>isomer) and its enantiomer <b>3f</b> ((<i>S</i>)<i>-</i>isomer). Hydrogen bonds are depicted as dashed red lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00076&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/medium/jm-2017-00076u_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>3m</b> blocks tyrosine kinase phosphorylation and downstream signaling in cells. Cells including NCI-H1581(A, left), KG1(A, right), KATOIII(B), UMUC14(C), NCI-H2286(D), Ba/F3/CCDC6-RET(E), and Ba/F3/TEL-KDR (F) treated with <b>3m</b> for 2 h at the indicated concentrations were lysed and subjected to Western blot analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00076&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/medium/jm-2017-00076u_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>3m</b> inhibits tumor growth in NCI-H1581 xenografts. Mice were randomly assigned to control vehicle and treatment groups (<i>n</i> = 6 in treated group, <i>n</i> = 12 in vehicle group) when the tumor volume reached 100–150 mm<sup>3</sup>. The control groups were given vehicle alone, and the treatment groups received <b>3m</b> or <b>16</b> at the indicated doses via oral administration once daily for 14 days. The results are expressed as the mean ± SEM with *<i>p</i> < 0.05, **<i>p</i> < 0.01, and ***<i>p</i> < 0.001 vs control group determined using Student’s <i>t</i> test. The relative tumor volume (RTV) was measured on the final day of the study for the drug-treated mice compared with the control mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00076&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i94">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58116" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58116" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 40 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Jemal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thun, M. J.</span><span> </span><span class="NLM_article-title">Cancer statistics, 2007</span> <span class="citation_source-journal">Ca-Cancer J. Clin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">43</span><span class="NLM_x">–</span> <span class="NLM_lpage">66</span><span class="refDoi"> DOI: 10.3322/canjclin.57.1.43</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.3322%2Fcanjclin.57.1.43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=17237035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FjvVKmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2007&pages=43-66&author=A.+Jemalauthor=R.+Siegelauthor=E.+Wardauthor=T.+Murrayauthor=J.+Xuauthor=M.+J.+Thun&title=Cancer+statistics%2C+2007&doi=10.3322%2Fcanjclin.57.1.43"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer statistics, 2007</span></div><div class="casAuthors">Jemal Ahmedin; Siegel Rebecca; Ward Elizabeth; Murray Taylor; Xu Jiaquan; Thun Michael J</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-66</span>
        ISSN:<span class="NLM_cas:issn">0007-9235</span>.
    </div><div class="casAbstract">Each year, the American Cancer Society (ACS) estimates the number of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics.  This report considers incidence data through 2003 and mortality data through 2004.  Incidence and death rates are age-standardized to the 2000 US standard million population.  A total of 1,444,920 new cancer cases and 559,650 deaths for cancers are projected to occur in the United States in 2007.  Notable trends in cancer incidence and mortality rates include stabilization of the age-standardized, delay-adjusted incidence rates for all cancers combined in men from 1995 through 2003; a continuing increase in the incidence rate by 0.3% per year in women; and a 13.6% total decrease in age-standardized cancer death rates among men and women combined between 1991 and 2004.  This report also examines cancer incidence, mortality, and survival by site, sex, race/ethnicity, geographic area, and calendar year, as well as the proportionate contribution of selected sites to the overall trends.  While the absolute number of cancer deaths decreased for the second consecutive year in the United States (by more than 3,000 from 2003 to 2004) and much progress has been made in reducing mortality rates and improving survival, cancer still accounts for more deaths than heart disease in persons under age 85 years.  Further progress can be accelerated by supporting new discoveries and by applying existing cancer control knowledge across all segments of the population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRpAWCsxi_XOhBrI9DTGjC0fW6udTcc2eYqoQO4xRdB7bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FjvVKmtA%253D%253D&md5=d82aa6c2ef180df91cec1814833c9004</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcanjclin.57.1.43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcanjclin.57.1.43%26sid%3Dliteratum%253Aachs%26aulast%3DJemal%26aufirst%3DA.%26aulast%3DSiegel%26aufirst%3DR.%26aulast%3DWard%26aufirst%3DE.%26aulast%3DMurray%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DThun%26aufirst%3DM.%2BJ.%26atitle%3DCancer%2520statistics%252C%25202007%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2007%26volume%3D57%26spage%3D43%26epage%3D66%26doi%3D10.3322%2Fcanjclin.57.1.43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span> </span><span class="NLM_article-title">The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">8629</span><span class="refDoi"> DOI: 10.1038/srep08629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1038%2Fsrep08629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=25720956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVCrtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=8629&author=Y.+Zhouauthor=Y.+Zhangauthor=H.+Zouauthor=N.+Caiauthor=X.+Chenauthor=L.+Xuauthor=X.+Kongauthor=P.+Liu&title=The+multi-targeted+tyrosine+kinase+inhibitor+vandetanib+plays+a+bifunctional+role+in+non-small+cell+lung+cancer+cells&doi=10.1038%2Fsrep08629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells</span></div><div class="casAuthors">Zhou, Yan; Zhang, Yuanliang; Zou, Hanbing; Cai, Ning; Chen, Xiaojing; Xu, Longmei; Kong, Xianming; Liu, Peifeng</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8629</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Vandetanib, a multikinase inhibitor, is a target of drug treatments for non-small cell lung cancer (NSCLC).  However, phase II and III clin. trials have not conclusively demonstrated the curative effects of vandetanib for NSCLC, and the reasons for this are unknown.  In the present study, we use the NSCLC cell line Calu-6 as a model to det. the cellular and biol. effects of vandetanib.  Our results demonstrate that vandetanib impairs Calu-6 cell migration and invasion.  We find that vandetanib can directly inhibit RET activity, which influences the Rho-JNK pathway.  Overexpression of a constitutively active Rho GTPase antagonizes the inhibitory effects of vandetanib on Calu-6 cells invasion and JNK pathway activation.  In addn., vandetanib induces autophagy by increasing the level of reactive oxygen species (ROS) in Calu-6 cells, and blockade of autophagy or ROS effectively enhances the cell death effect of vandetanib.  In this study, we find vandetanib is of a double effect in some NSCLC cells, presenting new possibilities for the pharmacol. treatment of NSCLC and introducing a novel role for vandetanib in treatment options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMuZHNy56DYLVg90H21EOLACvtfcHk0ljRmCjleNyDRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVCrtbk%253D&md5=20e56ddafc18a905ca4bd2031515805c</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fsrep08629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep08629%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DCai%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DP.%26atitle%3DThe%2520multi-targeted%2520tyrosine%2520kinase%2520inhibitor%2520vandetanib%2520plays%2520a%2520bifunctional%2520role%2520in%2520non-small%2520cell%2520lung%2520cancer%2520cells%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D8629%26doi%3D10.1038%2Fsrep08629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Lin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, H.</span><span> </span><span class="NLM_article-title">EGFR-TKI resistance in NSCLC patients: mechanisms and strategies</span> <span class="citation_source-journal">Am. J. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">411</span><span class="NLM_x">–</span> <span class="NLM_lpage">435</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=25232485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVOqsr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=411-435&author=Y.+Linauthor=X.+Wangauthor=H.+Jin&title=EGFR-TKI+resistance+in+NSCLC+patients%3A+mechanisms+and+strategies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR-TKI resistance in NSCLC patients: mechanisms and strategies</span></div><div class="casAuthors">Lin, Yuxin; Wang, Xian; Jin, Hongchuan</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">411-435, 25 pp.</span>CODEN:
                <span class="NLM_cas:coden">AJCRFT</span>;
        ISSN:<span class="NLM_cas:issn">2156-6976</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) is a kind of receptor tyrosine kinase (RTK) that plays a crit. role in the initiation and development of malignant tumors via modulating downstream signaling pathways.  In non-small cell lung cancer (NSCLC), the activating mutations located in the tyrosine kinase domains of EGFR have been demonstrated in multiple researches as the "Achilles' heel" of this deadly disease since they could be well-targeted by epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).  However, it's still too early to celebrate since the first-generation EGFR-TKIs such as gefitinib and erlotinib have only achieved limited clin. benefits and acquired resistance to this kind of drugs occurred inevitably in almost all the NSCLC patients.  In order to make the most of EGFR-TKIs and develop more effective regimens for the NSCLC patients, researchers majoring in different aspects start a battle against EGFR-TKI resistance.  Challenging as it is, we still progress stably and step firmly toward the final victory.  This review will summarize the major mechanisms of acquired resistance to EGFR-TKIs, and then discuss the development of rationally designed mol. target drugs in accordance with each mechanism, in the hope of shedding light on the great achievements we have obtained and tough obstacles we have to overcome in the battle against this deadly disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5q1xMeLLDIrVg90H21EOLACvtfcHk0ljRmCjleNyDRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVOqsr7F&md5=021beb6a44d84bbf6b2c5002921bb448</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DJin%26aufirst%3DH.%26atitle%3DEGFR-TKI%2520resistance%2520in%2520NSCLC%2520patients%253A%2520mechanisms%2520and%2520strategies%26jtitle%3DAm.%2520J.%2520Cancer%2520Res.%26date%3D2014%26volume%3D4%26spage%3D411%26epage%3D435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Shea, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rangachari, D.</span><span> </span><span class="NLM_article-title">Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches</span> <span class="citation_source-journal">Ther. Adv. Respir. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">129</span><span class="refDoi"> DOI: 10.1177/1753465815617871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1177%2F1753465815617871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=26620497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntFOrtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=113-129&author=M.+Sheaauthor=D.+B.+Costaauthor=D.+Rangachari&title=Management+of+advanced+non-small+cell+lung+cancers+with+known+mutations+or+rearrangements%3A+latest+evidence+and+treatment+approaches&doi=10.1177%2F1753465815617871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches</span></div><div class="casAuthors">Shea, Meghan; Costa, Daniel B.; Rangachari, Deepa</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Respiratory Disease</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-129</span>CODEN:
                <span class="NLM_cas:coden">TARDCZ</span>;
        ISSN:<span class="NLM_cas:issn">1753-4658</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Precision oncol. is now the evidence-based std. of care for the management of many advanced non-small cell lung cancers (NSCLCs).  Expert consensus has defined min. requirements for routine testing and identification of epidermal growth factor (EGFR) mutations (15% of tumors harbor EGFR exon 19 deletions or exon 21 L858R substitutions) and anaplastic lymphoma kinase (ALK) rearrangements (5% of tumors) in advanced lung adenocarcinomas (ACs).  Application of palliative targeted therapies with oral tyrosine kinase inhibitors (TKIs) in advanced/metastatic lung ACs harboring abnormalities in EGFR (gefitinib, erlotinib, afatinib) and ALK/ROS1/MET (crizotinib) has consistently led to more favorable outcomes compared with traditional cytotoxic agents.  In addn., mutations leading to resistance to first-line EGFR and ALK TKIs can now be successfully inhibited by soon to be approved third-generation EGFR TKIs (osimertinib, rociletinib) and second-generation ALK TKIs (ceritinib, alectinib).  Notably, increasing feasibility, accessibility, and application of mol. profiling technologies has permitted dynamic growth in the identification of actionable driver oncogenes.  Emerging genomic aberrations for which TKIs have shown impressive results in clin. trials and expansion of drug labels for approved agents are awaited include ROS1 rearrangements (1-2% of tumors, drug: crizotinib) and BRAF-V600E mutations (1-3% of tumors, drugs: vemurafenib, dafrafenib + trametinib).  Evolving genomic events in which TKI responses have been reported in smaller series include MET exon 14 skipping mutations (2-4% of tumors, drug: crizotinib); high-level MET amplification (1-2% of tumors, drug: crizotinib); RET rearrangements (1% of tumors, drug: cabozantinib); and ERBB2 mutations (2-3% of tumors, drug: afatinib), among others.  Unfortunately, the most common genomic event in NSCLC, KRAS mutations (25-30% of tumors), is not targetable with approved or in development small mol. inhibitors.  Here, we review currently approved, emerging, and evolving systemic precision therapies matched with their driver oncogenes for the management of advanced NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoNtXAJ4imrLVg90H21EOLACvtfcHk0ljdX92csX7cSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntFOrtbw%253D&md5=1ff6692d5cbef3da8a1e628f8b33cda9</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1177%2F1753465815617871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1753465815617871%26sid%3Dliteratum%253Aachs%26aulast%3DShea%26aufirst%3DM.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DRangachari%26aufirst%3DD.%26atitle%3DManagement%2520of%2520advanced%2520non-small%2520cell%2520lung%2520cancers%2520with%2520known%2520mutations%2520or%2520rearrangements%253A%2520latest%2520evidence%2520and%2520treatment%2520approaches%26jtitle%3DTher.%2520Adv.%2520Respir.%2520Dis.%26date%3D2016%26volume%3D10%26spage%3D113%26epage%3D129%26doi%3D10.1177%2F1753465815617871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Beenken, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammadi, M.</span><span> </span><span class="NLM_article-title">The FGF family: biology, pathophysiology and therapy</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">253</span><span class="refDoi"> DOI: 10.1038/nrd2792</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1038%2Fnrd2792" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=19247306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVShur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=235-253&author=A.+Beenkenauthor=M.+Mohammadi&title=The+FGF+family%3A+biology%2C+pathophysiology+and+therapy&doi=10.1038%2Fnrd2792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The FGF family: biology, pathophysiology and therapy</span></div><div class="casAuthors">Beenken, Andrew; Mohammadi, Moosa</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">235-253</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The family of fibroblast growth factors (FGFs) regulates a plethora of developmental processes, including brain patterning, branching morphogenesis and limb development.  Several mitogenic, cytoprotective and angiogenic therapeutic applications of FGFs are already being explored, and the recent discovery of the crucial roles of the endocrine-acting FGF19 subfamily in bile acid, glucose and phosphate homeostasis has sparked renewed interest in the pharmacol. potential of this family.  This review discusses traditional applications of recombinant FGFs and small-mol. FGF receptor kinase inhibitors in the treatment of cancer and cardiovascular disease and their emerging potential in the treatment of metabolic syndrome and hypophosphatemic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmidKyrdG0lbVg90H21EOLACvtfcHk0ljdX92csX7cSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVShur4%253D&md5=4789ed4cb521a92114063a400a138645</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd2792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2792%26sid%3Dliteratum%253Aachs%26aulast%3DBeenken%26aufirst%3DA.%26aulast%3DMohammadi%26aufirst%3DM.%26atitle%3DThe%2520FGF%2520family%253A%2520biology%252C%2520pathophysiology%2520and%2520therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D235%26epage%3D253%26doi%3D10.1038%2Fnrd2792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Turner, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grose, R.</span><span> </span><span class="NLM_article-title">Fibroblast growth factor signalling: from development to cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">116</span><span class="NLM_x">–</span> <span class="NLM_lpage">129</span><span class="refDoi"> DOI: 10.1038/nrc2780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1038%2Fnrc2780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=20094046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Gktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=116-129&author=N.+Turnerauthor=R.+Grose&title=Fibroblast+growth+factor+signalling%3A+from+development+to+cancer&doi=10.1038%2Fnrc2780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factor signalling: from development to cancer</span></div><div class="casAuthors">Turner, Nicholas; Grose, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">116-129</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Fibroblast growth factors (FGFs) and their receptors control a wide range of biol. functions, regulating cellular proliferation, survival, migration and differentiation.  Although targeting FGF signalling as a cancer therapeutic target has lagged behind that of other receptor tyrosine kinases, there is now substantial evidence for the importance of FGF signalling in the pathogenesis of diverse tumor types, and clin. reagents that specifically target the FGFs or FGF receptors are being developed.  Although FGF signalling can drive tumorigenesis, in different contexts FGF signalling can mediate tumor protective functions; the identification of the mechanisms that underlie these differential effects will be important to understand how FGF signalling can be most appropriately therapeutically targeted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUBfz6uAu97bVg90H21EOLACvtfcHk0ljdX92csX7cSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Gktg%253D%253D&md5=7963bc75c149981560dffc8d91b4aaf1</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrc2780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2780%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DGrose%26aufirst%3DR.%26atitle%3DFibroblast%2520growth%2520factor%2520signalling%253A%2520from%2520development%2520to%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D116%26epage%3D129%26doi%3D10.1038%2Fnrc2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Weiss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peifer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zander, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soltermann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagener, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heynck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schöttle, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leenders, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabler, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dabow, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Querings, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heukamp, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balke-Want, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ansén, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baessmann, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altmüller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wainer, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conron, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brambilla, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brambilla, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorimier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sollberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brustugun, O. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel-Riedel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petersen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sänger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clement, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timens, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sietsma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thunnissen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smit, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heideman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ligorio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damiani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beroukhim, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buettner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernestus, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoelben, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nürnberg, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span> </span><span class="NLM_article-title">Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">62ra93</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3001451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1126%2Fscitranslmed.3001451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=21160078" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=62ra93&author=J.+Weissauthor=M.+L.+Sosauthor=D.+Seidelauthor=M.+Peiferauthor=T.+Zanderauthor=J.+M.+Heuckmannauthor=R.+T.+Ullrichauthor=R.+Menonauthor=S.+Maierauthor=A.+Soltermannauthor=H.+Mochauthor=P.+Wagenerauthor=F.+Fischerauthor=S.+Heynckauthor=M.+Kokerauthor=J.+Sch%C3%B6ttleauthor=F.+Leendersauthor=F.+Gablerauthor=I.+Dabowauthor=S.+Queringsauthor=L.+C.+Heukampauthor=H.+Balke-Wantauthor=S.+Ans%C3%A9nauthor=D.+Rauhauthor=I.+Baessmannauthor=J.+Altm%C3%BCllerauthor=Z.+Wainerauthor=M.+Conronauthor=G.+Wrightauthor=P.+Russellauthor=B.+Solomonauthor=E.+Brambillaauthor=C.+Brambillaauthor=P.+Lorimierauthor=S.+Sollbergauthor=O.+T.+Brustugunauthor=W.+Engel-Riedelauthor=C.+Ludwigauthor=I.+Petersenauthor=J.+S%C3%A4ngerauthor=J.+Clementauthor=H.+Groenauthor=W.+Timensauthor=H.+Sietsmaauthor=E.+Thunnissenauthor=E.+Smitauthor=D.+Heidemanauthor=F.+Cappuzzoauthor=C.+Ligorioauthor=S.+Damianiauthor=M.+Hallekauthor=R.+Beroukhimauthor=W.+Paoauthor=B.+Kleblauthor=M.+Baumannauthor=R.+Buettnerauthor=K.+Ernestusauthor=E.+Stoelbenauthor=J.+Wolfauthor=P.+N%C3%BCrnbergauthor=S.+Pernerauthor=R.+K.+Thomas&title=Frequent+and+focal+FGFR1+amplification+associates+with+therapeutically+tractable+FGFR1+dependency+in+squamous+cell+lung+cancer&doi=10.1126%2Fscitranslmed.3001451"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3001451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3001451%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DSeidel%26aufirst%3DD.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DZander%26aufirst%3DT.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DUllrich%26aufirst%3DR.%2BT.%26aulast%3DMenon%26aufirst%3DR.%26aulast%3DMaier%26aufirst%3DS.%26aulast%3DSoltermann%26aufirst%3DA.%26aulast%3DMoch%26aufirst%3DH.%26aulast%3DWagener%26aufirst%3DP.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DSch%25C3%25B6ttle%26aufirst%3DJ.%26aulast%3DLeenders%26aufirst%3DF.%26aulast%3DGabler%26aufirst%3DF.%26aulast%3DDabow%26aufirst%3DI.%26aulast%3DQuerings%26aufirst%3DS.%26aulast%3DHeukamp%26aufirst%3DL.%2BC.%26aulast%3DBalke-Want%26aufirst%3DH.%26aulast%3DAns%25C3%25A9n%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DBaessmann%26aufirst%3DI.%26aulast%3DAltm%25C3%25BCller%26aufirst%3DJ.%26aulast%3DWainer%26aufirst%3DZ.%26aulast%3DConron%26aufirst%3DM.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DRussell%26aufirst%3DP.%26aulast%3DSolomon%26aufirst%3DB.%26aulast%3DBrambilla%26aufirst%3DE.%26aulast%3DBrambilla%26aufirst%3DC.%26aulast%3DLorimier%26aufirst%3DP.%26aulast%3DSollberg%26aufirst%3DS.%26aulast%3DBrustugun%26aufirst%3DO.%2BT.%26aulast%3DEngel-Riedel%26aufirst%3DW.%26aulast%3DLudwig%26aufirst%3DC.%26aulast%3DPetersen%26aufirst%3DI.%26aulast%3DS%25C3%25A4nger%26aufirst%3DJ.%26aulast%3DClement%26aufirst%3DJ.%26aulast%3DGroen%26aufirst%3DH.%26aulast%3DTimens%26aufirst%3DW.%26aulast%3DSietsma%26aufirst%3DH.%26aulast%3DThunnissen%26aufirst%3DE.%26aulast%3DSmit%26aufirst%3DE.%26aulast%3DHeideman%26aufirst%3DD.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DLigorio%26aufirst%3DC.%26aulast%3DDamiani%26aufirst%3DS.%26aulast%3DHallek%26aufirst%3DM.%26aulast%3DBeroukhim%26aufirst%3DR.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DBuettner%26aufirst%3DR.%26aulast%3DErnestus%26aufirst%3DK.%26aulast%3DStoelben%26aufirst%3DE.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DN%25C3%25BCrnberg%26aufirst%3DP.%26aulast%3DPerner%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26atitle%3DFrequent%2520and%2520focal%2520FGFR1%2520amplification%2520associates%2520with%2520therapeutically%2520tractable%2520FGFR1%2520dependency%2520in%2520squamous%2520cell%2520lung%2520cancer%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2010%26volume%3D2%26spage%3D62ra93%26doi%3D10.1126%2Fscitranslmed.3001451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Oxnard, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binder, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">New targetable oncogenes in non-small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1097</span><span class="NLM_x">–</span> <span class="NLM_lpage">1104</span><span class="refDoi"> DOI: 10.1200/JCO.2012.42.9829</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1200%2FJCO.2012.42.9829" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=23401445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltl2murw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1097-1104&author=G.+R.+Oxnardauthor=A.+Binderauthor=P.+A.+J%C3%A4nne&title=New+targetable+oncogenes+in+non-small-cell+lung+cancer&doi=10.1200%2FJCO.2012.42.9829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">New targetable oncogenes in non-small-cell lung cancer</span></div><div class="casAuthors">Oxnard, Geoffrey R.; Binder, Adam; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1097-1104</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The identification of oncogenic driver mutations underlying sensitivity to epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors has led to a surge of interest in identifying addnl. targetable oncogenes in non-small-cell lung cancer.  A no. of new potentially oncogenic gene alterations have been characterized in recent years, including BRAF mutations, HER2 insertions, PIK3CA mutations, FGFR1 amplifications, DDR2 mutations, ROS1 rearrangements, and RET rearrangements.  In this review, we will discuss the techniques used to discover each of these candidate oncogenes, the prevalence of each in non-small-cell lung cancer, the preclin. data supporting their role in lung cancer, and data on small mol. inhibitors in development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9d7dOluS9lLVg90H21EOLACvtfcHk0ljMrcqRW-y6PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltl2murw%253D&md5=4b40537217169227893de4f37f43f9df</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.42.9829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.42.9829%26sid%3Dliteratum%253Aachs%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DBinder%26aufirst%3DA.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DNew%2520targetable%2520oncogenes%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D1097%26epage%3D1104%26doi%3D10.1200%2FJCO.2012.42.9829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Zhao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henry, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zia-Ebrahimi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloem, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huss, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCann, D. J.</span><span> </span><span class="NLM_article-title">A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2200</span><span class="NLM_x">–</span> <span class="NLM_lpage">2210</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1158%2F1535-7163.MCT-11-0306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=21900693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVeltb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2200-2210&author=G.+Zhaoauthor=W.+Y.+Liauthor=D.+Chenauthor=J.+R.+Henryauthor=H.+Y.+Liauthor=Z.+Chenauthor=M.+Zia-Ebrahimiauthor=L.+Bloemauthor=Y.+Zhaiauthor=K.+Hussauthor=S.+B.+Pengauthor=D.+J.+McCann&title=A+novel%2C+selective+inhibitor+of+fibroblast+growth+factor+receptors+that+shows+a+potent+broad+spectrum+of+antitumor+activity+in+several+tumor+xenograft+models&doi=10.1158%2F1535-7163.MCT-11-0306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models</span></div><div class="casAuthors">Zhao, Genshi; Li, Wei-ying; Chen, Daohong; Henry, James R.; Li, Hong-Yu; Chen, Zhaogen; Zia-Ebrahimi, Mohammad; Bloem, Laura; Zhai, Yan; Huss, Karen; Peng, Sheng-bin; McCann, Denis J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2200-2210</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The fibroblast growth factor receptors (FGFR) are tyrosine kinases that are present in many types of endothelial and tumor cells and play an important role in tumor cell growth, survival, and migration as well as in maintaining tumor angiogenesis.  Overexpression of FGFRs or aberrant regulation of their activities has been implicated in many forms of human malignancies.  Therefore, targeting FGFRs represents an attractive strategy for development of cancer treatment options by simultaneously inhibiting tumor cell growth, survival, and migration as well as tumor angiogenesis.  Here, we describe a potent, selective, small-mol. FGFR inhibitor, (R)-(E)-2-(4-(2-(5-(1-(3,5-Dichloropyridin-4-yl)ethoxy)-1H-indazol-3yl)vinyl)-1H-pyrazol-1-yl)ethanol, designated as LY2874455.  This mol. is active against all 4 FGFRs, with a similar potency in biochem. assays.  It exhibits a potent activity against FGF/FGFR-mediated signaling in several cancer cell lines and shows an excellent broad spectrum of antitumor activity in several tumor xenograft models representing the major FGF/FGFR relevant tumor histologies including lung, gastric, and bladder cancers and multiple myeloma, and with a well-defined pharmacokinetic/pharmacodynamic relationship.  LY2874455 also exhibits a 6- to 9-fold in vitro and in vivo selectivity on inhibition of FGF- over VEGF-mediated target signaling in mice.  Furthermore, LY2874455 did not show VEGF receptor 2-mediated toxicities such as hypertension at efficacious doses.  Currently, this mol. is being evaluated for its potential use in the clinic.  Mol Cancer Ther; 10(11); 2200-10.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLrzAyZQK_grVg90H21EOLACvtfcHk0ljMrcqRW-y6PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVeltb7N&md5=eaf08fd213a836f48da2055e01bd9c29</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0306%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DW.%2BY.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DHenry%26aufirst%3DJ.%2BR.%26aulast%3DLi%26aufirst%3DH.%2BY.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZia-Ebrahimi%26aufirst%3DM.%26aulast%3DBloem%26aufirst%3DL.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DHuss%26aufirst%3DK.%26aulast%3DPeng%26aufirst%3DS.%2BB.%26aulast%3DMcCann%26aufirst%3DD.%2BJ.%26atitle%3DA%2520novel%252C%2520selective%2520inhibitor%2520of%2520fibroblast%2520growth%2520factor%2520receptors%2520that%2520shows%2520a%2520potent%2520broad%2520spectrum%2520of%2520antitumor%2520activity%2520in%2520several%2520tumor%2520xenograft%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2200%26epage%3D2210%26doi%3D10.1158%2F1535-7163.MCT-11-0306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Inoue, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masuda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koga, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sata, M.</span><span> </span><span class="NLM_article-title">Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3924</span><span class="NLM_x">–</span> <span class="NLM_lpage">2933</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-2041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1158%2F1078-0432.CCR-11-2041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=22611027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVelur3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=3924-2933&author=K.+Inoueauthor=T.+Torimuraauthor=T.+Nakamuraauthor=H.+Iwamotoauthor=H.+Masudaauthor=M.+Abeauthor=O.+Hashimotoauthor=H.+Kogaauthor=T.+Uenoauthor=H.+Yanoauthor=M.+Sata&title=Vandetanib%2C+an+inhibitor+of+VEGF+receptor-2+and+EGF+receptor%2C+suppresses+tumor+development+and+improves+prognosis+of+liver+cancer+in+mice&doi=10.1158%2F1078-0432.CCR-11-2041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Vandetanib, an Inhibitor of VEGF Receptor-2 and EGF Receptor, Suppresses Tumor Development and Improves Prognosis of Liver Cancer in Mice</span></div><div class="casAuthors">Inoue, Kinya; Torimura, Takuji; Nakamura, Toru; Iwamoto, Hideki; Masuda, Hiroshi; Abe, Mitsuhiko; Hashimoto, Osamu; Koga, Hironori; Ueno, Takato; Yano, Hirohisa; Sata, Michio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3924-3933</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: VEGF, EGF, and TGF-α are expressed in hepatocellular carcinomas (HCC) and play a role in its growth.  Vandetanib, a multikinase inhibitor, suppresses the phosphorylation of VEGF receptor 2 (VEGFR-2) and EGF receptor (EGFR).  The aim of this study was to clarify the antitumor effect of vandetanib in mouse HCCs.  Exptl. Design: We evaluated the effects of vandetanib on proliferation of human umbilical vein endothelial cells (HUVEC) and three hepatoma cell lines, as well as the phosphorylation of VEGFR-2 and EGFR in these cells.  Mice were implanted with hepatoma cells s.c. or orthotopically in the liver and treated with 50 or 75 mg/kg vandetanib.  We analyzed the effects of treatment on tumor cell proliferation and apoptosis, vessel d., phosphorylation of VEGFR-2 and EGFR, and prodn. of VEGF, TGF-α, and EGF in tumor tissues.  Adverse events on vandetanib administration were also investigated.  Results: Vandetanib suppressed phosphorylation of VEGFR-2 in HUVECs and EGFR in hepatoma cells and inhibited cell proliferation.  In tumor-bearing mice, vandetanib suppressed phosphorylation of VEGFR-2 and EGFR in tumor tissues, significantly reduced tumor vessel d., enhanced tumor cell apoptosis, suppressed tumor growth, improved survival, reduced no. of intrahepatic metastases, and upregulated VEGF, TGF-α, and EGF in tumor tissues.  Treatment with vandetanib was not assocd. with serious adverse events, including alanine aminotransferase abnormality, bone marrow suppression, or body wt. loss.  Conclusions: The antitumor effects of vandetanib in mice suggest that it is a potentially suitable and safe chemotherapeutic agent for HCCs.  Clin Cancer Res; 18(14); 3924-33. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonGLsy-nYGHbVg90H21EOLACvtfcHk0ljMrcqRW-y6PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVelur3J&md5=5fd21f90672f2a8f92e4d473e2d6f26f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2041%26sid%3Dliteratum%253Aachs%26aulast%3DInoue%26aufirst%3DK.%26aulast%3DTorimura%26aufirst%3DT.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DIwamoto%26aufirst%3DH.%26aulast%3DMasuda%26aufirst%3DH.%26aulast%3DAbe%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DO.%26aulast%3DKoga%26aufirst%3DH.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DSata%26aufirst%3DM.%26atitle%3DVandetanib%252C%2520an%2520inhibitor%2520of%2520VEGF%2520receptor-2%2520and%2520EGF%2520receptor%252C%2520suppresses%2520tumor%2520development%2520and%2520improves%2520prognosis%2520of%2520liver%2520cancer%2520in%2520mice%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D3924%26epage%3D2933%26doi%3D10.1158%2F1078-0432.CCR-11-2041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Matsui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funahashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruoka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakabayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uenaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asada, M.</span><span> </span><span class="NLM_article-title">E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">664</span><span class="NLM_x">–</span> <span class="NLM_lpage">671</span><span class="refDoi"> DOI: 10.1002/ijc.23131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1002%2Fijc.23131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=17943726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A280%3ADC%252BD2sjhvVGnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2008&pages=664-671&author=J.+Matsuiauthor=Y.+Yamamotoauthor=Y.+Funahashiauthor=A.+Tsuruokaauthor=T.+Watanabeauthor=T.+Wakabayashiauthor=T.+Uenakaauthor=M.+Asada&title=E7080%2C+a+novel+inhibitor+that+targets+multiple+kinases%2C+has+potent+antitumor+activities+against+stem+cell+factor+producing+human+small+cell+lung+cancer+H146%2C+based+on+angiogenesis+inhibition&doi=10.1002%2Fijc.23131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition</span></div><div class="casAuthors">Matsui Junji; Yamamoto Yuji; Funahashi Yasuhiro; Tsuruoka Akihiko; Watanabe Tatsuo; Wakabayashi Toshiaki; Uenaka Toshimitsu; Asada Makoto</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">664-71</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">E7080 is an orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors.  In this study, we show the inhibitory activity of E7080 against SCF-induced angiogenesis in vitro and tumor growth of SCF-producing human small cell lung carcinoma H146 cells in vivo.  E7080 inhibits SCF-driven tube formation of HUVEC, which express SCF receptor, KIT at the IC(50) value of 5.2 nM and it was almost identical for VEGF-driven one (IC(50) = 5.1 nM).  To assess the role of SCF/KIT signaling in tumor angiogenesis, we evaluated the effect of imatinib, a selective KIT kinase inhibitor, on tumor growth of H146 cells in nude mice.  Imatinib did not show the potent antitumor activity in vitro (IC(50) = 2,200 nM), because H146 cells did not express KIT.  However, oral administration of imatinib at 160 mg/kg clearly slowed tumor growth of H146 cells in nude mice, accompanied by decreased microvessel density.  Oral administration of E7080 inhibited tumor growth of H146 cells at doses of 30 and 100 mg/kg in a dose-dependent manner and caused tumor regression at 100 mg/kg.  While anti-VEGF antibody also slowed tumor growth, it did not cause tumor regression.  These results indicate that KIT signaling has a role in tumor angiogenesis of SCF-producing H146 cells, and E7080 causes regression of H146 tumors as a result of antiangiogenic activity mediated by inhibition of both KIT and VEGF receptor signaling.  E7080 may provide therapeutic benefits in the treatment of SCF-producing tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQxatmtwSKaDe98rul4nhSdfW6udTcc2eYbVqvbPieYOLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sjhvVGnsA%253D%253D&md5=cfa467e773fd98d6f95b0dded62d31ef</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fijc.23131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.23131%26sid%3Dliteratum%253Aachs%26aulast%3DMatsui%26aufirst%3DJ.%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DFunahashi%26aufirst%3DY.%26aulast%3DTsuruoka%26aufirst%3DA.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DWakabayashi%26aufirst%3DT.%26aulast%3DUenaka%26aufirst%3DT.%26aulast%3DAsada%26aufirst%3DM.%26atitle%3DE7080%252C%2520a%2520novel%2520inhibitor%2520that%2520targets%2520multiple%2520kinases%252C%2520has%2520potent%2520antitumor%2520activities%2520against%2520stem%2520cell%2520factor%2520producing%2520human%2520small%2520cell%2520lung%2520cancer%2520H146%252C%2520based%2520on%2520angiogenesis%2520inhibition%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2008%26volume%3D122%26spage%3D664%26epage%3D671%26doi%3D10.1002%2Fijc.23131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Roth, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heckel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colbatzky, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Handschuh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann-Lintz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lotz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tontsch-Grunt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilberg, F.</span><span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">4466</span><span class="NLM_x">–</span> <span class="NLM_lpage">4480</span><span class="refDoi"> DOI: 10.1021/jm900431g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900431g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntFygsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4466-4480&author=G.+J.+Rothauthor=A.+Heckelauthor=F.+Colbatzkyauthor=S.+Handschuhauthor=J.+Kleyauthor=T.+Lehmann-Lintzauthor=R.+Lotzauthor=U.+Tontsch-Gruntauthor=R.+Walterauthor=F.+Hilberg&title=Design%2C+synthesis%2C+and+evaluation+of+indolinones+as+triple+angiokinase+inhibitors+and+the+discovery+of+a+highly+specific+6-methoxycarbonyl-substituted+indolinone+%28BIBF+1120%29&doi=10.1021%2Fjm900431g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of Indolinones as Triple Angiokinase Inhibitors and the Discovery of a Highly Specific 6-Methoxycarbonyl-Substituted Indolinone (BIBF 1120)</span></div><div class="casAuthors">Roth, Gerald J.; Heckel, Armin; Colbatzky, Florian; Handschuh, Sandra; Kley, Jorg; Lehmann-Lintz, Thorsten; Lotz, Ralf; Tontsch-Grunt, Ulrike; Walter, Rainer; Hilberg, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4466-4480</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of tumor angiogenesis through blockade of the vascular endothelial growth factor (VEGF) signaling pathway is a new treatment modality in oncol.  Preclin. findings suggest that blockade of addnl. pro-angiogenic kinases, such as fibroblast and platelet-derived growth factor receptors (FGFR and PDGFR), may improve the efficacy of pharmacol. cancer treatment.  Indolinones substituted in position 6 were identified as selective inhibitors of VEGF-, PDGF-, and FGF-receptor kinases.  In particular, 6-methoxycarbonyl-substituted indolinones showed a highly favorable selectivity profile.  Optimization identified potent inhibitors of VEGF-related endothelial cell proliferation with addnl. efficacy on pericyctes and smooth muscle cells.  In contrast, no direct inhibition of tumor cell proliferation was obsd.  Compds. 2 (BIBF 1000) and 3 (BIBF 1120) are orally available and display encouraging efficacy in in vivo tumor models while being well tolerated.  The triple angiokinase inhibitor 3 (I) is currently in phase III clin. trials for the treatment of nonsmall cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvvcX-_HYCS7Vg90H21EOLACvtfcHk0lilvZqkfLKJuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntFygsL4%253D&md5=1b8af461631ae3117520fc4811130bb3</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm900431g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900431g%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DG.%2BJ.%26aulast%3DHeckel%26aufirst%3DA.%26aulast%3DColbatzky%26aufirst%3DF.%26aulast%3DHandschuh%26aufirst%3DS.%26aulast%3DKley%26aufirst%3DJ.%26aulast%3DLehmann-Lintz%26aufirst%3DT.%26aulast%3DLotz%26aufirst%3DR.%26aulast%3DTontsch-Grunt%26aufirst%3DU.%26aulast%3DWalter%26aufirst%3DR.%26aulast%3DHilberg%26aufirst%3DF.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520indolinones%2520as%2520triple%2520angiokinase%2520inhibitors%2520and%2520the%2520discovery%2520of%2520a%2520highly%2520specific%25206-methoxycarbonyl-substituted%2520indolinone%2520%2528BIBF%25201120%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4466%26epage%3D4480%26doi%3D10.1021%2Fjm900431g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Gozgit, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loriaux, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohemmad, Q. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narasimhan, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span> </span><span class="NLM_article-title">Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1028</span><span class="NLM_x">–</span> <span class="NLM_lpage">1035</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-10-1044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1158%2F1535-7163.MCT-10-1044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=21482694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnt1anurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=1028-1035&author=J.+M.+Gozgitauthor=M.+J.+Wongauthor=S.+Wardwellauthor=J.+W.+Tynerauthor=M.+M.+Loriauxauthor=Q.+K.+Mohemmadauthor=N.+I.+Narasimhanauthor=W.+C.+Shakespeareauthor=F.+Wangauthor=B.+J.+Drukerauthor=T.+Clacksonauthor=V.+M.+Rivera&title=Potent+activity+of+ponatinib+%28AP24534%29+in+models+of+FLT3-driven+acute+myeloid+leukemia+and+other+hematologic+malignancies&doi=10.1158%2F1535-7163.MCT-10-1044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies</span></div><div class="casAuthors">Gozgit, Joseph M.; Wong, Matthew J.; Wardwell, Scott; Tyner, Jeffrey W.; Loriaux, Marc M.; Mohemmad, Qurish K.; Narasimhan, Narayana I.; Shakespeare, William C.; Wang, Frank; Druker, Brian J.; Clackson, Tim; Rivera, Victor M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1028-1035</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Ponatinib (AP24534) is a novel multitargeted kinase inhibitor that potently inhibits native and mutant BCR-ABL at clin. achievable drug levels.  Ponatinib also has in vitro inhibitory activity against a discrete set of kinases implicated in the pathogenesis of other hematol. malignancies, including FLT3, KIT, fibroblast growth factor receptor 1 (FGFR1), and platelet derived growth factor receptor α (PDGFRα).  Here, using leukemic cell lines contg. activated forms of each of these receptors, we show that ponatinib potently inhibits receptor phosphorylation and cellular proliferation with IC50 values comparable to those required for inhibition of BCR-ABL (0.3 to 20 nmol/L).  The activity of ponatinib against the FLT3-ITD mutant, found in up to 30% of acute myeloid leukemia (AML) patients, was particularly notable.  In MV4-11 (FLT3-ITD+/+) but not RS4;11 (FLT3-ITD-/-) AML cells, ponatinib inhibited FLT3 signaling and induced apoptosis at concns. of less than 10 nmol/L.  In an MV4-11 mouse xenograft model, once daily oral dosing of ponatinib led to a dose-dependent inhibition of signaling and tumor regression.  Ponatinib inhibited viability of primary leukemic blasts from a FLT3-ITD pos. AML patient (IC50 4 nmol/L) but not those isolated from 3 patients with AML expressing native FLT3.  Overall, these results support the investigation of ponatinib in patients with FLT3-ITD-driven AML and other hematol. malignancies driven by KIT, FGFR1, or PDGFRα.  Mol Cancer Ther; 10(6); 1028-35.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9zB1-MfOsuLVg90H21EOLACvtfcHk0liAdMmIjVv7tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnt1anurw%253D&md5=3448caf6ca749c1bdd49355fa48ee1d2</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-1044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-1044%26sid%3Dliteratum%253Aachs%26aulast%3DGozgit%26aufirst%3DJ.%2BM.%26aulast%3DWong%26aufirst%3DM.%2BJ.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26atitle%3DPotent%2520activity%2520of%2520ponatinib%2520%2528AP24534%2529%2520in%2520models%2520of%2520FLT3-driven%2520acute%2520myeloid%2520leukemia%2520and%2520other%2520hematologic%2520malignancies%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D1028%26epage%3D1035%26doi%3D10.1158%2F1535-7163.MCT-10-1044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, Y.</span><span> </span><span class="NLM_article-title">Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors</span> <span class="citation_source-journal">J. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">105</span><span class="refDoi"> DOI: 10.1186/s13045-016-0332-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1186%2Fs13045-016-0332-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=27716285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVajsbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=105&author=Y.+Sunauthor=W.+Niuauthor=F.+Duauthor=C.+Duauthor=S.+Liauthor=J.+Wangauthor=L.+Liauthor=F.+Wangauthor=Y.+Haoauthor=C.+Liauthor=Y.+Chi&title=Safety%2C+pharmacokinetics%2C+and+antitumor+properties+of+anlotinib%2C+an+oral+multi-target+tyrosine+kinase+inhibitor%2C+in+patients+with+advanced+refractory+solid+tumors&doi=10.1186%2Fs13045-016-0332-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors</span></div><div class="casAuthors">Sun, Yongkun; Niu, Wei; Du, Feng; Du, Chunxia; Li, Shuting; Wang, Jinwan; Li, Li; Wang, Fengqing; Hao, Yu; Li, Chuan; Chi, Yihebali</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">105/1-105/9</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Anlotinib is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit VEGFR2/3, FGFR1-4, PDGFR α/β, c-Kit, and Ret.  We aimed to evaluate the safety, pharmacokinetics, and antitumor activity of anlotinib in patients with advanced refractory solid tumors.  Methods: Anlotinib (5-16 mg) was orally administered in patients with solid tumor once a day on two schedules: (1) four consecutive weeks (4/0) or (2) 2-wk on/1-wk off (2/1).  Pharmacokinetic sampling was performed in all patients.  Twenty-one patients were further enrolled in an expanded cohort study on the recommended dose and schedule.  Preliminary tumor response was also assessed.  Results: On the 4/0 schedule, dose-limiting toxicity (DLT) was grade 3 hypertension at 10 mg.  On the 2/1 schedule, DLT was grade 3 hypertension and grade 3 fatigue at 16 mg.  Pharmacokinetic assessment indicated that anlotinib had long elimination half-lives and significant accumulation during multiple oral doses.  The 2/1 schedule was selected, with 12 mg once daily as the max. tolerated dose for the expanding study.  Twenty of the 21 patients (with colon adenocarcinoma, non-small cell lung cancer, renal clear cell cancer, medullary thyroid carcinoma, and soft tissue sarcoma) were assessable for antitumor activity of anlotinib: 3 patients had partial response, 14 patients had stable disease including 12 tumor burden shrinkage, and 3 had disease progression.  The main serious adverse effects were hypertension, triglyceride elevation, hand-foot skin reaction, and lipase elevation.  Conclusions: At the dose of 12 mg once daily at the 2/1 schedule, anlotinib displayed manageable toxicity, long circulation, and broad-spectrum antitumor potential, justifying the conduct of further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDNQUtYXwHILVg90H21EOLACvtfcHk0liAdMmIjVv7tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVajsbjN&md5=38e37bd976e43f78f9d2ddae6fe61c97</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0332-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0332-8%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%26aulast%3DNiu%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DF.%26aulast%3DDu%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DHao%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DChi%26aufirst%3DY.%26atitle%3DSafety%252C%2520pharmacokinetics%252C%2520and%2520antitumor%2520properties%2520of%2520anlotinib%252C%2520an%2520oral%2520multi-target%2520tyrosine%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520refractory%2520solid%2520tumors%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D105%26doi%3D10.1186%2Fs13045-016-0332-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Morton, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keir, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorlick, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolb, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billups, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, P. J.</span><span> </span><span class="NLM_article-title">Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program</span> <span class="citation_source-journal">Pediatr. Blood Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">566</span><span class="NLM_x">–</span> <span class="NLM_lpage">571</span><span class="refDoi"> DOI: 10.1002/pbc.23159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1002%2Fpbc.23159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=21538824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A280%3ADC%252BC383is1CqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2012&pages=566-571&author=C.+L.+Mortonauthor=J.+M.+Marisauthor=S.+T.+Keirauthor=R.+Gorlickauthor=E.+A.+Kolbauthor=C.+A.+Billupsauthor=J.+Wuauthor=M.+A.+Smithauthor=P.+J.+Houghton&title=Combination+testing+of+cediranib+%28AZD2171%29+against+childhood+cancer+models+by+the+pediatric+preclinical+testing+program&doi=10.1002%2Fpbc.23159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program</span></div><div class="casAuthors">Morton Christopher L; Maris John M; Keir Stephen T; Gorlick Richard; Kolb E Anders; Billups Catherine A; Wu Jianrong; Smith Malcolm A; Houghton Peter J</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric blood & cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">566-71</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Cediranib (AZD2171) is a potent small molecule inhibitor of vascular endothelial growth factor (VEGF) receptors.  Cediranib has demonstrated single agent activity in several adult cancers and is being studied in combination with standard cytotoxic agents in multiple disease settings.  PROCEDURES:  Cediranib was tested in vivo against six childhood tumor xenograft models (four sarcomas, one glioblastoma, one neuroblastoma) alone or combined with cyclophosphamide (two models), vincristine (three models) or cisplatin (one model), each administered at its maximum tolerated dose, or rapamycin (six models).  RESULTS:  The combination of cediranib with standard cytotoxic agents was superior to the cytotoxic agent used alone for a single xenograft (one of the three xenografts evaluated for the vincristine-cediranib combination).  The cediranib-cyclophosphamide combination was inferior to single agent cyclophosphamide in time to event for both models studied and was significantly inferior for one of the models.  Cediranib combined with rapamycin was superior to each of the agents used alone in two of the six models and was determined to be additive or supra-additive with rapamycin in four models, although the effects were not large.  CONCLUSIONS:  Cediranib combined with cytotoxic chemotherapy agents demonstrated little or no benefit (and in one case was significantly inferior) compared to chemotherapy alone for the six pediatric cancer xenografts studied.  By contrast, the combination of cediranib with rapamycin was additive or supra-additive in four of the six models in terms of prolongation of time to event, though tumor regressions were not observed for this combination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR9RI-zRIITRJdYoSR9eyvsfW6udTcc2eaJh9J7jpaY2bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383is1CqtQ%253D%253D&md5=69e1a1c566f37b84974332b76e3cc761</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fpbc.23159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpbc.23159%26sid%3Dliteratum%253Aachs%26aulast%3DMorton%26aufirst%3DC.%2BL.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26aulast%3DKeir%26aufirst%3DS.%2BT.%26aulast%3DGorlick%26aufirst%3DR.%26aulast%3DKolb%26aufirst%3DE.%2BA.%26aulast%3DBillups%26aufirst%3DC.%2BA.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DM.%2BA.%26aulast%3DHoughton%26aufirst%3DP.%2BJ.%26atitle%3DCombination%2520testing%2520of%2520cediranib%2520%2528AZD2171%2529%2520against%2520childhood%2520cancer%2520models%2520by%2520the%2520pediatric%2520preclinical%2520testing%2520program%26jtitle%3DPediatr.%2520Blood%2520Cancer%26date%3D2012%26volume%3D58%26spage%3D566%26epage%3D571%26doi%3D10.1002%2Fpbc.23159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Bello, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarlato, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliva, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berndt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valbusa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serra, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Incalci, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalletti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giavazzi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camboni, G.</span><span> </span><span class="NLM_article-title">E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">1396</span><span class="NLM_x">–</span> <span class="NLM_lpage">1405</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-2700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1158%2F0008-5472.CAN-10-2700" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=1396-1405&author=E.+Belloauthor=G.+Colellaauthor=V.+Scarlatoauthor=P.+Olivaauthor=A.+Berndtauthor=G.+Valbusaauthor=S.+C.+Serraauthor=M.+D%E2%80%99Incalciauthor=E.+Cavallettiauthor=R.+Giavazziauthor=G.+Damiaauthor=G.+Camboni&title=E-3810+is+a+potent+dual+inhibitor+of+VEGFR+and+FGFR+that+exerts+antitumor+activity+in+multiple+preclinical+models&doi=10.1158%2F0008-5472.CAN-10-2700"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2700%26sid%3Dliteratum%253Aachs%26aulast%3DBello%26aufirst%3DE.%26aulast%3DColella%26aufirst%3DG.%26aulast%3DScarlato%26aufirst%3DV.%26aulast%3DOliva%26aufirst%3DP.%26aulast%3DBerndt%26aufirst%3DA.%26aulast%3DValbusa%26aufirst%3DG.%26aulast%3DSerra%26aufirst%3DS.%2BC.%26aulast%3DD%25E2%2580%2599Incalci%26aufirst%3DM.%26aulast%3DCavalletti%26aufirst%3DE.%26aulast%3DGiavazzi%26aufirst%3DR.%26aulast%3DDamia%26aufirst%3DG.%26aulast%3DCamboni%26aufirst%3DG.%26atitle%3DE-3810%2520is%2520a%2520potent%2520dual%2520inhibitor%2520of%2520VEGFR%2520and%2520FGFR%2520that%2520exerts%2520antitumor%2520activity%2520in%2520multiple%2520preclinical%2520models%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D1396%26epage%3D1405%26doi%3D10.1158%2F0008-5472.CAN-10-2700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Bhide, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, L. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leavitt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leith, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wautlet, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortillo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeyaseelan, R.,  Sr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukral, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Arienzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derbin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span> </span><span class="NLM_article-title">Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an <i>in vivo</i> active potent VEGFR-2 inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">2143</span><span class="NLM_x">–</span> <span class="NLM_lpage">2146</span><span class="refDoi"> DOI: 10.1021/jm051106d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm051106d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=2143-2146&author=R.+S.+Bhideauthor=Z.+W.+Caiauthor=Y.+Z.+Zhangauthor=L.+Qianauthor=D.+Weiauthor=S.+Barbosaauthor=L.+J.+Lombardoauthor=R.+M.+Borzilleriauthor=X.+Zhengauthor=L.+I.+Wuauthor=J.+C.+Barrishauthor=S.+H.+Kimauthor=K.+Leavittauthor=A.+Mathurauthor=L.+Leithauthor=S.+Chaoauthor=B.+Wautletauthor=S.+Mortilloauthor=R.+Jeyaseelanauthor=D.+Kukralauthor=J.+T.+Huntauthor=A.+Kamathauthor=A.+Furaauthor=V.+Vyasauthor=P.+Maratheauthor=C.+D%E2%80%99Arienzoauthor=G.+Derbinauthor=J.+Fargnoli&title=Discovery+and+preclinical+studies+of+%28R%29-1-%284-%284-fluoro-2-methyl-1H-indol-5-yloxy%29-5-+methylpyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazin-6-yloxy%29propan-+2-ol+%28BMS-540215%29%2C+an+in+vivo+active+potent+VEGFR-2+inhibitor&doi=10.1021%2Fjm051106d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm051106d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm051106d%26sid%3Dliteratum%253Aachs%26aulast%3DBhide%26aufirst%3DR.%2BS.%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DZhang%26aufirst%3DY.%2BZ.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DBarbosa%26aufirst%3DS.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DL.%2BI.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DLeavitt%26aufirst%3DK.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DLeith%26aufirst%3DL.%26aulast%3DChao%26aufirst%3DS.%26aulast%3DWautlet%26aufirst%3DB.%26aulast%3DMortillo%26aufirst%3DS.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DKukral%26aufirst%3DD.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DVyas%26aufirst%3DV.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DDerbin%26aufirst%3DG.%26aulast%3DFargnoli%26aufirst%3DJ.%26atitle%3DDiscovery%2520and%2520preclinical%2520studies%2520of%2520%2528R%2529-1-%25284-%25284-fluoro-2-methyl-1H-indol-5-yloxy%2529-5-%2520methylpyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazin-6-yloxy%2529propan-%25202-ol%2520%2528BMS-540215%2529%252C%2520an%2520in%2520vivo%2520active%2520potent%2520VEGFR-2%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D2143%26epage%3D2146%26doi%3D10.1021%2Fjm051106d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Fei, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidhuber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moll, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groffen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heisterkamp, N.</span><span> </span><span class="NLM_article-title">Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib)</span> <span class="citation_source-journal">Mol. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">42</span><span class="refDoi"> DOI: 10.1186/1476-4598-11-42</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1186%2F1476-4598-11-42" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=22721004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVSrsbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=42&author=F.+Feiauthor=M.+Limauthor=S.+Schmidhuberauthor=J.+Mollauthor=J.+Groffenauthor=N.+Heisterkamp&title=Treatment+of+human+pre-B+acute+lymphoblastic+leukemia+with+the+Aurora+kinase+inhibitor+PHA-739358+%28Danusertib%29&doi=10.1186%2F1476-4598-11-42"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib)</span></div><div class="casAuthors">Fei, Fei; Lim, Min; Schmidhuber, Sabine; Moll, Jurgen; Groffen, John; Heisterkamp, Nora</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Treatment of Philadelphia chromosome-pos. acute lymphoblastic leukemias (Ph-pos. ALL) with clin. approved inhibitors of the Bcr/Abl tyrosine kinase frequently results in the emergence of a leukemic clone carrying the T315I mutation in Bcr/Abl, which confers resistance to these drugs.  PHA-739358, an Aurora kinase inhibitor, was reported to inhibit the Bcr/Abl T315I mutant in CML cells but no preclin. studies have examd. this in detail in human ALL.  Results: We compared the sensitivity of human Bcr/Abl T315I, Bcr/Abl wild type and non-Bcr/Abl ALL cells to this drug.  PHA-739358 inhibited proliferation and induced apoptosis independently of Bcr/Abl, the T315I mutation, or presence of the tumor suppressor p53, but the degree of effectiveness varied between different ALL samples.  Since short-term treatment with a single dose of drug only transiently inhibited proliferation, we tested combination treatments of PHA-739358 with the farnesyltransferase inhibitor Lonafarnib, with vincristine and with dasatinib.  All combinations reduced viability and cell nos. compared to treatment with a single drug.  Clonogenic assays showed that 25 nM PHA-739358 significantly reduced the colony growth potential of Ph-pos. ALL cells, and combined treatment with a second drug abrogated colony growth in this assay.  PHA-739358 further effectively blocked Bcr/Abl tyrosine kinase activity and Aurora kinase B in vivo, and mice transplanted with human Bcr/Abl T315I ALL cells treated with a 3 × 7-day cycle of PHA-739358 as mono-treatment had significantly longer survival.  Conclusions: PHA-739358 represents an alternative drug for the treatment of both Ph-pos. and neg. ALL, although combined treatment with a second drug may be needed to eradicate the leukemic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-u39qxs0SR7Vg90H21EOLACvtfcHk0lizGxU4lIoACg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVSrsbvM&md5=41d906feb25050fe9e5ad7745088192a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-11-42&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-11-42%26sid%3Dliteratum%253Aachs%26aulast%3DFei%26aufirst%3DF.%26aulast%3DLim%26aufirst%3DM.%26aulast%3DSchmidhuber%26aufirst%3DS.%26aulast%3DMoll%26aufirst%3DJ.%26aulast%3DGroffen%26aufirst%3DJ.%26aulast%3DHeisterkamp%26aufirst%3DN.%26atitle%3DTreatment%2520of%2520human%2520pre-B%2520acute%2520lymphoblastic%2520leukemia%2520with%2520the%2520Aurora%2520kinase%2520inhibitor%2520PHA-739358%2520%2528Danusertib%2529%26jtitle%3DMol.%2520Cancer%26date%3D2012%26volume%3D11%26spage%3D42%26doi%3D10.1186%2F1476-4598-11-42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Cohen, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hainsworth, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madajewicz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosgriff, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liau, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healey, D.</span><span> </span><span class="NLM_article-title">A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">89</span><span class="refDoi"> DOI: 10.1007/s00280-006-0352-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1007%2Fs00280-006-0352-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=17031646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksVOgsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2007&pages=81-89&author=R.+B.+Cohenauthor=C.+J.+Langerauthor=G.+R.+Simonauthor=P.+D.+Eisenbergauthor=J.+D.+Hainsworthauthor=S.+Madajewiczauthor=T.+M.+Cosgriffauthor=K.+Pierceauthor=H.+Xuauthor=K.+Liauauthor=D.+Healey&title=A+phase+I%2Frandomized+phase+II%2C+non-comparative%2C+multicenter%2C+open+label+trial+of+CP-547%2C632+in+combination+with+paclitaxel+and+carboplatin+or+paclitaxel+and+carboplatin+alone+as+first-line+treatment+for+advanced+non-small+cell+lung+cancer+%28NSCLC%29&doi=10.1007%2Fs00280-006-0352-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)</span></div><div class="casAuthors">Cohen, Roger B.; Langer, Corey J.; Simon, George Rajan; Eisenberg, Peter David; Hainsworth, John Daniel; Madajewicz, Stefan; Cosgriff, Thomas Michael; Pierce, Kristen; Xu, Huiping; Liau, Katherine; Healey, Diane</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">81-89</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: To evaluate the toxicity profile and pharmacol. properties of oral CP-547,632 alone and in combination with paclitaxel and carboplatin administered every 3 wk, and to assess efficacy as measured by the objective response and progressive disease rates of oral CP-547,632 administered in combination with paclitaxel and carboplatin.  Patients and methods: Patients with stage IIIB/IV or recurrent non-small cell lung cancer receiving first-line chemotherapy were treated with oral daily CP-547,632 in combination with paclitaxel 225 mg/m2 and carboplatin AUC = 6 every 3 wk.  Pharmacokinetics parameters for CP-547,632 and paclitaxel were detd. independently and during co-administration.  Results: Seventy patients were enrolled and 68 patients were treated, 37 in phase 1 and 31 in phase 2 (14 with the combination and 17 with chemotherapy alone).  Dose-limiting toxicity of CP-547,632 250 mg by mouth daily in combination with paclitaxel and carboplatin was grade 3 rash and grade 3 diarrhea despite medical intervention.  CP-547,632 did not significantly affect the pharmacol. profiles of paclitaxel and carboplatin.  No subject had CR.  In phase I, seven subjects (22.6%) had a confirmed partial response.  In phase II, four subjects (28.6%) receiving CP-547,632 plus chemotherapy had a confirmed partial response.  In the phase II chemotherapy alone group, four subjects (25%) had a confirmed partial response.  Conclusion: The combination of CP-547,632 and paclitaxel and carboplatin was well-tolerated at doses up to 200 mg by mouth daily.  Dose-limiting toxicity of CP-547,632 at 250 mg consisted of diarrhea and rash.  CP-547,632 did not increase the objective response rate to chemotherapy alone in patients with advanced non-small cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopzOmygcNSSLVg90H21EOLACvtfcHk0lizGxU4lIoACg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksVOgsLY%253D&md5=82853265274c80dc446731445b0c7707</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs00280-006-0352-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-006-0352-0%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DR.%2BB.%26aulast%3DLanger%26aufirst%3DC.%2BJ.%26aulast%3DSimon%26aufirst%3DG.%2BR.%26aulast%3DEisenberg%26aufirst%3DP.%2BD.%26aulast%3DHainsworth%26aufirst%3DJ.%2BD.%26aulast%3DMadajewicz%26aufirst%3DS.%26aulast%3DCosgriff%26aufirst%3DT.%2BM.%26aulast%3DPierce%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DLiau%26aufirst%3DK.%26aulast%3DHealey%26aufirst%3DD.%26atitle%3DA%2520phase%2520I%252Frandomized%2520phase%2520II%252C%2520non-comparative%252C%2520multicenter%252C%2520open%2520label%2520trial%2520of%2520CP-547%252C632%2520in%2520combination%2520with%2520paclitaxel%2520and%2520carboplatin%2520or%2520paclitaxel%2520and%2520carboplatin%2520alone%2520as%2520first-line%2520treatment%2520for%2520advanced%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2007%26volume%3D60%26spage%3D81%26epage%3D89%26doi%3D10.1007%2Fs00280-006-0352-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Moreno, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morland, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell-Hewson, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halford, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazmi-Stokes, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lock, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boddy, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yule, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargrave, D.</span><span> </span><span class="NLM_article-title">A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">267</span><span class="NLM_x">–</span> <span class="NLM_lpage">273</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-1592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1158%2F1078-0432.CCR-14-1592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=25370467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlGrsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=267-273&author=L.+Morenoauthor=L.+V.+Marshallauthor=A.+D.+Pearsonauthor=B.+Morlandauthor=M.+Elliottauthor=Q.+Campbell-Hewsonauthor=G.+Makinauthor=S.+E.+Halfordauthor=G.+Actonauthor=P.+Rossauthor=S.+Kazmi-Stokesauthor=V.+Lockauthor=A.+Rodriguezauthor=J.+F.+Lyonsauthor=A.+V.+Boddyauthor=M.+J.+Griffinauthor=M.+Yuleauthor=D.+Hargrave&title=A+phase+I+trial+of+AT9283+%28a+selective+inhibitor+of+aurora+kinases%29+in+children+and+adolescents+with+solid+tumors%3A+a+Cancer+Research+UK+study&doi=10.1158%2F1078-0432.CCR-14-1592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study</span></div><div class="casAuthors">Moreno, Lucas; Marshall, Lynley V.; Pearson, Andrew D. J.; Morland, Bruce; Elliott, Martin; Campbell-Hewson, Quentin; Makin, Guy; Halford, Sarah E. R.; Acton, Gary; Ross, Philip; Kazmi-Stokes, Shamim; Lock, Victoria; Rodriguez, Ana; Lyons, John F.; Boddy, Alan V.; Griffin, Melanie J.; Yule, Murray; Hargrave, Darren</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">267-273</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: A phase I trial of AT9283 (a multitargeted inhibitor of Aurora kinases A and B) was conducted in children and adolescents with solid tumors, to identify max.-tolerated dose (MTD), safety, efficacy, pharmacokinetics, and pharmacodynamic (PD) activity.  Exptl. Design: AT9283 was administered as a 72-h continuous i.v. infusion every 3 wk.  A rolling-six design, explored six dose levels (7, 9, 11.5, 14.5, 18.5, and 23 mg/m2/d).  Pharmacokinetic and PD assessments, included inhibition of phospho-histone 3 (pHH3) in paired skin punch biopsies.  Results: Thirty-three patients were evaluable for toxicity.  There were six dose-limiting toxicities and the MTD was 18.5 mg/m2/d.  Most common drug-related toxicities were hematol. (neutropenia, anemia, and thrombocytopenia in 36.4%, 18.2%, and 21.2% of patients), which were grade ≥3 in 30.3%, 6.1%, and 3% of patients.  Nonhematol. toxicities included fatigue, infections, febrile neutropenia and ALT elevation.  One patient with central nervous system-primitive neuroectodermal tumor (CNS-PNET) achieved a partial response after 16 cycles and 3 cases were stable for four or more cycles.  Plasma concns. were comparable with those in adults at the same dose level, clearance was similar although half-life was shorter (4.9 ± 1.5 h, compared with 8.4 ± 3.7 h in adults).  Inhibition of Aurora kinase B was shown by redn. in pHH3 in 17 of 18 patients treated at ≥11.5 mg/m2/d.  Conclusion: AT9283 was well tolerated in children and adolescents with solid tumors with manageable hematol. toxicity.  Target inhibition was demonstrated.  Disease stabilization was documented in intracranial and extracranial pediatric solid tumors and a phase II dose detd.  Clin Cancer Res; 21(2); 267-73. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxp9EKAjYXabVg90H21EOLACvtfcHk0lizGxU4lIoACg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlGrsrk%253D&md5=f1277d4edd2b7e36c542ce5e19fece8d</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-1592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-1592%26sid%3Dliteratum%253Aachs%26aulast%3DMoreno%26aufirst%3DL.%26aulast%3DMarshall%26aufirst%3DL.%2BV.%26aulast%3DPearson%26aufirst%3DA.%2BD.%26aulast%3DMorland%26aufirst%3DB.%26aulast%3DElliott%26aufirst%3DM.%26aulast%3DCampbell-Hewson%26aufirst%3DQ.%26aulast%3DMakin%26aufirst%3DG.%26aulast%3DHalford%26aufirst%3DS.%2BE.%26aulast%3DActon%26aufirst%3DG.%26aulast%3DRoss%26aufirst%3DP.%26aulast%3DKazmi-Stokes%26aufirst%3DS.%26aulast%3DLock%26aufirst%3DV.%26aulast%3DRodriguez%26aufirst%3DA.%26aulast%3DLyons%26aufirst%3DJ.%2BF.%26aulast%3DBoddy%26aufirst%3DA.%2BV.%26aulast%3DGriffin%26aufirst%3DM.%2BJ.%26aulast%3DYule%26aufirst%3DM.%26aulast%3DHargrave%26aufirst%3DD.%26atitle%3DA%2520phase%2520I%2520trial%2520of%2520AT9283%2520%2528a%2520selective%2520inhibitor%2520of%2520aurora%2520kinases%2529%2520in%2520children%2520and%2520adolescents%2520with%2520solid%2520tumors%253A%2520a%2520Cancer%2520Research%2520UK%2520study%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D267%26epage%3D273%26doi%3D10.1158%2F1078-0432.CCR-14-1592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Wesche, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haglund, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haugsten, E. M.</span><span> </span><span class="NLM_article-title">Fibroblast growth factors and their receptors in cancer</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">437</span><span class="NLM_x">, </span> <span class="NLM_fpage">199</span><span class="NLM_x">–</span> <span class="NLM_lpage">213</span><span class="refDoi"> DOI: 10.1042/BJ20101603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1042%2FBJ20101603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=21711248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotFSmtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=437&publication_year=2011&pages=199-213&author=J.+Wescheauthor=K.+Haglundauthor=E.+M.+Haugsten&title=Fibroblast+growth+factors+and+their+receptors+in+cancer&doi=10.1042%2FBJ20101603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast growth factors and their receptors in cancer</span></div><div class="casAuthors">Wesche, Jorgen; Haglund, Kaisa; Haugsten, Ellen Margrethe</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">437</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-213</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  FGFs (fibroblast growth factors) and their receptors (FGFRs) play essential roles in tightly regulating cell proliferation, survival, migration and differentiation during development and adult life.  Deregulation of FGFR signaling, on the other hand, was assocd. with many developmental syndromes, and with human cancer.  In cancer, FGFRs were found to become overactivated by several mechanisms, including gene amplification, chromosomal translocation and mutations.  FGFR alterations are detected in a variety of human cancers, such as breast, bladder, prostate, endometrial and lung cancers, as well as haematol. malignancies.  Accumulating evidence indicates that FGFs and FGFRs may act in an oncogenic fashion to promote multiple steps of cancer progression by inducing mitogenic and survival signals, as well as promoting epithelial-mesenchymal transition, invasion and tumor angiogenesis.  Therapeutic strategies targeting FGFs and FGFRs in human cancer are therefore currently being explored.  In the present review we will give an overview of FGF signaling, the main FGFR alterations found in human cancer to date, how they may contribute to specific cancer types and strategies for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkZsZJgfVo0rVg90H21EOLACvtfcHk0lhGrLpei5NDiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotFSmtbc%253D&md5=9b5249fe623e39e0445dedfc38537075</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1042%2FBJ20101603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20101603%26sid%3Dliteratum%253Aachs%26aulast%3DWesche%26aufirst%3DJ.%26aulast%3DHaglund%26aufirst%3DK.%26aulast%3DHaugsten%26aufirst%3DE.%2BM.%26atitle%3DFibroblast%2520growth%2520factors%2520and%2520their%2520receptors%2520in%2520cancer%26jtitle%3DBiochem.%2520J.%26date%3D2011%26volume%3D437%26spage%3D199%26epage%3D213%26doi%3D10.1042%2FBJ20101603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Turner, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharpe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambros, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geyer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Garcia, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natrajan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iorns, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillett, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grigoriadis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis-Filho, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">2085</span><span class="NLM_x">–</span> <span class="NLM_lpage">2094</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-3746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1158%2F0008-5472.CAN-09-3746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=20179196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFWis7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=2085-2094&author=N.+Turnerauthor=A.+Pearsonauthor=R.+Sharpeauthor=M.+Lambrosauthor=F.+Geyerauthor=M.+A.+Lopez-Garciaauthor=R.+Natrajanauthor=C.+Marchioauthor=E.+Iornsauthor=A.+Mackayauthor=C.+Gillettauthor=A.+Grigoriadisauthor=A.+Tuttauthor=J.+S.+Reis-Filhoauthor=A.+Ashworth&title=FGFR1+amplification+drives+endocrine+therapy+resistance+and+is+a+therapeutic+target+in+breast+cancer&doi=10.1158%2F0008-5472.CAN-09-3746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer</span></div><div class="casAuthors">Turner, Nicholas; Pearson, Alex; Sharpe, Rachel; Lambros, Maryou; Geyer, Felipe; Lopez-Garcia, Maria A.; Natrajan, Rachael; Marchio, Caterina; Iorns, Elizabeth; Mackay, Alan; Gillett, Cheryl; Grigoriadis, Anita; Tutt, Andrew; Reis-Filho, Jorge S.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2085-2094</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Amplification of fibroblast growth factor receptor 1 (FGFR1) occurs in ∼10% of breast cancers and is assocd. with poor prognosis.  However, it is uncertain whether overexpression of FGFR1 is causally linked to the poor prognosis of amplified cancers.  Here, we show that FGFR1 overexpression is robustly assocd. with FGFR1 amplification in two independent series of breast cancers.  Breast cancer cell lines with FGFR1 overexpression and amplification show enhanced ligand-dependent signaling, with increased activation of the mitogen-activated protein kinase and phosphoinositide 3-kinase-AKT signaling pathways in response to FGF2, but also show basal ligand-independent signaling, and are dependent on FGFR signaling for anchorage-independent growth.  FGFR1-amplified cell lines show resistance to 4-hydroxytamoxifen, which is reversed by small interfering RNA silencing of FGFR1, suggesting that FGFR1 overexpression also promotes endocrine therapy resistance.  FGFR1 signaling suppresses progesterone receptor (PR) expression in vitro, and likewise, amplified cancers are frequently PR neg., identifying a potential biomarker for FGFR1 activity.  Furthermore, we show that amplified cancers have a high proliferative rate assessed by Ki67 staining and that FGFR1 amplification is found in 16% to 27% of luminal B-type breast cancers.  Our data suggest that amplification and overexpression of FGFR1 may be a major contributor to poor prognosis in luminal-type breast cancers, driving anchorage-independent proliferation and endocrine therapy resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbsQ_wPmoftLVg90H21EOLACvtfcHk0lhGrLpei5NDiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFWis7s%253D&md5=d14ce3b47614b090c4f7bfa7e4ce8a38</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3746%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%26aulast%3DPearson%26aufirst%3DA.%26aulast%3DSharpe%26aufirst%3DR.%26aulast%3DLambros%26aufirst%3DM.%26aulast%3DGeyer%26aufirst%3DF.%26aulast%3DLopez-Garcia%26aufirst%3DM.%2BA.%26aulast%3DNatrajan%26aufirst%3DR.%26aulast%3DMarchio%26aufirst%3DC.%26aulast%3DIorns%26aufirst%3DE.%26aulast%3DMackay%26aufirst%3DA.%26aulast%3DGillett%26aufirst%3DC.%26aulast%3DGrigoriadis%26aufirst%3DA.%26aulast%3DTutt%26aufirst%3DA.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DFGFR1%2520amplification%2520drives%2520endocrine%2520therapy%2520resistance%2520and%2520is%2520a%2520therapeutic%2520target%2520in%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D2085%26epage%3D2094%26doi%3D10.1158%2F0008-5472.CAN-09-3746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Dutt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvesen, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramos, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onofrio, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatton, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoletti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winckler, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grewal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyhs, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziaugra, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trovik, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelsen, I. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefansson, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fennell, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cibulskis, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zody, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akslen, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span> </span><span class="NLM_article-title">Drug-sensitive FGFR2 mutations in endometrial carcinoma</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">8713</span><span class="NLM_x">–</span> <span class="NLM_lpage">8717</span><span class="refDoi"> DOI: 10.1073/pnas.0803379105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1073%2Fpnas.0803379105" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=8713-8717&author=A.+Duttauthor=H.+B.+Salvesenauthor=T.+H.+Chenauthor=A.+H.+Ramosauthor=R.+C.+Onofrioauthor=C.+Hattonauthor=R.+Nicolettiauthor=W.+Wincklerauthor=R.+Grewalauthor=M.+Hannaauthor=N.+Wyhsauthor=L.+Ziaugraauthor=D.+J.+Richterauthor=J.+Trovikauthor=I.+B.+Engelsenauthor=I.+M.+Stefanssonauthor=T.+Fennellauthor=K.+Cibulskisauthor=M.+C.+Zodyauthor=L.+A.+Akslenauthor=S.+Gabrielauthor=K.+K.+Wongauthor=W.+R.+Sellersauthor=M.+Meyersonauthor=H.+Greulich&title=Drug-sensitive+FGFR2+mutations+in+endometrial+carcinoma&doi=10.1073%2Fpnas.0803379105"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0803379105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0803379105%26sid%3Dliteratum%253Aachs%26aulast%3DDutt%26aufirst%3DA.%26aulast%3DSalvesen%26aufirst%3DH.%2BB.%26aulast%3DChen%26aufirst%3DT.%2BH.%26aulast%3DRamos%26aufirst%3DA.%2BH.%26aulast%3DOnofrio%26aufirst%3DR.%2BC.%26aulast%3DHatton%26aufirst%3DC.%26aulast%3DNicoletti%26aufirst%3DR.%26aulast%3DWinckler%26aufirst%3DW.%26aulast%3DGrewal%26aufirst%3DR.%26aulast%3DHanna%26aufirst%3DM.%26aulast%3DWyhs%26aufirst%3DN.%26aulast%3DZiaugra%26aufirst%3DL.%26aulast%3DRichter%26aufirst%3DD.%2BJ.%26aulast%3DTrovik%26aufirst%3DJ.%26aulast%3DEngelsen%26aufirst%3DI.%2BB.%26aulast%3DStefansson%26aufirst%3DI.%2BM.%26aulast%3DFennell%26aufirst%3DT.%26aulast%3DCibulskis%26aufirst%3DK.%26aulast%3DZody%26aufirst%3DM.%2BC.%26aulast%3DAkslen%26aufirst%3DL.%2BA.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DGreulich%26aufirst%3DH.%26atitle%3DDrug-sensitive%2520FGFR2%2520mutations%2520in%2520endometrial%2520carcinoma%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D8713%26epage%3D8717%26doi%3D10.1073%2Fpnas.0803379105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Shoichet, B. K.</span><span> </span><span class="NLM_article-title">Virtual screening of chemical libraries</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">432</span><span class="NLM_x">, </span> <span class="NLM_fpage">862</span><span class="NLM_x">–</span> <span class="NLM_lpage">865</span><span class="refDoi"> DOI: 10.1038/nature03197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1038%2Fnature03197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=15602552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVOht7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=432&publication_year=2004&pages=862-865&author=B.+K.+Shoichet&title=Virtual+screening+of+chemical+libraries&doi=10.1038%2Fnature03197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Virtual screening of chemical libraries</span></div><div class="casAuthors">Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">432</span>
        (<span class="NLM_cas:issue">7019</span>),
    <span class="NLM_cas:pages">862-865</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Virtual screening uses computer-based methods to discover new ligands on the basis of biol. structures.  Although widely heralded in the 1970s and 1980s, the technique has since struggled to meet its initial promise, and drug discovery remains dominated by empirical screening.  Recent successes in predicting new ligands and their receptor-bound structures, and better rates of ligand discovery compared to empirical screening, have reignited interest in virtual screening, which is now widely used in drug discovery, albeit on a more limited scale than empirical screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSY9IbbFldkrVg90H21EOLACvtfcHk0lhGrLpei5NDiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVOht7jK&md5=e351e226e8985d7c304a05fb67dfdc60</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnature03197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03197%26sid%3Dliteratum%253Aachs%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DVirtual%2520screening%2520of%2520chemical%2520libraries%26jtitle%3DNature%26date%3D2004%26volume%3D432%26spage%3D862%26epage%3D865%26doi%3D10.1038%2Fnature03197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span> </span><span class="NLM_article-title">Rapid generation of privileged substructure-based compound libraries with structural diversity and drug-likeness</span> <span class="citation_source-journal">ACS Comb. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">184</span><span class="NLM_x">–</span> <span class="NLM_lpage">191</span><span class="refDoi"> DOI: 10.1021/co4001309</span> </span><div class="citationLinks">[<a href="/doi/10.1021/co4001309" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFKht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=184-191&author=L.+Zhangauthor=M.+Y.+Zhengauthor=F.+Zhaoauthor=Y.+Zhaiauthor=H.+Liu&title=Rapid+generation+of+privileged+substructure-based+compound+libraries+with+structural+diversity+and+drug-likeness&doi=10.1021%2Fco4001309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid Generation of Privileged Substructure-Based Compound Libraries with Structural Diversity and Drug-Likeness</span></div><div class="casAuthors">Zhang, Lei; Zheng, Mingyue; Zhao, Fei; Zhai, Yun; Liu, Hong</div><div class="citationInfo"><span class="NLM_cas:title">ACS Combinatorial Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">184-191</span>CODEN:
                <span class="NLM_cas:coden">ACSCCC</span>;
        ISSN:<span class="NLM_cas:issn">2156-8944</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A library of privileged-substructure-based, heterocyclic compds. was constructed by a sequence of Ugi four-component reactions incorporating the indole motif and microwave-assisted cyclizations in branched pathways.  Cheminformatic anal. confirmed that the library exhibited a high degree of structural diversity and good drug-likeness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs3GfYzj0NNbVg90H21EOLACvtfcHk0ljVUL9H56gpHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFKht70%253D&md5=43ed67ba33c8765f1ebc3fa0ad4fd033</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fco4001309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fco4001309%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DM.%2BY.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DRapid%2520generation%2520of%2520privileged%2520substructure-based%2520compound%2520libraries%2520with%2520structural%2520diversity%2520and%2520drug-likeness%26jtitle%3DACS%2520Comb.%2520Sci.%26date%3D2014%26volume%3D16%26spage%3D184%26epage%3D191%26doi%3D10.1021%2Fco4001309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Drewry, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macarron, R.</span><span> </span><span class="NLM_article-title">Enhancements of screening collections to address areas of unmet medical need: an industry perspective</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">289</span><span class="NLM_x">–</span> <span class="NLM_lpage">298</span><span class="refDoi"> DOI: 10.1016/j.cbpa.2010.03.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1016%2Fj.cbpa.2010.03.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=20413343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmvVWqs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=289-298&author=D.+H.+Drewryauthor=R.+Macarron&title=Enhancements+of+screening+collections+to+address+areas+of+unmet+medical+need%3A+an+industry+perspective&doi=10.1016%2Fj.cbpa.2010.03.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancements of screening collections to address areas of unmet medical need: an industry perspective</span></div><div class="casAuthors">Drewry, David H.; Macarron, Ricardo</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">289-298</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The past 20 years have witnessed an impressive expansion of the  drug space'; defined as the intersection of the Medicinal Chem. space and the Biol. Active space relevant in the quest for new treatments for disease.  Despite the success of known lead discovery tactics, areas of unmet medical need are often linked to challenging or novel targets and are poorly served by current screening collections.  A successful strategy to fill the gaps is to diversify the approaches taken in the enhancement of screening collections.  Possible strategies include investments through proven methods, exploring areas of chem. space previously neglected (e.g. hydrophilic compds., natural product mimics), and applying tactics to the lead discovery process that are complementary to HTS (e.g. fragment based screening or multidisciplinary team efforts to tackle new target classes).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG12E8gELNY7Vg90H21EOLACvtfcHk0ljVUL9H56gpHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmvVWqs7Y%253D&md5=42466fea7e20ea8e1170303cb44e7339</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2010.03.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2010.03.024%26sid%3Dliteratum%253Aachs%26aulast%3DDrewry%26aufirst%3DD.%2BH.%26aulast%3DMacarron%26aufirst%3DR.%26atitle%3DEnhancements%2520of%2520screening%2520collections%2520to%2520address%2520areas%2520of%2520unmet%2520medical%2520need%253A%2520an%2520industry%2520perspective%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D14%26spage%3D289%26epage%3D298%26doi%3D10.1016%2Fj.cbpa.2010.03.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Bleicher, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohm, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alanine, A. I.</span><span> </span><span class="NLM_article-title">Hit and lead generation: beyond high-throughput screening</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">369</span><span class="NLM_x">–</span> <span class="NLM_lpage">378</span><span class="refDoi"> DOI: 10.1038/nrd1086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1038%2Fnrd1086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=12750740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjslamtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=369-378&author=K.+H.+Bleicherauthor=H.+J.+Bohmauthor=K.+Mullerauthor=A.+I.+Alanine&title=Hit+and+lead+generation%3A+beyond+high-throughput+screening&doi=10.1038%2Fnrd1086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A guide to drug discovery: Hit and lead generation: beyond high-throughput screening</span></div><div class="casAuthors">Bleicher, Konrad H.; Boehm, Hans-Joachim; Mueller, Klaus; Alanine, Alexander I.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">369-378</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The identification of small-mol. modulators of protein function, and the process of transforming these into high-content lead series, are key activities in modern drug discovery.  The decisions taken during this process have far-reaching consequences for success later in lead optimization and even more crucially in clin. development.  Recently, there has been an increased focus on these activities due to escalating downstream costs resulting from high clin. failure rates.  In addn., the vast emerging opportunities from efforts in functional genomics and proteomics demands a departure from the linear process of identification, evaluation and refinement activities towards a more integrated parallel process.  This calls for flexible, fast and cost-effective strategies to meet the demands of producing high-content lead series with improved prospects for clin. success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9IQCsTR8tobVg90H21EOLACvtfcHk0ljVUL9H56gpHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjslamtb8%253D&md5=b54e55c1f0d34fbd172c8aa9b996591d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnrd1086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1086%26sid%3Dliteratum%253Aachs%26aulast%3DBleicher%26aufirst%3DK.%2BH.%26aulast%3DBohm%26aufirst%3DH.%2BJ.%26aulast%3DMuller%26aufirst%3DK.%26aulast%3DAlanine%26aufirst%3DA.%2BI.%26atitle%3DHit%2520and%2520lead%2520generation%253A%2520beyond%2520high-throughput%2520screening%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D369%26epage%3D378%26doi%3D10.1038%2Fnrd1086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Spandl, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spring, D. R.</span><span> </span><span class="NLM_article-title">Diversity-oriented synthesis; a spectrum of approaches and results</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1149</span><span class="NLM_x">–</span> <span class="NLM_lpage">1158</span><span class="refDoi"> DOI: 10.1039/b719372f</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1039%2Fb719372f" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=18362950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjs12ntbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=1149-1158&author=R.+J.+Spandlauthor=A.+Benderauthor=D.+R.+Spring&title=Diversity-oriented+synthesis%3B+a+spectrum+of+approaches+and+results&doi=10.1039%2Fb719372f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Diversity-oriented synthesis; a spectrum of approaches and results</span></div><div class="casAuthors">Spandl, Richard J.; Bender, Andreas; Spring, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1149-1158</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Since our emerging area article, diversity-oriented synthesis (DOS), which aims to prep. efficiently collections of skeletally diverse small mols., has developed in the synthetic approaches it employs.  This article describes three general strategies, highlighting some successful examples.  The utility of DOS, in the interrogation of chem. space and in the identification of novel biol. active lead compds., is also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzIOlcPxM_ybVg90H21EOLACvtfcHk0ljVUL9H56gpHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjs12ntbg%253D&md5=b5e117edf6c8e56ba42fd33cfd39f9b1</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1039%2Fb719372f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb719372f%26sid%3Dliteratum%253Aachs%26aulast%3DSpandl%26aufirst%3DR.%2BJ.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DSpring%26aufirst%3DD.%2BR.%26atitle%3DDiversity-oriented%2520synthesis%253B%2520a%2520spectrum%2520of%2520approaches%2520and%2520results%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2008%26volume%3D6%26spage%3D1149%26epage%3D1158%26doi%3D10.1039%2Fb719372f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Golebiowski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klopfenstein, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Portlock, D. E.</span><span> </span><span class="NLM_article-title">Lead compounds discovered from libraries</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">–</span> <span class="NLM_lpage">284</span><span class="refDoi"> DOI: 10.1016/S1367-5931(00)00203-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1016%2FS1367-5931%2800%2900203-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=11479119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktlShtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2001&pages=273-284&author=A.+Golebiowskiauthor=S.+R.+Klopfensteinauthor=D.+E.+Portlock&title=Lead+compounds+discovered+from+libraries&doi=10.1016%2FS1367-5931%2800%2900203-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Lead compounds discovered from libraries</span></div><div class="casAuthors">Golebiowski, Adam; Klopfenstein, Sean R.; Portlock, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">273-284</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 77 refs.  Lead compds. with the potential to progress to viable drug candidates have been identified from libraries using several strategies.  These include rapid screening of large diverse collections, thematic libraries, project-directed libraries, and three-dimensional mol. models of corporate databases.  There have been numerous success stories, including the identification of several clin. candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKddxA9JYAmLVg90H21EOLACvtfcHk0lhLoD8bH2Tt3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktlShtLk%253D&md5=63b8228151566795939f5b7249b62b96</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FS1367-5931%2800%2900203-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1367-5931%252800%252900203-9%26sid%3Dliteratum%253Aachs%26aulast%3DGolebiowski%26aufirst%3DA.%26aulast%3DKlopfenstein%26aufirst%3DS.%2BR.%26aulast%3DPortlock%26aufirst%3DD.%2BE.%26atitle%3DLead%2520compounds%2520discovered%2520from%2520libraries%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2001%26volume%3D5%26spage%3D273%26epage%3D284%26doi%3D10.1016%2FS1367-5931%2800%2900203-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Geysen, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoenen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, R.</span><span> </span><span class="NLM_article-title">Combinatorial compound libraries for drug discovery: An ongoing challenge</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">222</span><span class="NLM_x">–</span> <span class="NLM_lpage">230</span><span class="refDoi"> DOI: 10.1038/nrd1035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1038%2Fnrd1035" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=222-230&author=H.+M.+Geysenauthor=F.+Schoenenauthor=D.+Wagnerauthor=R.+Wagner&title=Combinatorial+compound+libraries+for+drug+discovery%3A+An+ongoing+challenge&doi=10.1038%2Fnrd1035"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnrd1035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1035%26sid%3Dliteratum%253Aachs%26aulast%3DGeysen%26aufirst%3DH.%2BM.%26aulast%3DSchoenen%26aufirst%3DF.%26aulast%3DWagner%26aufirst%3DD.%26aulast%3DWagner%26aufirst%3DR.%26atitle%3DCombinatorial%2520compound%2520libraries%2520for%2520drug%2520discovery%253A%2520An%2520ongoing%2520challenge%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D222%26epage%3D230%26doi%3D10.1038%2Fnrd1035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Orry, A. J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abagyan, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavasotto, C. N.</span><span> </span><span class="NLM_article-title">Structure-based development of target-specific compound libraries</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">266</span><span class="refDoi"> DOI: 10.1016/S1359-6446(05)03717-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1016%2FS1359-6446%2805%2903717-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=16580603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtFagsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2006&pages=261-266&author=A.+J.+W.+Orryauthor=R.+A.+Abagyanauthor=C.+N.+Cavasotto&title=Structure-based+development+of+target-specific+compound+libraries&doi=10.1016%2FS1359-6446%2805%2903717-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based development of target-specific compound libraries</span></div><div class="casAuthors">Orry, Andrew J. W.; Abagyan, Ruben A.; Cavasotto, Claudio N.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5 & 6</span>),
    <span class="NLM_cas:pages">261-266</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The success or failure of a small-mol. drug discovery project ultimately lies in the choice of the scaffolds to be screened - chosen from among the many millions of available compds.  Therefore, the methods used to design compd. screening libraries are key for the development of new drugs that target a wide range of diseases.  Currently, there is a trend towards the construction of receptor-structure-based focused libraries.  Recent advances in high-throughput computational docking, NMR and crystallog. have facilitated the development of these libraries.  A structure-based target-specific library can save time and money by reducing the no. of compds. to be exptl. tested, also improving the drug discovery success rate by identifying more-potent and specific binders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBfW1A60Omu7Vg90H21EOLACvtfcHk0lhLoD8bH2Tt3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtFagsbY%253D&md5=53c0a7688115e7fed06edebafe97844a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2805%2903717-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252805%252903717-7%26sid%3Dliteratum%253Aachs%26aulast%3DOrry%26aufirst%3DA.%2BJ.%2BW.%26aulast%3DAbagyan%26aufirst%3DR.%2BA.%26aulast%3DCavasotto%26aufirst%3DC.%2BN.%26atitle%3DStructure-based%2520development%2520of%2520target-specific%2520compound%2520libraries%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2006%26volume%3D11%26spage%3D261%26epage%3D266%26doi%3D10.1016%2FS1359-6446%2805%2903717-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Welsch, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stockwell, B. R.</span><span> </span><span class="NLM_article-title">Privileged scaffolds for library design and drug discovery</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">347</span><span class="NLM_x">–</span> <span class="NLM_lpage">361</span><span class="refDoi"> DOI: 10.1016/j.cbpa.2010.02.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1016%2Fj.cbpa.2010.02.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=20303320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmvVWqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=347-361&author=M.+E.+Welschauthor=S.+A.+Snyderauthor=B.+R.+Stockwell&title=Privileged+scaffolds+for+library+design+and+drug+discovery&doi=10.1016%2Fj.cbpa.2010.02.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Privileged scaffolds for library design and drug discovery</span></div><div class="casAuthors">Welsch, Matthew E.; Snyder, Scott A.; Stockwell, Brent R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-361</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This review explores the concept of using privileged scaffolds to identify biol. active compds. through building chem. libraries.  We hope to accomplish three main objectives: to provide one of the most comprehensive listings of privileged scaffolds; to reveal through four selected examples the present state of the art in privileged scaffold library synthesis (in hopes of inspiring new and even more creative approaches); and also to offer some thoughts on how new privileged scaffolds might be identified and exploited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWQPxdsWawiLVg90H21EOLACvtfcHk0lhLoD8bH2Tt3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmvVWqsLs%253D&md5=fd0c2a642f063fd6f42f2c34fd186f8a</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2010.02.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2010.02.018%26sid%3Dliteratum%253Aachs%26aulast%3DWelsch%26aufirst%3DM.%2BE.%26aulast%3DSnyder%26aufirst%3DS.%2BA.%26aulast%3DStockwell%26aufirst%3DB.%2BR.%26atitle%3DPrivileged%2520scaffolds%2520for%2520library%2520design%2520and%2520drug%2520discovery%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D14%26spage%3D347%26epage%3D361%26doi%3D10.1016%2Fj.cbpa.2010.02.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Lopez-Vallejo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giulianotti, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghten, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina-Franco, J. L.</span><span> </span><span class="NLM_article-title">Expanding the medicinally relevant chemical space with compound libraries</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">718</span><span class="NLM_x">–</span> <span class="NLM_lpage">726</span><span class="refDoi"> DOI: 10.1016/j.drudis.2012.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1016%2Fj.drudis.2012.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=22515962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtFektL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=718-726&author=F.+Lopez-Vallejoauthor=M.+A.+Giulianottiauthor=R.+A.+Houghtenauthor=J.+L.+Medina-Franco&title=Expanding+the+medicinally+relevant+chemical+space+with+compound+libraries&doi=10.1016%2Fj.drudis.2012.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Expanding the medicinally relevant chemical space with compound libraries</span></div><div class="casAuthors">Lopez-Vallejo, Fabian; Giulianotti, Marc A.; Houghten, Richard A.; Medina-Franco, Jose L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">13-14</span>),
    <span class="NLM_cas:pages">718-726</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Anal. of marketed drugs and com. vendor libraries used in high-throughput screening suggests that the medicinally relevant chem. space may be expanded to unexplored regions.  Novel regions of the chem. space can be conveniently explored with structurally unique mols. with increased complexity and balanced physicochem. properties.  As a case study, we discuss the chemoinformatic profile of natural products in the Traditional Chinese Medicine (TCM) database and a large collection assembled from 30 small-mol. combinatorial libraries with emphasis on assessing mol. complexity.  The herein surveyed combinatorial libraries have been successfully used over the past 20 years to identify novel bioactive compds. across different therapeutic areas.  Combinatorial libraries and natural products are suitable sources to expand the traditional relevant medicinal chem. space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhT55nczC7sbVg90H21EOLACvtfcHk0lgCtS-KyL3Z9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtFektL0%253D&md5=e47776f21c5f0154c37094db030b2b9a</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2012.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2012.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DLopez-Vallejo%26aufirst%3DF.%26aulast%3DGiulianotti%26aufirst%3DM.%2BA.%26aulast%3DHoughten%26aufirst%3DR.%2BA.%26aulast%3DMedina-Franco%26aufirst%3DJ.%2BL.%26atitle%3DExpanding%2520the%2520medicinally%2520relevant%2520chemical%2520space%2520with%2520compound%2520libraries%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26spage%3D718%26epage%3D726%26doi%3D10.1016%2Fj.drudis.2012.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Guagnano, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spanka, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Douget, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamm, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brueggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wartmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berghausen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drueckes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerlin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bussiere, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graus Porta, D.</span><span> </span><span class="NLM_article-title">Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7066</span><span class="NLM_x">–</span> <span class="NLM_lpage">7083</span><span class="refDoi"> DOI: 10.1021/jm2006222</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2006222" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1SrsrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7066-7083&author=V.+Guagnanoauthor=P.+Furetauthor=C.+Spankaauthor=V.+Bordasauthor=M.+Le+Dougetauthor=C.+Stammauthor=J.+Brueggenauthor=M.+R.+Jensenauthor=C.+Schnellauthor=H.+Schmidauthor=M.+Wartmannauthor=J.+Berghausenauthor=P.+Drueckesauthor=A.+Zimmerlinauthor=D.+Bussiereauthor=J.+Murrayauthor=D.+Graus+Porta&title=Discovery+of+3-%282%2C6-dichloro-3%2C5-dimethoxy-phenyl%29-1-%7B6-%5B4-%284-ethyl-piperazin-1-yl%29-phenylamin+o%5D-pyrimidin-4-yl%7D-1-methyl-urea+%28NVP-BGJ398%29%2C+a+potent+and+selective+inhibitor+of+the+fibroblast+growth+factor+receptor+family+of+receptor+tyrosine+kinase&doi=10.1021%2Fjm2006222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase</span></div><div class="casAuthors">Guagnano, Vito; Furet, Pascal; Spanka, Carsten; Bordas, Vincent; Le Douget, Mickael; Stamm, Christelle; Brueggen, Josef; Jensen, Michael R.; Schnell, Christian; Schmid, Herbert; Wartmann, Markus; Berghausen, Joerg; Drueckes, Peter; Zimmerlin, Alfred; Bussiere, Dirksen; Murray, Jeremy; Graus Porta, Diana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7066-7083</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of N-aryl-N'-pyrimidin-4-yl ureas has been optimized to afford potent and selective inhibitors of the fibroblast growth factor receptor tyrosine kinases 1, 2, and 3 by rationally designing the substitution pattern of the aryl ring.  On the basis of its in vitro profile, compd. 1h (NVP-BGJ398) was selected for in vivo evaluation and showed significant antitumor activity in RT112 bladder cancer xenografts models overexpressing wild-type FGFR3.  These results support the potential therapeutic use of 1h as a new anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSC1v0A_6I_bVg90H21EOLACvtfcHk0lgCtS-KyL3Z9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1SrsrvK&md5=f9a2d742294cd3814e872bdd8add1ffa</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm2006222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2006222%26sid%3Dliteratum%253Aachs%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DSpanka%26aufirst%3DC.%26aulast%3DBordas%26aufirst%3DV.%26aulast%3DLe%2BDouget%26aufirst%3DM.%26aulast%3DStamm%26aufirst%3DC.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DSchmid%26aufirst%3DH.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DBerghausen%26aufirst%3DJ.%26aulast%3DDrueckes%26aufirst%3DP.%26aulast%3DZimmerlin%26aufirst%3DA.%26aulast%3DBussiere%26aufirst%3DD.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DGraus%2BPorta%26aufirst%3DD.%26atitle%3DDiscovery%2520of%25203-%25282%252C6-dichloro-3%252C5-dimethoxy-phenyl%2529-1-%257B6-%255B4-%25284-ethyl-piperazin-1-yl%2529-phenylamin%2520o%255D-pyrimidin-4-yl%257D-1-methyl-urea%2520%2528NVP-BGJ398%2529%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520the%2520fibroblast%2520growth%2520factor%2520receptor%2520family%2520of%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7066%26epage%3D7083%26doi%3D10.1021%2Fjm2006222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Friesner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repasky, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenwood, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halgren, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanschagrin, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mainz, D. T.</span><span> </span><span class="NLM_article-title">Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6177</span><span class="NLM_x">–</span> <span class="NLM_lpage">6196</span><span class="refDoi"> DOI: 10.1021/jm051256o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm051256o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvVGmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6177-6196&author=R.+A.+Friesnerauthor=R.+B.+Murphyauthor=M.+P.+Repaskyauthor=L.+L.+Fryeauthor=J.+R.+Greenwoodauthor=T.+A.+Halgrenauthor=P.+C.+Sanschagrinauthor=D.+T.+Mainz&title=Extra+precision+glide%3A+docking+and+scoring+incorporating+a+model+of+hydrophobic+enclosure+for+protein-ligand+complexes&doi=10.1021%2Fjm051256o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein-Ligand Complexes</span></div><div class="casAuthors">Friesner, Richard A.; Murphy, Robert B.; Repasky, Matthew P.; Frye, Leah L.; Greenwood, Jeremy R.; Halgren, Thomas A.; Sanschagrin, Paul C.; Mainz, Daniel T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6177-6196</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel scoring function to est. protein-ligand binding affinities has been developed and implemented as the Glide 4.0 XP scoring function and docking protocol.  In addn. to unique water desolvation energy terms, protein-ligand structural motifs leading to enhanced binding affinity are included:(1) hydrophobic enclosure where groups of lipophilic ligand atoms are enclosed on opposite faces by lipophilic protein atoms, (2) neutral-neutral single or correlated hydrogen bonds in a hydrophobically enclosed environment, and (3) five categories of charged-charged hydrogen bonds.  The XP scoring function and docking protocol have been developed to reproduce exptl. binding affinities for a set of 198 complexes (RMSDs of 2.26 and 1.73 kcal/mol over all and well-docked ligands, resp.) and to yield quality enrichments for a set of fifteen screens of pharmaceutical importance.  Enrichment results demonstrate the importance of the novel XP mol. recognition and water scoring in sepg. active and inactive ligands and avoiding false positives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohZiwN12vaY7Vg90H21EOLACvtfcHk0lgCtS-KyL3Z9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvVGmurg%253D&md5=ea428c82ead0d8c27f8c1a7b694a1edf</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm051256o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm051256o%26sid%3Dliteratum%253Aachs%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DRepasky%26aufirst%3DM.%2BP.%26aulast%3DFrye%26aufirst%3DL.%2BL.%26aulast%3DGreenwood%26aufirst%3DJ.%2BR.%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26aulast%3DSanschagrin%26aufirst%3DP.%2BC.%26aulast%3DMainz%26aufirst%3DD.%2BT.%26atitle%3DExtra%2520precision%2520glide%253A%2520docking%2520and%2520scoring%2520incorporating%2520a%2520model%2520of%2520hydrophobic%2520enclosure%2520for%2520protein-ligand%2520complexes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6177%26epage%3D6196%26doi%3D10.1021%2Fjm051256o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Gavine, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooney, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilgour, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Kadhimi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rooney, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span> </span><span class="NLM_article-title">AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">2045</span><span class="NLM_x">–</span> <span class="NLM_lpage">2056</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-3034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1158%2F0008-5472.CAN-11-3034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=22369928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC38Xls1Wgsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=2045-2056&author=P.+Gavineauthor=L.+Mooneyauthor=E.+Kilgourauthor=A.+Thomasauthor=K.+Al-Kadhimiauthor=S.+Beckauthor=C.+Rooneyauthor=T.+Colemanauthor=D.+Bakerauthor=M.+Mellorauthor=A.+Brooksauthor=T.+Klinowska&title=AZD4547%3A+an+orally+bioavailable%2C+potent%2C+and+selective+inhibitor+of+the+fibroblast+growth+factor+receptor+tyrosine+kinase+family&doi=10.1158%2F0008-5472.CAN-11-3034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family</span></div><div class="casAuthors">Gavine, Paul R.; Mooney, Lorraine; Kilgour, Elaine; Thomas, Andrew P.; Al-Kadhimi, Katherine; Beck, Sarah; Rooney, Claire; Coleman, Tanya; Baker, Dawn; Mellor, Martine J.; Brooks, A. Nigel; Klinowska, Teresa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2045-2056</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The fibroblast growth factor (FGF) signaling axis is increasingly implicated in tumorigenesis and chemoresistance.  Several small-mol. FGF receptor (FGFR) kinase inhibitors are currently in clin. development; however, the predominant activity of the most advanced of these agents is against the kinase insert domain receptor (KDR), which compromises the FGFR selectivity.  Here, we report the pharmacol. profile of AZD4547, a novel and selective inhibitor of the FGFR1, 2, and 3 tyrosine kinases.  AZD4547 inhibited recombinant FGFR kinase activity in vitro and suppressed FGFR signaling and growth in tumor cell lines with deregulated FGFR expression.  In a representative FGFR-driven human tumor xenograft model, oral administration of AZD4547 was well tolerated and resulted in potent dose-dependent antitumor activity, consistent with plasma exposure and pharmacodynamic modulation of tumor FGFR.  Importantly, at efficacious doses, no evidence of anti-KDR-related effects were obsd., confirming the in vivo FGFR selectivity of AZD4547.  Taken together, our findings show that AZD4547 is a novel selective small-mol. inhibitor of FGFR with potent antitumor activity against FGFR-deregulated tumors in preclin. models.  AZD4547 is under clin. investigation for the treatment of FGFR-dependent tumors.  Cancer Res; 72(8); 2045-56.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnpExryJc9xbVg90H21EOLACvtfcHk0ljn41iFc9166w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xls1Wgsrs%253D&md5=cba90ad8f9b9e51cd10288868bbcc85e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3034%26sid%3Dliteratum%253Aachs%26aulast%3DGavine%26aufirst%3DP.%26aulast%3DMooney%26aufirst%3DL.%26aulast%3DKilgour%26aufirst%3DE.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DBeck%26aufirst%3DS.%26aulast%3DRooney%26aufirst%3DC.%26aulast%3DColeman%26aufirst%3DT.%26aulast%3DBaker%26aufirst%3DD.%26aulast%3DMellor%26aufirst%3DM.%26aulast%3DBrooks%26aufirst%3DA.%26aulast%3DKlinowska%26aufirst%3DT.%26atitle%3DAZD4547%253A%2520an%2520orally%2520bioavailable%252C%2520potent%252C%2520and%2520selective%2520inhibitor%2520of%2520the%2520fibroblast%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520family%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D2045%26epage%3D2056%26doi%3D10.1158%2F0008-5472.CAN-11-3034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Cheng, Z.; Han, X.; Jiang, M.; Wang, J.; Wang, M.; Yang, S.; Zhou, C.</span><span> </span><span class="NLM_article-title">New substituted pyridine compounds used for treating cancers e.g. glioma, colorectal and pancreatic cancers and cancers of larynx, lymphatic system, liver, and skin</span>. WO2014/090692, June 19,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=Z.+Cheng&author=X.+Han&author=M.+Jiang&author=J.+Wang&author=M.+Wang&author=S.+Yang&author=C.+Zhou&title=New+substituted+pyridine+compounds+used+for+treating+cancers+e.g.+glioma%2C+colorectal+and+pancreatic+cancers+and+cancers+of+larynx%2C+lymphatic+system%2C+liver%2C+and+skin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DZ.%26atitle%3DNew%2520substituted%2520pyridine%2520compounds%2520used%2520for%2520treating%2520cancers%2520e.g.%2520glioma%252C%2520colorectal%2520and%2520pancreatic%2520cancers%2520and%2520cancers%2520of%2520larynx%252C%2520lymphatic%2520system%252C%2520liver%252C%2520and%2520skin%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez-Rosello, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acena, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">del Pozo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorochinsky, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fustero, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soloshonok, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span> </span><span class="NLM_article-title">Fluorine in pharmaceutical industry: fluorine-containing drugs introduced to the market in the last decade (2001–2011)</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">2432</span><span class="NLM_x">–</span> <span class="NLM_lpage">2506</span><span class="refDoi"> DOI: 10.1021/cr4002879</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr4002879" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFegsb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2014&pages=2432-2506&author=J.+Wangauthor=M.+Sanchez-Roselloauthor=J.+L.+Acenaauthor=C.+del+Pozoauthor=A.+E.+Sorochinskyauthor=S.+Fusteroauthor=V.+A.+Soloshonokauthor=H.+Liu&title=Fluorine+in+pharmaceutical+industry%3A+fluorine-containing+drugs+introduced+to+the+market+in+the+last+decade+%282001%E2%80%932011%29&doi=10.1021%2Fcr4002879"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001-2011)</span></div><div class="casAuthors">Wang, Jiang; Sanchez-Rosello, Maria; Acena, Jose Luis; del Pozo, Carlos; Sorochinsky, Alexander E.; Fustero, Santos; Soloshonok, Vadim A.; Liu, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2432-2506</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A historic review.  As expected from the fluorine position on the periodic table of elements, it possesses some extreme properties, in particular, ultimate electronegativity and oxidn. potential.  Therefore,elemental fluorine can not be prepd. by chem. reaction, and its isolation in 1886 by Henri Moissan required scientific ingenuity and great personal courage.  His historic effort earned him a Noble Prize (1906), and the developed electrolysis method is still in use for industrial prodn. of fluorine gas.  However, further development of fluorine chem. was extremely sluggish, pursued by a handful of experts capable of handling the violent gas using specially designed lab. equipment.  Industrial-scale prodn. of fluorochems. dates back to late 1930s.  Currently, there are about 200 pharmaceuticals containingfluorine, including the 40 new compds. discussed in this review.  One may agree that the contribution of the past decade indicates a significant 20% increase in the no. of fluorinated drugs on the market.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQTzcNC3MEA7Vg90H21EOLACvtfcHk0ljn41iFc9166w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFegsb7I&md5=07faac419cd090503e82c6f00d05c338</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fcr4002879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr4002879%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DSanchez-Rosello%26aufirst%3DM.%26aulast%3DAcena%26aufirst%3DJ.%2BL.%26aulast%3Ddel%2BPozo%26aufirst%3DC.%26aulast%3DSorochinsky%26aufirst%3DA.%2BE.%26aulast%3DFustero%26aufirst%3DS.%26aulast%3DSoloshonok%26aufirst%3DV.%2BA.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DFluorine%2520in%2520pharmaceutical%2520industry%253A%2520fluorine-containing%2520drugs%2520introduced%2520to%2520the%2520market%2520in%2520the%2520last%2520decade%2520%25282001%25E2%2580%25932011%2529%26jtitle%3DChem.%2520Rev.%26date%3D2014%26volume%3D114%26spage%3D2432%26epage%3D2506%26doi%3D10.1021%2Fcr4002879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acena, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soloshonok, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span> </span><span class="NLM_article-title">Next generation of fluorine-containing pharmaceuticals, compounds currently in phase II-III clinical trials of major pharmaceutical companies: new structural trends and therapeutic areas</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">422</span><span class="NLM_x">–</span> <span class="NLM_lpage">518</span><span class="refDoi"> DOI: 10.1021/acs.chemrev.5b00392</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.5b00392" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVGms7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2016&pages=422-518&author=Y.+Zhouauthor=J.+Wangauthor=Z.+Guauthor=S.+Wangauthor=W.+Zhuauthor=J.+L.+Acenaauthor=V.+A.+Soloshonokauthor=K.+Izawaauthor=H.+Liu&title=Next+generation+of+fluorine-containing+pharmaceuticals%2C+compounds+currently+in+phase+II-III+clinical+trials+of+major+pharmaceutical+companies%3A+new+structural+trends+and+therapeutic+areas&doi=10.1021%2Facs.chemrev.5b00392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II-III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas</span></div><div class="casAuthors">Zhou, Yu; Wang, Jiang; Gu, Zhanni; Wang, Shuni; Zhu, Wei; Acena, Jose Luis; Soloshonok, Vadim A.; Izawa, Kunisuke; Liu, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">422-518</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  We focus herein on a new collection of 51 fluorine-contg. mols. that either were approved after 2011 by the corresponding agencies or still are on clin. development.  These compds. cover a large no. of therapeutic areas and, on this occasion, we decided to classify them according to the no. of fluorine atoms or fluorinated moieties.  In each case, the structures and modes of action of these new drugs are revised, with a particular focus on the role of fluorine in the biol. and pharmaceutical properties, when appropriate.  Finally, representative synthetic routes are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh-rq_ZyY_jrVg90H21EOLACvtfcHk0ljlBC-mjCKUnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVGms7o%253D&md5=e3d07d070fcf5b69a54f70bdba99acd4</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.5b00392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.5b00392%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DAcena%26aufirst%3DJ.%2BL.%26aulast%3DSoloshonok%26aufirst%3DV.%2BA.%26aulast%3DIzawa%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DNext%2520generation%2520of%2520fluorine-containing%2520pharmaceuticals%252C%2520compounds%2520currently%2520in%2520phase%2520II-III%2520clinical%2520trials%2520of%2520major%2520pharmaceutical%2520companies%253A%2520new%2520structural%2520trends%2520and%2520therapeutic%2520areas%26jtitle%3DChem.%2520Rev.%26date%3D2016%26volume%3D116%26spage%3D422%26epage%3D518%26doi%3D10.1021%2Facs.chemrev.5b00392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Guagnano, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wohrle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamm, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barys, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pornon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Douget, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaither, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borawski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monahan, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatesan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brummendorf, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graus-Porta, D.</span><span> </span><span class="NLM_article-title">FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1118</span><span class="NLM_x">–</span> <span class="NLM_lpage">1133</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;key=10.1158%2F2159-8290.CD-12-0210" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=1118-1133&author=V.+Guagnanoauthor=A.+Kauffmannauthor=S.+Wohrleauthor=C.+Stammauthor=M.+Itoauthor=L.+Barysauthor=A.+Pornonauthor=Y.+Yaoauthor=F.+Liauthor=Y.+Zhangauthor=Z.+Chenauthor=C.+J.+Wilsonauthor=V.+Bordasauthor=M.+Le+Dougetauthor=L.+A.+Gaitherauthor=J.+Borawskiauthor=J.+E.+Monahanauthor=K.+Venkatesanauthor=T.+Brummendorfauthor=D.+M.+Thomasauthor=C.+Garcia-Echeverriaauthor=F.+Hofmannauthor=W.+R.+Sellersauthor=D.+Graus-Porta&title=FGFR+genetic+alterations+predict+for+sensitivity+to+NVP-BGJ398%2C+a+selective+pan-FGFR+inhibitor&doi=10.1158%2F2159-8290.CD-12-0210"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0210%26sid%3Dliteratum%253Aachs%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DKauffmann%26aufirst%3DA.%26aulast%3DWohrle%26aufirst%3DS.%26aulast%3DStamm%26aufirst%3DC.%26aulast%3DIto%26aufirst%3DM.%26aulast%3DBarys%26aufirst%3DL.%26aulast%3DPornon%26aufirst%3DA.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DWilson%26aufirst%3DC.%2BJ.%26aulast%3DBordas%26aufirst%3DV.%26aulast%3DLe%2BDouget%26aufirst%3DM.%26aulast%3DGaither%26aufirst%3DL.%2BA.%26aulast%3DBorawski%26aufirst%3DJ.%26aulast%3DMonahan%26aufirst%3DJ.%2BE.%26aulast%3DVenkatesan%26aufirst%3DK.%26aulast%3DBrummendorf%26aufirst%3DT.%26aulast%3DThomas%26aufirst%3DD.%2BM.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DGraus-Porta%26aufirst%3DD.%26atitle%3DFGFR%2520genetic%2520alterations%2520predict%2520for%2520sensitivity%2520to%2520NVP-BGJ398%252C%2520a%2520selective%2520pan-FGFR%2520inhibitor%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26spage%3D1118%26epage%3D1133%26doi%3D10.1158%2F2159-8290.CD-12-0210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3TT0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3TT0','PDB','3TT0'); return false;">PDB: 3TT0</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i89"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00076">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_83714"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00076">10.1021/acs.jmedchem.7b00076</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">HPLC analysis data of all final compounds, illustration of the potential internal H-bond of compound <b>2m</b>, and the putative binding mode of <b>3m</b> with FGFR1 protein (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00076/suppl_file/jm7b00076_si_001.pdf">PDF</a>)</p></li><li><p class="inline">SMILES strings of 57 candidate compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00076/suppl_file/jm7b00076_si_003.xlsx">XLSX</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00076/suppl_file/jm7b00076_si_001.pdf">jm7b00076_si_001.pdf (223.49 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00076/suppl_file/jm7b00076_si_003.xlsx">jm7b00076_si_003.xlsx (20.03 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00076&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-14%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00076%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00076" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677aac588e073ce2","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
